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ABSTRACT 
 Complications of type 2 diabetes (T2DM) are severe but can be minimized 
through excellent glycemic control, optimally achieved by using intensive, or basal-
bolus, insulin management.  The quality of life (QOL) effects of basal-bolus insulin 
management are not fully known.  This cross-sectional, observational study was based 
on the Revised Wilson and Cleary Model for Health Related Quality of Life, which 
measures five QOL domains (biological function, symptoms, functional status, general 
health perceptions, and overall QOL).   The study aims were to describe, compare, and 
predict QOL in persons with T2DM based on type of insulin management (oral meds 
only, basal insulin only, or basal-bolus insulin).  A convenience sample of adults with 
T2DM (n=107; 76% women; 84% non-Hispanic whites) completed self-report surveys 
(Chronic Illness Resources Survey, Diabetes Symptom Checklist-Revised, Well-Being 
Questionnaire 12, SF-12 Health Survey-version 2, Self-Care Inventory-Revised, Appraisal 
of Diabetes Scale, Quality of Life Index: Diabetes Version) and a bloodspot HBA1c test 
via postal mail.  The sample reported high QOL (21.8±4.7).  Female participants reported 
lower well-being (23.0 vs 27.5, p<.01), greater negative well-being (2.2 vs 1.0, p<.05), 
and lower QOL than study males (21.1 vs 24.0, p<.01).  Per multiple regression, general 
well-being (β = .51, p<.001) and appraisal of diabetes (β = -.23, p<.05) predicted QOL [R2 
= .49, F (5, 90) = 17.04, p< .001].  Multiple regression analysis revealed that self-care 
xv 
 
moderates the relationship between general well-being and QOL [R2 = .45, F (3, 102) = 
27.73, p<.001].  No significant differences were detected in QOL between insulin 
management groups.  This study may provide greater insight into the QOL in adults with 
T2DM. 
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CHAPTER ONE 
PROBLEM STATEMENT 
 Diabetes is a significant cause of death and disability across the world.  Diabetes-
related complications were documented as the seventh leading cause of death in the US 
in 2010 (Centers for Disease Control and Prevention [CDC], 2014).  The mortality risk for 
other leading causes of death, such as heart attack and stroke, is nearly doubled by 
diabetes mellitus (DM; CDC, 2014).   Diabetes is the leading cause of new cases of 
blindness, renal failure, and non-traumatic lower limb amputations in US adults (CDC, 
2014).  In the US, DM-related complications are costly, resulting in 176 billion dollars of 
medical costs and over 69 billion dollars of indirect costs related to disability and 
premature death (CDC, 2014).   
Although complications of DM are severe, they can be minimized or avoided 
through excellent glycemic control (The Diabetes Control and Complications Trial [DCCT] 
Research Group, 1993; UK Prospective Diabetes Study [UKPDS] Group, 1998).  Optimal 
glycemic control can be achieved through intensive insulin therapy but requires 
significant patient commitment.  Increased hypoglycemia is common with insulin use, 
especially when given three or more times daily (Frier, 2008; Levy, Christensen, & 
Johnson, 2008).  However, dietary freedom is increased with more frequent insulin 
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dosing (DAFNE Study Group, 2002) and may lead to increased quality of life (QOL; 
Manini, Foriani, Moscatiello, Zannoni, Marzocchi & Marchesini, 2007; Ashwell, Witthaus,  
Bradley, Home & Stephens, 2008).  QOL studies in DM managed with basal-bolus, or 
intensive, insulin dosing have shown mixed findings (Ashwell et al., 2008; Bendik et al., 
2009; DAFNE Study Group, 2002; Kalergis, Pacaud, Strychar, Meltzer, Jones & Yale, 
2000; Linkeschova, Raoul, Bott, Berger & Spraul, 2002; Schiel & Muller, 1999).  As 
diabetes is a self-managed disease, it is important to understand the impact of insulin 
management on health-related QOL (HRQOL). 
Current treatment recommendations for DM emphasize the use of technology 
and self-care to optimize glycemic control.   Dietary modification and exercise are 
universally recommended for all patients with DM.  Patients with insulin-dependent 
diabetes (IDDM) include all requiring insulin, regardless of age at diagnosis.  Of the 21 
million persons with diagnosed DM in the US, approximately 6 million adults require 
exogenous insulin to survive (CDC, 2014).  For these persons, insulin is the foundation of 
treatment, but cannot be used in isolation to achieve glycemic control.  Diabetes self-
management (DSM), which combines self-monitoring of blood glucose (SMBG), dietary 
modification, and exercise, with insulin dosing, is necessary to optimize control of blood 
sugars (American Diabetes Association, 2014).  The “gold standard” of diabetes care is 
intensive diabetes management, defined as “a mode of treatment for the person with 
diabetes that has the goal of achieving euglycemia or near-normal glycemia, using all 
available resources to accomplish this goal” (Wolfsdorf, 2009).  Intensive diabetes 
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management is recommended by the American Diabetes Association (ADA, 2014).  
Intensive insulin management uses DSM and insulin administered in a basal-bolus 
format, typically three or more times per day.  The doses may be given through multiple 
daily injections of insulin (MDI) or continuous subcutaneous insulin infusion (CSII) to 
achieve near-normal levels of blood sugar, as measured by SMBG and glycosylated 
hemoglobin (A1C).  Most patients using basal-bolus insulin management use 
carbohydrate counting to determine the food-based amount of bolus insulin to be 
given.  Often, intensive diabetes management requires recognition of glycemic patterns 
over hours or days.   
Traditional management of DM also uses medical nutrition therapy, exercise, 
SMBG, and insulin.  However, in this treatment strategy, insulin is given in fixed doses.  
Some patients with Type 2 DM (T2DM) may be prescribed daily long-acting insulin 
analogue injections in addition to oral medications.  Other patients with IDDM may give 
insulin once or twice daily, adjusting doses according to a sliding-scale based on SMBG 
readings.  This method of insulin administration is called basal insulin dosing.  Patients 
using basal insulin dosing do not have a prescribed method of adjusting insulin doses 
based on dietary intake or activity.  Thus, for success, this strategy requires eating set 
amounts of carbohydrates at scheduled times and maintaining a predetermined level of 
activity.  
In reality, despite ADA practice guidelines, intensive diabetes management is not 
universally used for all patients with IDDM.  Although the exact rates of patients using 
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basal vs. basal-bolus insulin management are not known, basal-only insulin is still used 
by many patients with T2DM.  One strategy used for basal insulin administration of DM 
is insulin premix, a combination product requiring fixed dietary intake and timing 
(Henske, Griffith & Fowler, 2009; Hirsch, Bergenstal, Parkin, Wright & Buse, 2005; 
Niswender, 2009).  The use of premix insulin has increased over the last ten years: 
instead of declining production, leading insulin manufacturers have produced more 
premix products (e.g., Humalog Mix 75/25, Humalog Mix 50/50, NovoLog Mix 70/30) in 
response to demand (Lilly USA, 2014; Novo Nordisk A/S, 2014).   Why is intensive 
diabetes management not used universally?  Although basal-bolus insulin management 
can produce optimal glycemic control, it requires substantial patient involvement.  
Increased hypoglycemia is associated with basal-bolus insulin management (Frier, 2008; 
Levy, Christensen, & Johnson, 2008).  However, more frequent insulin dosing is 
associated with dietary freedom (DAFNE Study Group, 2002) and may lead to increased 
quality of life (QOL).  From the patient’s perspective, QOL may be a more important goal 
than glycemic control, due to its tangibility.  Perhaps because intensive diabetes 
management is so demanding, glycemic goals are not consistently met by many patients 
with DM.  Per national studies, only 52.5% of patients with DM have achieved glycemic 
control, as measured by A1C less than seven percent (Casagrande, Fradkin, Saydah, Rust 
& Cowie, 2013).   
Successful intensive diabetes management requires significant patient 
engagement.  Patients’ beliefs have been shown to influence treatment adherence in 
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chronic illness (DiMatteo, Haskard & Williams, 2007).  It is likely that perceived QOL 
benefits can impact adherence to intensive diabetes management.  Limited evidence 
has shown that intensive DM management can increase QOL (Bendik et al., 2009; 
Hanberger, Ludvigsson, & Nordfeldt, 2009; Menard et al., 2007).  However, other QOL 
studies in IDDM related to basal-bolus insulin management have shown mixed findings, 
partially due to inadequate measurement of QOL.  As DM is a self-managed disease, it is 
important to understand the impact of intensive insulin management on health-related 
QOL (HRQOL). 
Purpose 
The study examined the quality of life in patients with type 2 diabetes according 
to type of glycemic management.  In this study, quality of life is assumed to be a 
multidimensional construct, including biological, symptomatic, functional, and 
comprehensive factors.  Guided by the revised Wilson and Cleary Model for Health-
Related Quality of Life, the study utilized psychosocial instruments and hemoglobin A1C 
testing to comprehensively assess quality of life in patients with type 2 diabetes 
according to insulin management strategy. 
Theoretical Framework 
Wilson and Cleary (1995) proposed a conceptual model of health-related QOL 
(HRQOL) to define and clarify the multifactorial nature of QOL as related to health.  The 
model was modified by Ferrans, Zerwic, Wilbur, and Larson (2005) to depict the 
individual and environmental factors that influence HRQOL (Figure 1).  In the model, 
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both the environment and the individual can impact patient outcomes, all of which 
contribute to HRQOL.  Patient outcomes comprise the center of the model and are 
divided into five types of measures: biological, symptoms, functional status, general 
health perceptions, and overall QOL (Ferrans et al., 2005).  The five types are causally 
linked to each other, and all are influenced by individual and environmental 
characteristics.  Biological measures are basic physiologic variables such as labs, vital 
signs, and body mass index.  Symptoms are the physical, emotional, and psychological 
symptoms reported by the patient.  Functional status refers to the patient’s ability to 
function physically, psychologically, socially, and in assumed roles.  General health 
perceptions include the patient’s subjective evaluation of health, including biological, 
symptom-related, and functional influences.  Finally, overall quality of life is the 
patient’s general satisfaction with life as a whole.  The model acknowledges that 
relationships between model components may be reciprocal but typical directionality is 
indicated in the arrows (Figure 1).  The revised Wilson and Cleary model is useful in 
directing the assessment of DM-related QOL because it is multidimensional and includes 
individual and environmental influences. 
The concept of quality of life has been depicted in many different ways.  The use 
of a model in quality of life research provides an organizing framework and description 
of a complex concept.  The Revised Wilson and Cleary model has been used to study 
QOL in a few distinct populations: 1) persons on hemodialysis (Kring, 2008), 2) persons 
with HIV and liver problems (Henderson, 2007), and 3) patients with T2DM (Chia, 2007).  
7 
 
 
For patients with T2DM, Chia (2007) found the model to be valid in relating 
demographic and physiological variables to QOL.  The only weakness in using this model 
in studying QOL in intensive insulin management of DM is that it does not emphasize 
the complex nature of diabetes self-management.  However, self-management can be 
included in the functional status component of the model.  The model is depicted in 
Figure 1. 
 
 
Figure 1.  Revised Wilson and Cleary Model of Health-Related Quality of Life 
 
Specific Aims 
The aims for this study were (1) to describe the HRQOL of persons with T2DM   
Biological 
function 
Functional 
Status 
Symptoms General 
Health 
Perceptions 
Overall 
quality of 
life 
Characteristics of 
the individual 
Characteristics of 
the environment 
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according to type of glycemic management [Oral meds only, Basal insulin only (once or 
twice daily), Basal-bolus insulin (three or more times daily)], (2) to determine if HRQOL 
of persons with T2DM differs depending on type of glycemic management, and (3) to 
determine if type of glycemic management is predictive of HRQOL after controlling for 
covariates.   
In summary, QOL in T2DM is a critical construct which has not been adequately 
studied.  The impact of glycemic management strategies in T2DM on QOL has not been 
determined.  The revised Wilson and Cleary Model of Health-Related Quality of Life was 
used to guide this study of the impact of insulin management on QOL in T2DM.  Aims of 
the study included describing and determining QOL differences based on glycemic 
management strategy which provided greater insight into QOL in T2DM.
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CHAPTER TWO 
LITERATURE REVIEW 
 A literature search was conducted to examine the relationship between 
intensive diabetes management of DM and QOL which included the years 1996 to 2009 
and 32 articles were identified.  All articles examined quality of life in intensively 
managed DM.  Databases searched were CINAHL, Medline, PsycINFO, Cochrane, Pub 
Med, and SSCI.  Search limits included English language, human, and research articles.  
Keywords included:  insulin, diabetes, diabetes mellitus, quality of life, flexible, multiple 
daily, intensive, insulin pump, continuous subcutaneous insulin, and CSI*.  Since that 
time, there have been 12 new studies which are included at the end of this review.   
Results 
 For the 32 studies, the majority of studies in the literature review (n=18) 
examined QOL in patients already using intensive diabetes management.  The remaining 
studies (n=14) compared various types of intensive diabetes management with 
traditional treatment, typically fixed-dose insulin.  Of the 32 studies in the literature 
review, five studies examined QOL in CSII; ten studies compared QOL in CSII vs. MDI 
(Table 1).  Ten studies evaluated MDI subjects only (Table 1).    Seven studies examined 
intensive diabetes management by combining CSII and MDI subjects in the same group 
(n=3) or intensifying the subjects’ prior regimens (n=4; Table 1).  To summarize the 
10 
 
 
 
studies, QOL outcomes will be reported in biologic, symptomatic, psychosocial, and 
functional dimensions. 
Table 1.  Intensive Diabetes Management Studies: Sample, Design, and Outcomes 
Study Sample Design Outcomes 
CSII only 
Aberle, 2009 n=51 German patients 
w/T1DM 
Age 36.5±12yr 
59% female 
Educational years 11±3 
DM Duration 19±10 
years 
Cross-
sectional 
descriptive 
Glycemic control, QOL, 
treatment satisfaction, 
depressive symptoms, 
coping style, locus of control, 
self-efficacy 
Bruttomesso, 
2002 
n=138 Italian patients 
w/ T1DM 
Age 33±1 years 
64% female 
DM duration 13.1±0.7 
years 
Cross-
sectional: 
Retrospective 
descriptive 
Glycemic control, QOL 
(partial data only), severe 
hypoglycemia, DKA  
Gimenez, 
2007 
n=153 Spain patients 
w/ T1DM 
Age 35±11 years 
71% female 
DM duration 18.5±9.5 
years 
Longitudinal: 
Prospective, 
observational 
Glycemic control, QOL, 
severe hypoglycemia, 
hypoglycemia 
Linkeschova, 
2002 
n=103 German patients 
w/ T1DM 
Age 33±11 years 
56% female 
27% with late 
complications of DM 
Longitudinal: 
Pre-Post 
Observational 
Glycemic Control, Severe 
Hypoglycemia; QOL; 
treatment satisfaction 
Ritholz, 2007 n=30 US patients w/ 
IDDM, CSII users 
Age 47±9.5 
59% female 
97% white, 76% 
married 
A1C: low (6.8±0.4%) 
Qualitative: 
Focus Groups 
Psychosocial factors, self-
care, emotional reactions 
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mid (7.8±0.3%) high 
(9.1±0.5%) 
DM duration 27.3±13.1 
years 
educational years 
15.4±1.5 
CSII vs. MDI 
Barnard & 
Skinner, 2008 
n=642 U.K. patients w/ 
T1DM 
Age 45±14 
69% female 
DM duration 24±12 
years 
Cross-
sectional 
matched 
group survey 
QOL, treatment satisfaction, 
hypoglycemia fear, “problem 
areas” in DM, glycemic 
control (proxy measure via 
SMBG frequency) 
DeVries, 2002 All Dutch patients 
w/T1DM in poor 
control (A1C≥8.5%) 
Group A: n=39, age 
36±10, 46% female, DM 
duration 18±10 years, 
49% retinopathy;   
Group B: n=40, age 
37±11, 47% female, DM 
duration 18±9 years, 
42.5% retinopathy 
RCT:  Cross-
over 
Glycemic control; QOL 
Doyle, 2004 All U.S. youth w/T1DM, 
age range 8-21 years;  
Group A: n=16, age 
12.5±3.2, 63% female, 
68% Caucasian, 19% 
Hispanic, 13% Black,  
DM duration 7±4 years 
Group B: n=16, age 
13±2.8, 50% female, 
81% Caucasian, 13% 
Hispanic, 6% Black,  DM 
duration 6±4 years 
RCT Glycemic control, QOL 
(incomplete data) 
EQuality1 
Study Group, 
2008 
All Italian patients w/ 
T1DM, 69% employed 
Group A: n=481, age 
35±11, 57% female; 
Cross-
sectional 
case-control 
Glycemic control; QOL; 
treatment satisfaction 
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31% retinopathy;  
Group B: n=860, age 
35±12, 46% female, 
22% retinopathy 
Herman, 2005 All U.S. older adults 
w/T2DM (IDDM), age 
>60 years (mean age 
66±5);  
Group A: n=53, 28% 
female, 81% Caucasian, 
8% Hispanic, 8% Black,  
DM duration 17±9 yr, 
42% retinopathy;   
Group B: n=54, 64% 
female, 91% Caucasian, 
4% Hispanic, 4% Black,  
DM duration 15±9 yr; 
36% retinopathy 
RCT Glycemic control; QOL; 
hypoglycemia; treatment 
satisfaction 
Hoogma, 
2006 
All European patients 
w/ T1DM 
Group A: n=129, age 
37±11, 53% female; 
Group B: n=127, age 
35±10, 52% female 
RCT: 2-way 
crossover 
Glycemic control, 
Hypoglycemia; QOL; severe 
adverse events 
Hoogma, 
2004 
All Dutch patients 
w/T1DM 
Group A: n=49, age 
41±11,73% female, 65% 
had DM duration >10 
years;   
Group B: n=79, age 
43±15 yr, 46% female, 
73% had DM duration 
>10 yrs. 
Cross-
sectional 
Glycemic control; QOL; 
treatment satisfaction, well-
being 
Kamoi, 2004 All Japan patients w/ 
T1DM 
Group A: n=16, age 
48±17, 62.5% female, 
DM duration 7±6 yr, 
13% retinopathy 
Longitudinal: 
Prospective 
experimental  
Glycemic control; QOL; 
hypoglycemia  
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Group B: n=12, age 
55±13, 66% female, DM 
Duration 21±7.9yr, 25% 
retinopathy 
Scheidegger, 
2007 
All Swiss patients 
w/T1DM 
Group A: n=78, age 
43±13, 47% female, DM 
duration 19±11 yr, 29% 
retinopathy, 73% 
professional education, 
86% working;  
Group B: n=81, age 
42±11, 48% female, DM 
duration 17±11 yr, 27% 
retinopathy, 72% 
professional education, 
89% working 
Cross-
sectional  
Glycemic control; QOL, 
treatment satisfaction, 
severe hypoglycemia 
Group L: n=19, age 
43±11, 74% female, DM 
duration 18±11 yr, 47% 
retinopathy, 68% 
professional education, 
79% working 
Longitudinal 
study 
Tsui, 2001 All Canadian patients 
w/T1DM 
Group A: n=13, age 
36±12, 38% female, DM 
duration 17±10 years;  
Group B: n=14, age 
36±10, 29% female, DM 
duration 15±9yr 
RCT Glycemic control, 
Hypoglycemia; QOL 
MDI only 
Bendik, 2009 n=45 Swiss patients w/ 
T1DM 
age 41 (range 18-74), 
47% female, DM 
duration 10 (range 1-
49) years 
Longitudinal: 
Pre-Post 
Glycemic control; QOL; 
severe hypoglycemia, locus 
of control, DM knowledge, 
SMBG frequency 
DAFNE, 2002 N=169 U.K. patients w/ RCT: control Glycemic control; severe 
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T1DM in moderate 
glycemic control (HA1c 
7.5-12%), age 40±9 yr, 
56% female, 37% 
retinopathy 
crossover hypoglycemia; QOL; 
Psychological well-being; 
treatment satisfaction, CV 
risk factors 
Gale, 2000 n= 93 U.K. patients w/ 
T1DM, on MDI 
Age 35 (range 18-63), 
47% female 
DM duration 13 (range 
1-51) years 
RCT Glycemic control; QOL; 
hypoglycemia 
Jansa, 2006 All patients in Spain w/ 
T1DM, 100% employed 
or full-time students, 
race unspecified;  
Group A: n=19, age 
27±11, 47% female, DM 
duration 12±6 years;  
Group B: n=16, age 
23±5, 31% female, DM 
duration 10±6 years 
RCT Glycemic control; QOL; 
hypoglycemia; self-
management (SMBG, insulin 
dose adjustment frequency), 
DM knowledge  
Kalergis, 2000 n=15 Canadians w/ 
T1DM; Age 38 (range 
23-59 yr); 60% female; 
race unspecified 
RCT: 
crossover 
Glycemic control; QOL, self-
efficacy, stress, perceived 
complexity 
Langewitz, 
1997 
n=43 Swiss patients 
w/T1DM, Age 33±10, 
61% female, DM 
Duration 15±10 years 
Longitudinal: 
Pre-Post  
Glycemic control; QOL; 
severe hypoglycemia, 
anxiety, depression; self-
determination/responsibility; 
hierarchy MD-patient 
Lowe, 2008 n=137 Australians 
w/IDDM; age 47±15 
years; 55% female; 40% 
T2DM 
Longitudinal: 
Prospective 
Observational 
Glycemic control; self-
efficacy; QOL 
Manini, 2007 All Italian patients w/ 
T1DM 
Group A: n=47, age 46 
(range 25-74), 46% 
female, DM duration 19 
(range 4-61) years, 32% 
Longitudinal: 
Pre-post, 
external 
group used as 
controls 
Glycemic control; QOL, 
hypoglycemia 
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retinopathy;  
Group B: n=40, age 44 
(range 23-70), 36% 
female, DM duration 22 
(range 7-60) years; 17% 
retinopathy 
Pfutzner, 
1996 
n=107 German patients 
w/ T1DM; age 32±10 
years; 50% female 
DM duration 10±8 
years 
RCT: control 
crossover 
Glycemic control; QOL; 
glucose variability, 
hypoglycemia, adverse 
events 
Zoppini, 2003 All Italian patients w/ 
T1DM 
Age 26±6 yr, 43% 
female, Duration DM 
14±7 years  
Cross-
sectional 
Glycemic control; QOL 
Intensive Diabetes Management 
Ashwell, 2008 n=48 U.K. patients w/ 
T1DM; 62.5% female; 
Group1: Age 42±14  
Group2: Age 42±9   
RCT: 2-way 
crossover 
QOL; treatment satisfaction 
Chantelau, 
1997 
All German patients w/ 
IDDM 
Group A: n=77, Age 
32±9, 49% female, 30% 
retinopathy, 49% white 
collar job; Group B: 
n=55, Age 31±8; 49% 
female; 35% 
retinopathy; 62% white 
collar job 
Longitudinal: 
Prospective 
Cohort (self-
selected) 
Glycemic control; QOL 
(satisfaction) 
DCCT 
Research 
Group, 1996 
n=1441 US patients w/ 
IDDM, age 27±0.3 yrs., 
96% Caucasian;  
Group A: 49% female, 
51% retinopathy;  
Group B: 46% female, 
48% retinopathy 
RCT: 
Longitudinal 
Glycemic control; DM 
complications; QOL, 
psychiatric symptoms, 
psychosocial event data 
Forlani, 2006 All Italian patients w/ 
T1DM 
Longitudinal: 
Experimental 
Glycemic control; QOL; 
mood/emotional status 
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Group A: n=54, age 43 
(range 18-65), 62% 
female; 17% 
retinopathy 
Group B: n=36, age 41 
(range 26-65), 34% 
female, 37% 
retinopathy 
Pre-Post 
(refusers as 
controls) 
Insabella, 
2007 
n= 117 U.S. youth 
w/T1DM 
Age 14.4±2, 61.5% 
female, 93% Caucasian, 
3.5% Hispanic, 3.5% 
black,  DM duration 
5.7±3.7 years 
Longitudinal: 
Prospective 
Glycemic control; QOL, 
depressive symptoms, 
functional outcomes, DM 
complications 
Schiel & 
Muller, 1999 
All German patients w/ 
IDDM (T2) 
Group A: n=40, Age 
51±7, 22% female, 23% 
disabled;  
Group B: n=77, Age 
54±5.9, 41% female, 
26% disabled 
Cross-
sectional 
descriptive 
Glycemic control; QOL; 
treatment satisfaction; 
acute/long-term 
complications 
Weinger, 
2001 
n=55 US patients w/ 
T1DM using intensive 
diabetes management, 
age 34±8, 56% female, 
DM Duration 9±3 years, 
NO complications 
Longitudinal: 
Pre-post 
Glycemic control; QOL, 
emotional distress, hypo-
glycemia fears, DM hassles, 
“problem areas” in DM, self-
management problems, 
SMBG frequency 
 
Note.  CV = cardiovascular; CSII = continuous subcutaneous insulin infusion; DKA = diabetic ketoacidosis; 
DM = diabetes mellitus; MDI = multiple daily injections; QOL = quality of life; RCT = randomized controlled 
trial; SMBG = self-monitoring of blood glucose; T1DM = type one diabetes mellitus; T2DM = type two 
diabetes mellitus 
Intensive Diabetes Management:  QOL Dimensions 
Biologic 
Biologic dimensions of QOL range from demographic factors to glycemic control   
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and diabetic complications.  All have the potential to impact QOL in IDDM.  Glycemic 
control, as measured by A1C, is reported as an outcome in the majority of diabetes 
studies over the past 30 years (Jeffcoate, 2004).  Glycemic control was measured by A1C 
in 31 of 32 studies.  The literature has documented weak relationships between QOL 
and improved A1C (Barnard, Lloyd & Skinner, 2007).  Glycemic variability was examined 
in select studies of the literature review via glucose profiles, or graphs of seven-point 
daily SMBG results (DeVries, Snoek, Kostense, Masurel & Heine, 2002), and post-
prandial glucose excursions (Pfutzner et al., 1996).   The majority of the studies’ subjects 
were in young to middle adulthood, with the exception of older adults in Herman et al. 
(2005) and two studies of “youth”, inclusive of adolescents and young adults (Doyle et 
al., 2004; Insabella, Grey, Knafl & Tamborlane, 2007).  Subjects’ age had no significant 
impact on QOL findings.  Diabetes complications (micro- and/or macrovascular) were 
assessed at baseline by ten studies (Bruttomesso et al., 2002; Chantelau, Schiffers, 
Schutze & Hansen, 1997; EQuality1 Study Group, 2008, Herman et al., 2005; Insabella et 
al., 2007; Kamoi, Miyakoshi & Maruyama, 2004; Linkeshova, Raoul, Bot, Berger & Spraul, 
2002; Manini et al., 2007; Schiel & Muller, 1999; Zoppini, Carlini & Muggeo, 2003).  QOL 
effects according to DM complication rates were not reported in these 10 studies; 
however, other studies have examined QOL in DM with complications. The presence of 
co-morbid diagnoses and DM-related complications significantly decreases QOL in 
patients with type 2 DM (Goddijn et al., 1999; Lloyd, Sawyer, & Hopkinson, 2001; Solli, 
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Stavem & Kristiansen, 2010).  In the absence of late-stage complications of DM, higher 
QOL and better glycemic control has been reported in patients with Type 1 diabetes 
(T1DM; Bott, Mulhauser, Overmann & Berger, 1998).  Duration of DM was reported in 
21 studies; however, none reported a relationship with QOL.  In patients with T2DM 
treated with oral medications only, increased duration of DM is associated with 
decreased psychological QOL (β = -0.29, SD = -5.87, P = 0.007; Fal et al., 2010).  The 
majority of the studies do not mention subjects’ race or ethnicity.  This may be due to 
the European origin of many studies in the literature review. 
Prescribed method of DM control is a biological factor related to QOL.  The 
Diabetes Control and Complications Trial (DCCT, 1993), provided strong evidentiary 
support for the use of intensive diabetes management as a method for preventing or 
delaying DM-related complications.  QOL did not differ between groups of experimental 
and control DCCT subjects and remained stable over time (DCCT, 1993).  In other 
studies, intensification of DSM to MDI regimens using analogue insulin was associated 
with improved QOL over time (Manini et al., 2007; Ashwell, Witthaus, Bradley, Home & 
Stephens, 2008). Intensive insulin management may provide QOL benefits in 
comparison to fixed-dose insulin therapy; at the very least, it has not been associated 
with QOL deterioration.  Research has not conclusively proven which type of intensive 
insulin management, CSII vs. MDI, is superior as related to QOL.  Studies comparing CSII 
and MDI have shown mixed findings.  Of the reviewed articles, six studies have shown 
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significantly improved QOL scores in CSII subjects (Barnard & Skinner, 2008; DeVries et 
al., 2002; EQuality1 Study Group, 2008; Hoogma et al., 2006; Kamoi et al., 2004; 
Scheidegger, Allemann, Scheidegger & Diem, 2007).  Four studies showed no difference 
in QOL results between groups of CSII vs. MDI (Doyle et al., 2004; Herman et al., 2005; 
Hoogma et al., 2004; Tsui, Barnie, Ross, Parkes & Zinman, 2001).  It should be noted that 
all four studies had relatively small samples (n= 32, 107, 49, 27), decreasing the 
likelihood of detecting significant findings.  Method of intensive insulin management is 
one biological factor that may impact QOL in DM. 
QOL in intensively managed DM has been largely studied in T1DM.  The majority 
of reviewed studies examined subjects with T1DM only, with the exception of two 
studies that enrolled all adults with T2DM (Herman et al., 2005; Schiel & Muller, 1999), 
and Lowe, Linjawi, Mensch, James, and Attia (2008), who had a mixed sample of T1 and 
T2DM patients.  These studies had mixed findings on the relationship between QOL and 
intensive diabetes management.  In Herman et al. (2005), both groups of adults with 
T2DM reported increased QOL while in the study; however, subjects using intensive 
diabetes management did not show a significant difference from controls.  In an 
admittedly underpowered small study (n=117), Schiel and Muller (1999) were unable to 
detect group differences between subjects using basal-bolus or fixed-dosing of insulin.  
Lowe et al. (2008) reported a borderline improvement in QOL (p=.05) among subjects 
using intensive diabetes management; however, approximately 75 percent of subjects 
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had missing data or did not complete the program.  The study of QOL in intensively 
managed T2DM is incomplete.  There is a need to study this phenomenon in persons 
with T2DM, especially as it is becoming more prevalent.  Type 2 diabetes is closely 
related to sedentary lifestyle and obesity—all are rising to epidemic levels in the United 
States.  In the last 30 years, the incidence of T2DM has doubled in adults (Fox et al., 
2006).  In 2012, the prevalence of DM was 12.3 percent of U.S. adults, with 90 to 95% 
T2DM (CDC, 2014).  More than one-fourth of adults with DM are insulin-dependent 
(with or without oral medication; CDC, 2014).  Experts recommend the early initiation of 
insulin therapy in T2DM to protect beta cell mass and function (DeFronzo, 2009; 
Niswender, 2009).  For patients with insulin-dependent T2DM, glycemic control is still 
the primary goal, best achieved through intensive diabetes management (DeFronzo, 
2009).  Many patients with insulin-dependent T2DM are not using intensive diabetes 
management; however, this is expected to change due to the epidemic of T2DM in this 
country (Niswender, 2009).  Although related, T1 and T2DM are not the same illness, 
differing in age of onset, pathophysiology, progression, duration, and severity.  QOL in 
intensively managed T1 and T2DM cannot be assumed to be the same.  
Symptoms 
Many DM-related symptoms exist, including those related to hypo- or 
hyperglycemia.  Hypoglycemia is considered to be particularly dangerous and disruptive 
to patients with DM; indeed, hypoglycemia has been noted to be the single most 
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limiting factor to obtaining tight glucose control (Cryer, 2008; Heller, 2008).  Intensive 
insulin management increases the frequency of hypoglycemia (DCCT, 1993): one 
estimate reported that on average, a patient with intensively managed T1DM 
experiences up to 10 episodes of symptomatic hypoglycemia per week and at least one 
episode of severe hypoglycemia per year (Briscoe & Davis, 2006). However, 
hypoglycemia is somewhat abated by the use of rapid-acting analogues and CSII (Cryer 
2008; Heller, 2008; Pfutzner et al., 1996; Gale, 2000).  CSII may be associated with less 
frequent or severe hypoglycemia than MDI (Fatourechi et al., 2009).  QOL is decreased 
by hypoglycemia that is frequent (Tierney et al., 2008) or severe (Davis et al., 2005).  Of 
the studies reviewed, over half assessed hypoglycemia by patient report, medical record 
review, or glucose meter downloading (n=19; Table 2).  Most useful is the assessment of 
severe hypoglycemia, defined as hypoglycemia requiring assistance of another person.  
Severe hypoglycemia is disruptive, alarming, and dangerous, producing significantly 
negative QOL effects.  Thirteen of the reviewed studies examined rates of severe 
hypoglycemia (Table 2).  Significant decreases in severe hypoglycemic episodes were 
strongly associated with QOL improvement in five studies (Table 2).  Changes in mild or 
overall hypoglycemia were shown to be associated with QOL improvement in a few 
studies (n=4; Table 2).  For patients treated with insulin, regardless of DM type, 
hypoglycemia is a frequent reality, with overall (mild to severe) prevalence of up to 93 
percent (Zammitt & Frier, 2005).  Hypoglycemia is less frequent in insulin-dependent 
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T2DM, with a rate of 16 events of overall hypoglycemia per patient-year, compared to 
43 events per patient-year in T1DM (Briscoe & Davis, 2006).  Due to physiologic 
differences, patients with T2DM experience hypoglycemia with less severity and more 
warning symptoms (Zammitt & Frier, 2005).  Only one study examined hypoglycemia 
and QOL in T2DM; no significant relationships were detected (Herman et al., 2005).   
Table 2.  Hypoglycemia and Quality of Life: Longitudinal Studies and Randomized 
Controlled Trials 
Study 
Hypoglycemic Frequency QOL effects 
Other 
Baseline Follow-up Baseline Follow-up 
Severe Hypoglycemia 
Bendik, 2009  Events/6 months DQOL: ↓score= ↑QOL  
.33  .03 * 91.8±22.5 85.6±20.0*** 
Bruttomesso, 
2002 
Events/year DQOL  
.31±0.07  .09±0.02 ** -- 73.0±1.8 
DAFNE, 2002 % patients with ≥1 event/6 
months 
ADDQOL: AWI QOL between 
groups at 6 
months** Experimental  22 18 -2.0±1.6 -1.6±1.6 
Controls 11 15 1.9±1.3 -1.9±1.4 
DCCT, 1996  ≥1 event in 
last year 
Events/100 
patient-years 
DQOL: 
 
No change in 
QOL  
Intensive 
5% of 
subjects 
62*** 78±8 78±9 
Controls 
4% of 
subjects 
19  78±9 78±9 
Doyle, 2004 Events/16 weeks 
No change in QOL; data 
not reported 
Baseline 
HYPO not 
reported 
CSII -- 2 
MDI -- 5 
Gimenez, 
2007 
Events/patient-year DQOL: impact All subscales 
of DQOL 
improved, no 
total scores 
given 
Severe HYPO 0.31±0.46 0.07±0.25*** 
44.8±9.5 39.5±7.4*** Overall HYPO 
(>5/week) 
44% of 
subjects 
5% of 
subjects*** 
Herman, Events/patient-year DQOL-CTQ: Impact scores Severe HYPO 
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2005 increased +2 points from 
baseline in both 
groups**, no between 
group differences 
shown/no 
differences in 
mild HYPO; 
T2DM’s 
CSII -- .08 
MDI 
-- .23 
Hoogma, 
2006 
Events/patient-year DQOL total: ↓severe 
HYPO and 
↑QOL in CSII 
at follow-
up*** 
CSII -- 0.2 -- 75 
MDI 
-- 0.5 -- 71 
Insabella, 
2007 
No events 
in last 6 
months 
16.7 events/ 
100 patient-
years 
DQOL-Y: Impact Severe HYPO 
increased, no 
sig reported 
47±3 43±6 (n.s.) 
Langewitz, 
1997 
% of patients w/ event last 
year 
DQOL: satisfaction  
18.6 7* 33.3±8 25.8±7.7*** 
Linkeschova, 
2002 
Cases/patient-year All subscales of DSQOLS 
improved (p=.025-.000); 
no total scores given 
 
0.70 0.06*** 
Scheidegger, 
2007 
 
50 events in 
228 subject-
months 
1 event in 
104 subject-
months 
DSQOLS: 
248±45 
 
277±34* 
No sig. 
reported for 
HYPO data 
 
Tsui, 2001 No between-group or over 
time differences 
No between-group or 
over time differences 
Severe and 
mild HYPO 
Mild Hypoglycemia 
DeVries,2002  Events/week SF-36: General, Mental No 
differences in 
severe HYPO 
(not shown) 
CSII 2.13±2.05  .98±2.02* -- +5.9*,  +5.2 
MDI 1.97±1.53  -.02±1.18  --  -1.2, -0.6 
Jansa, 2006 % of patients with ≥3 
events/ week 
DQOL: Impact No between-
groups 
differences at 
any time; 
Only DQOL 
impact scale 
sig. (others 
n.s.) 
Telecare 75 6*** 44±6 41±7 (n.s.) 
Controls 79 15*** 43±7 38±6* 
Nocturnal Hypoglycemia 
Gale, 2000 Events/month No change in QOL; no 
scores reported 
Overall HYPO 
rates not Lispro -- 0.7 ±1.6*** 
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Controls -- 1.8±3.1 shown (n.s.) 
Overall Hypoglycemia 
Kalergis, 
2000 
20 events/100 patient-years 
DQOL (total scaled 
score): 2.0±0.1 
 
No change 
from baseline 
or between 
groups 
Kamoi, 2004 Events/3 months ITR-QOL: Odd HYPO 
stats  (n.s.); 
QOL 
difference 
between 
groups** 
MDI 10.8±23.9  6.3±12.6 80.2±20.9 86.3±21.8 
CSII 
0.9±1.6  0.5±1.4  99.4±13.3 101.8±11.6 
Pfutzner, 
1996 Events/month 
QOL: satisfaction 
improved in lispro group; 
no differences in other 
domains 
No baseline 
HYPO rates 
reported; less 
HYPO during 
lispro (than 
w/ regular 
human 
insulin)** 
Lispro -- 8.57±0.7 ** 
Controls 
-- 9.61±0.72 
Note.  --  No data provided by study authors.   
ADDQOL-AWI = Audit of Diabetes-Dependent Quality of Life—Adjusted Weighted Index; CSII = continuous 
subcutaneous insulin infusion; DQOL = Diabetes Quality of Life instrument; DQOL-CTQ = Diabetes Quality 
of Life—Clinical Trial Questionnaire; DQOL-Y = Diabetes Quality of Life—Youth; DSQOLS = Diabetes-
Specific Quality of Life Scale; HYPO = hypoglycemia; ITR-QOL = Insulin therapy-related—Quality-of-Life 
instrument; MDI = multiple daily injections; QOL = quality of life; SF-36 = Medical Outcomes Study Short 
Form-36; T2DM = type two diabetes mellitus 
*p<.05, **p<.01, ***p<.001 
 
Hyperglycemia can also impact QOL.  In patients with T2DM, symptoms of high 
blood sugar have been associated with decreased QOL (Goddijn et al., 1999).  Symptoms 
of hyperglycemia were assessed in the DCCT (1996) and by Jansa et al. (2006); no 
relationship between these symptoms and QOL was detected.  Diabetic ketoacidosis, 
usually requiring hospitalization, has substantial potential to impact QOL and was 
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assessed by six studies (Bruttomesso et al., 2002; Doyle et al., 2004; Gimenez et al., 
2007; Linkeschova, Raoul, Bott, Berger & Spraul, 2002; Schiel & Muller, 1999; Tsui et al., 
2001).  Symptoms related to glycemic extremes have strong effects on QOL. 
Patients with DM have other symptoms which can affect QOL.  More recently, 
symptoms of emotional distress (e.g., anxiety, depression, DM-related distress) have 
also been shown to have a significant impact of QOL as well.  Psychological distress is 
reportedly experienced by one-third of young adults with T1DM (Hislop, Fegan, 
Schlaeppi, Duck & Yeap, 2008).  In a study of 51 adults on CSII, depressive symptoms 
significantly correlated with lower QOL (r=-0.542, p<0.01; Aberle et al., 2009).  As 
compared to peers without DM, patients with T2DM have increased depression, which 
results in decreased QOL, especially in those patients prescribed insulin (Aikens, Perkins, 
Piette & Lipton, 2008).  Less depressive symptoms and DM-related distress are related 
to improved QOL and glycemic control (Langewitz, Wossmer, Iseli & Berger, 1997).  
Other studies have examined psychological symptoms as related to QOL, including 
anxiety and DM-related distress (Table 3).  Presence of symptoms due to complications 
of DM can decrease QOL (Garratt, Schmidt, Mackintosh & Fitzpatrick, 2000).  Chronic 
pain and visual impairment are associated with decreased QOL in patients with T2DM 
(Boutoille, Feraille, Maulaz & Krempf, 2008; Smith et al., 2008).  In the literature review, 
no significant relationship between QOL and DM-complications was reported; however, 
this relationship was not often examined.  One unexpected finding was the decreased 
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energy levels in patients with T2DM on basal-bolus insulin management, compared to 
controls using fixed insulin dosing (Schiel & Muller, 1999).  Patients with DM have 
reported increased suicidal thoughts and lower QOL than similar peers without DM 
(Pompili et al., 2009).  Clearly, many symptoms can affect QOL in patients with IDDM. 
Table 3.  Psychosocial Outcomes and Quality of Life  
Outcome 
Study Design 
Cross-Sectional Longitudinal RCT 
Depressive 
Symptoms or 
Depression 
Aberle, 2009 Insabella, 2007 
Langewitz, 1997 
 
Anxiety  Langewitz, 1997  
Coping Aberle 2009   
Self-efficacy Aberle, 2009 Linkeschova, 2002 
Lowe, 2008 
 
Locus of Control Aberle, 2009   
Self-control  Bendik, 2009 
 
 
Self-
determination/self-
responsibility 
 Langewitz, 1997  
DM-related 
emotional distress  
Barnard & 
Skinner,2008 
Bruttomesso, 2002 
Hoogma, 2004 
Zoppini, 2003 
Bendik, 2009 
Chantelau, 1997 
Forlani, 2006 
Gimenez, 2007 
Insabella, 2007 
Langewitz, 1997 
Weinger, 2001 
DCCT, 1996 
Doyle, 2004 
Herman, 2005 
Hoogma, 2006 
Jansa, 2006 
Kalergis, 2000 
Tsui, 2001 
Social worries  Bruttomesso, 2002 
Hoogma, 2004 
Scheidegger, 2007 
Zoppini, 2003 
Bendik, 2009 
Chantelau, 1997 
Gimenez, 2007 
Insabella, 2007 
Langewitz, 1997 
Linkeschova, 2002 
Scheidegger, 2007 
Weinger, 2001 
DCCT, 1996 
Doyle, 2004 
Herman, 2005 
Hoogma, 2006 
Jansa, 2006 
Kalergis, 2000 
Tsui, 2001 
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Well-being  Forlani, 2006 DAFNE, 2002 
Note. DCCT = Diabetes Control and Complications Trial; DM = diabetes mellitus; RCT = Randomized 
Controlled Trial 
Psychosocial 
For patients with IDDM, psychosocial dimensions can have considerable impact 
on QOL.  Intensive diabetes management requires self-efficacy and self-motivation.  
Table 3 reports psychosocial constructs examined by studies in the literature review.  
Aberle et al. (2009) found that among CSII users, higher self-efficacy was correlated with 
better QOL and less depressive symptoms (r=0.601 and -0.453 respectively, p<0.01).  In 
the same study, locus of control was found to be the most significant predictor of A1C 
(R2=0.479, p<0.01), with a significant correlation between high external locus of control 
and increased A1C (r=0.56, p<.01).  In a focus group study, an external locus of control 
was commonly found in CSII subjects in poor glycemic control (A1C>8.0%; Ritholz et al., 
2007).  In the same study, focus groups with well-controlled T1DM (A1C<7.0%) reported 
using an active approach to DSM and feeling more “normal” since beginning CSII (Ritholz 
et al., 2007).  Weinger and Jacobson (2001) conducted a prospective study of 55 adults 
with T1DM.  The subjects attended an intensive diabetes management clinic and 
educational program over four to five months.  The study revealed that patients with 
improvements in DM-related emotional distress also improved their glycemic control 
(r=0.38, p<0.02) and satisfaction-related QOL (p<0.001).  Intensive diabetes 
management can impact psychosocial outcomes: initial functional insulin therapy 
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testing showed a reduction in depression and anxiety after training (t=4.37 and 5.52, 
p<0.001; Langewitz et al., 1997).  These preliminary studies clearly indicate a 
relationship between psychosocial outcomes and QOL in intensively managed DM, but 
further inquiry is required. 
Functional Status 
Patients’ ability to function physically, emotionally, and socially is a primary 
determinant of QOL.  Cognitive function is an important component of role 
performance.  Increased AIC over time has been linked to cognitive dysfunction or 
decline in elderly and young adult patients with DM (Munshi et al., 2006; Musen et al., 
2008).  In a large, multi-site, longitudinal randomized controlled trial of patients with 
IDDM, neither intensive insulin management nor severe hypoglycemia had an impact on 
cognitive performance in young adults (Musen et al., 2008).  Physical abilities also affect 
role performance.  Decreased mobility and activity tolerance due to DM-related 
complications has been linked to lower QOL scores (Boutoille et al., 2008).  In a study of 
53 young adult T1DM patients, self-reported regular exercise was significantly 
associated with higher QOL (p<0.05, Forlani, Zannoni, Tarrini, Melchionda & Marchesini, 
2006).  Frequent hypoglycemia is linked to decreased work productivity in patients with 
T1 and T2DM (Davis et al., 2005).  Of the literature reviewed, only four examined 
employment (Forlani et al., 2006; Scheidegger et al., 2007) or functional outcomes 
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(Insabella et al., 2007; Jansa, et al., 2006) as related to QOL; no significant findings were 
reported. 
One critical functional dimension for patients with DM is self-care, or the 
performance of DSM behaviors.  Successful performance of DSM has been linked to 
higher QOL (Ayalon, Gross, Tabenkin, Porath, Heymann & Porter, 2008).  Of the studies 
in the literature review, none reported deterioration in QOL, despite the 
implementation or continuation of complex and time-consuming DSM behaviors.  Some 
studies (n=6), reported increased QOL after changing from fixed-dose to basal-bolus 
insulin management (Bendik et al. 2009; Chantelau et al., 1997; DAFNE Study Group, 
2002;  Langewitz et al., 1997; Linkeshova et al., 2002; Lowe et al., 2008).  Table 4 reports 
self-care practices measured by the studies of the literature review.  SMBG frequency 
was documented in one-fourth of the studies in the literature review (Table 4).  In 
T1DM, increased frequency of SMBG has been linked to improved glycemic control and 
QOL (Schiel & Muller, 1999).  Self-adjustment of insulin doses according to activity, food, 
and SMBG results is an important DSM behavior in intensive insulin management.  
While only measured by a few studies in the literature review, higher frequency of 
insulin dose self-adjustment was associated with improved glycemic control (Jansa et 
al., 2006; Schiel & Muller, 1999) and QOL improvements (EQuality1 Study Group, 2008; 
Jansa et al., 2006). For patients with T2DM using intensive insulin management, self-
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adjustment of insulin doses was not associated with improved QOL (Schiel & Muller, 
1999).   
 
Table 4.  Self-Care Measures and Quality of Life  
Self-care activity 
Study Design 
Cross-sectional Longitudinal RCT 
Diet EQuality1 Study 
Group, 2008 
Lowe, 2008  
Exercise Zoppini, 2003 Lowe, 2008  
SMBG frequency 
Barnard & 
Skinner,2008 
Hoogma, 2004 
Scheidegger, 2007 
Schiel & Muller, 
1999 
Bendik, 2009 
Scheidegger, 2007 
Weinger, 2001 
Doyle, 2004 
Jansa, 2006 
Insulin dose 
adjustment 
EQuality1 Study 
Group, 2008 
Schiel & Muller, 
1999 
 Jansa, 2006 
“Self-management”  Weinger, 2001  
Note.  RCT = Randomized controlled trial; SMBG = self-monitoring of blood glucose 
 
Kalergis et al. (2000) examined the relationship between self-management and 
QOL in a very small study of adults with T1DM (n=15).  Pre-study insulin regimens were 
MDI with minimal to no self-adjustments of insulin doses.  Three treatment strategies 
were used: simplified, qualitative, and quantitative.  In the simplified strategy, subjects 
had a set meal plan and were permitted insulin self-adjustments based on SMBG results 
only.  In the qualitative strategy, subjects were permitted to self-adjust insulin 
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qualitatively based on SMBG results, food intake (according to food exchange lists), 
exercise, and stress.  In the quantitative strategy, subjects used carbohydrate counting, 
insulin-to-carbohydrate ratios, and correction factors to self-adjust insulin doses for 
SMBG results, food intake, exercise, and stress.  All subjects (n=5 per group) followed 
each strategy for 3.5 months before rotating.  The groups did not significantly differ in 
terms of metabolic control (A1C), frequency of severe hypoglycemia, QOL, or self-
efficacy.  As expected, the most frequent dose adjustments were made in the 
quantitative regimen (p<0.01).  The same strategy, quantitative, was also perceived as 
the most complex (p<0.001).  Surprisingly, at the conclusion of the study, the majority of 
patients (n=12) chose to continue with the qualitative regimen, whereas only three 
subjects continued with the quantitative strategy.  The authors concluded that patients 
with T1DM would prefer an intensive insulin management regimen that maximizes 
flexibility but does not require very complex calculations of insulin dosing.  The study 
provides a unique outlook on intensive diabetes management; however, larger studies 
must be conducted before conclusions can be drawn. 
Basal-bolus insulin management requires a high degree of DSM and can provide 
better glycemic control.  During periods of glycemic control, persons with DM are able 
to optimize their social and role functioning.  However, mood disturbances and DM-
related distress can affect self-management and glycemic control.  Depressive 
symptoms occur in many patients with T1 and T2DM.  In a study of adults with T1DM, 
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increased prevalence of anxiety in women and depression in men was reported 
(Shaban, Fosbury, Kerr & Cavan, 2006). In patients with T2DM, a meta-analysis 
estimated the rate of depression to be 17.6 percent, or 1 out of every 6 adults with 
T2DM (Ali, Stone, Peters & Khunti, 2006).  Patients with DM and mood disturbances 
have decreased glycemic control (Hislop et al., 2008) and self-care (Ciechanowski, Katon, 
Russo, & Hirsch, 2003).  Stress, coping skills, and depressive symptoms have an impact 
on self-care practices (Peyrot, McMurry & Kruger, 1999) and glycemic control 
(Ciechanowski et al., 2003) in DM.  Pediatric patients with T1DM and depression have 
poorer glycemic control, adherence, and QOL than their non-depressed peers (Hassan, 
Loar, Anderson & Heptulla, 2006; Korbel, Wiebe, Berg & Palmer, 2007).  Negative 
stressors and DM-related distress have been linked to decreased self-care in DM (Lloyd, 
Smith & Weinger, 2005).  None of the studies in the literature review examined 
depressive symptoms, DSM, and QOL; however, Weinger and Jacobson (2001) 
demonstrated that patients with high DM-related distress have worse glycemic control 
and self-management, despite interventions (p<.05).  Depressive symptoms can affect 
self-management and glycemic control, leading to a decrease in overall functional 
status.  Although the relationships between depression, glycemic control, and functional 
status are not fully established, it is clear that all contribute to QOL.   
Conventional Measurement of QOL 
Many studies have been conducted regarding diabetes and QOL, in both T1DM  
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and T2DM.  In the past, QOL was infrequently used as the primary outcome measure but 
rather a supplemental measure to glycemic control.  Over the last decade, QOL has been 
used as a major study variable, especially in comparisons between CSII and MDI.  The 
relationship between CSII and QOL was examined in a systematic literature review by 
Barnard, Lloyd, and Skinner, finding no clear QOL benefit from CSII use (2007).  A meta-
analysis of children with intensively managed T1DM revealed mixed QOL benefits from 
CSII vs. MDI (Pankowska, Blazik, Dziechchiarz, Szypowska & Szajewska, 2009).  In both 
reviews, the authors noted a problematic lack of consistency in QOL measurement.  In 
many studies, QOL is measured using the Diabetes Quality of Life (DQOL) instrument; 
however, the DQOL may not be sensitive or specific enough to measure HRQOL in 
diabetes, especially when related to treatment differences (Speight, J. in Barnard, Lloyd 
& Skinner, 2007, p.614).  The 32 studies of the literature review utilized over 12 
different instruments to measure QOL (Table 5).  This study is different because it uses 
multiple components to measure the unique factors that contribute to HRQOL.  By 
measuring QOL comprehensively, differences related to type of diabetes management 
will be identified. 
Table 5. Quality of Life Measures Used by Study Design 
QOL Measure 
Study Design 
Cross-Sectional Longitudinal RCT 
ADDQOL (n=3)  Lowe, 2008 Ashwell, 2008 
DAFNE, 2002 
DQOL (n=13) Bruttomesso, 2002 
Hoogma, 2004 
Bendik, 2009 
Chantelau, 1997 
DCCT, 1996 
Hoogma, 2006 
34 
 
 
 
Zoppini, 2003 Gimenez, 2007 
Langewitz, 1997 
Weinger, 2001 
Jansa, 2006 
Kalergis, 2000 
Tsui, 2001 
      DQOL-CTQ (n=1)   Herman, 2005 
      DQOL-Y (n=2)  Insabella, 2007 Doyle, 2004 
DSQOLS (n=3) EQ1 Study Group, 
2008 
Scheidegger, 2007 
Linkeschova, 2002 
Scheidegger, 2007 
 
DTSQ (n=1 primary, 
6 secondary) 
EQ1 Study Group, 
2008τ  
Hoogma, 2004 τ 
(2nd) Schiel & 
Mueller, 1999 τ  
 Ashwell, 2008 τ  
DAFNE, 2002 τ  
DeVries, 2002 τ  
Gale, 2000  
ITR-QOL (n=1)  Kamoi, 2004  
SF-36 (n=2 primary; 
n=4 secondary) 
EQ1 Study Group, 
2008 τ 
 
Forlani, 2006 
Kalergis, 2000 
(MOS) τ 
 
DCCT, 1996 τ 
DeVries, 2002 
Herman, 2005 τ 
SF-12 as secondary 
measure (n=2) 
 Gimenez, 2007 τ Hoogma, 2006 τ 
VITA (n=1) Aberle, 2009   
W-BQ12    DAFNE, 2002 τ  
Gale, 2000 
WED (n=2)  Manini, 2007 
Forlani, 2006 τ 
 
WHO Well-Being 
Questionnaire (n=1) 
Hoogma, 2004 τ    
WHOQOL-BREF 
(n=1) 
Barnard & 
Skinner,2008 
  
Unspecified (n=2) Schiel & Muller, 
1999 
 Pfutzner, 1996 
Note.  ADDQOL = Audit of Diabetes-Dependent Quality of Life; DCCT = Diabetes Control and Complications 
Trial; DQOL = Diabetes Quality of Life instrument; DQOL-CTQ = Diabetes Quality of Life—Clinical Trial 
Questionnaire; DQOL-Y = Diabetes Quality of Life—Youth; DSQOLS = Diabetes-Specific Quality of Life 
Scale; DTSQ = Diabetes Treatment Satisfaction Questionnaire; ITR-QOL = Insulin therapy-related—Quality-
of-Life instrument; QOL = quality of life; SF-12 = Short Form-12; SF-36 = Medical Outcomes Study Short 
Form-36; RCT = Randomized controlled trial; W-BQ12 = Well-Being Questionnaire 12; WED = Well-Being 
Enquiry for Diabetics; WHO = World Health Organization; WHOQOL-BREF = World Health Organization 
Quality of Life-Brief instrument  
τ
 Used as secondary measure  
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Supplemental Literature Review 
A supplemental review of the literature was conducted to describe the current 
status of research related to intensively-managed T2DM and QOL.  The detailed search 
strategy is provided in Appendix A.  The review identified 12 articles reporting the 
findings from nine research projects (Appendix A).  The updated search provides a much 
greater representation of T2DM in intensively-managed DM research; that is, 11 out of 
12 studies exclusively enrolled subjects with T2DM.  The remaining study was primarily 
composed of participants with T2DM (80%; Testa et al., 2012).  Studies have also 
improved in methodology:  of the nine research studies, five are randomized controlled 
trials and four are longitudinal.  None were cross-sectional.  Sample sizes ranged from 
34 to 66,726.  Of the reviewed articles, eight examined multiple daily injections (basal-
bolus; Banerjee, Maji & Baruah, 2013; Hajos et al., 2012; Levin et al., 2011; Opsteen et 
al., 2012; Peyrot & Rubin, 2011; Shah et al., 2011; Testa et al., 2012; Vinagre et al., 
2013), 2 studied CSII (Peyrot et al., 2011 and Rubin et al., 2010), and one reported an 
intensive management educational program (Hermanns et al., 2012).  The remaining 
study examined a decrease in intensity of insulin management and will be discussed in 
detail below (Dieuzeide et al., 2014).   
All studies examined glycemic control, primarily through A1C, but Testa and 
colleagues also examined glucose variability (2012).  Significant A1C reductions were 
reported with improved QOL in six articles (Banerjee, Maji & Baruah, 2013; Hajos et al., 
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2012; Hermanns et al., 2012; Opsteen et al., 2012; Shah et al., 2011; Testa et al., 2012).  
Several studies reported hypoglycemia data; none reported associations between 
hypoglycemia and QOL.  Diabetes symptoms were examined in four papers; three 
studies linked reductions in symptoms with  improved QOL (Hajos et al., 2012; Opsteen 
et al., 2012; Rubin et al., 2010).  Depression, anxiety, and DM-distress were measured by 
Hermanns et al., who reported decreased depressive symptoms in insulin-naïve subjects 
after three months of basal-bolus insulin therapy (2010).   
Similar to the initial literature review, the authors used a large variety of 
instruments to study QOL.  QOL instruments included the DQOL (n=4), SF-12 or SF-36 
(n=3), EQ-5DTM (n=6), the WHO-5 Wellbeing Index (n=1), and an author’s own 
instrument (n=1; Testa et al., 2012).  The diversity of measures used makes comparison 
difficult; however, the majority of the articles (n=7) revealed significantly improved QOL 
(Appendix A).  Lack of QOL effects could be due to small sample sizes (n=37, Vinagre et 
al., 2013; n=54, Peyrot et al., 2011) or using instruments with lower sensitivity to QOL in 
DM (DQOL, Levin et al., 2011; SF-36, Peyrot & Rubin, 2011).  It should be noted that no 
studies showed decreased QOL after beginning intensive insulin management. 
One article of the literature review had unique findings.  Dieuzeide and 
colleagues conducted a sub-study (n=1024) of the data from the A1chieve study, a large 
multi-national trial of analog insulin initiation (n=66,726).  In the sub-study, patients on 
multiple daily injections (basal-bolus) changed to analog premixed insulin (basal only; 
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Dieuzeide et al., 2014).  Significantly improved QOL was found with this less intensive 
insulin management strategy (p<.001).  However, it should be noted that over 88% of 
subjects in the study were using non-analog insulin (Regular and/or NPH) prior to study 
enrollment.  Use of analog insulin has been linked to improved QOL (Hartman, 2008).  
The sub-study subjects also experienced significantly improved glycemic control (mean 
A1C decrease by 2%, p<.001) and less hypoglycemia, especially in the baseline NPH 
group (n=770; p<.001).  Both of these factors may be confounding variables in the 
analysis of insulin management strategy and QOL.  Finally, the Dieuzeide study suffered 
from large sample attrition as 491 subjects (48%) were lost to follow-up.  Attrition 
greater than 20% may affect generalizability and internal validity (Polit & Beck, 2004).  
The findings of this study must be considered carefully and should be replicated before 
making final conclusions regarding QOL in intensive insulin management.
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CHAPTER THREE 
METHODOLOGY 
The study was an observational study to examine quality of life in patients with 
type 2 diabetes, according to type of glycemic management.  The aims are as follows: (1) 
to describe the HRQOL of persons with T2DM according to type of glycemic 
management [Oral meds only, Insulin once or twice daily (basal only), Insulin three or 
more times daily (basal-bolus)], (2) to determine if HRQOL of persons with T2DM differs 
depending on type of glycemic management, and (3) To determine if type of glycemic 
management is predictive of HRQOL after controlling for covariates (i.e., age, gender, 
complications of DM, duration of DM).   
Design 
The study was a cross-sectional, observational study exploring differences in 
HRQOL outcomes in patients with type 2 diabetes, based on type of diabetes 
management.  The study attempted to determine whether the type of insulin 
management has a significant impact on HRQOL in persons with T2DM.   
Setting 
 The study was conducted through the mail, with recruitment of participants 
through clinic, electronic, and community sources.  Data collection occurred over a 
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period of 15 months (January 2012 to March 2013).  All participants lived within the 
United States. 
Sample 
Inclusion Criteria 
All adults 18 years and older who reported that they had “adult onset” or “type 2 
diabetes” for at least six months and could read, write, and speak English were eligible 
for the study.  Participants had to have been taking antihyperglycemic medications at 
least daily (insulin or oral) and be using the same medication regimen (insulin or oral) 
for the past three months.  The inclusion criteria of having diabetes for at least six 
months was selected as it is the time where the maintenance phase of treatment occurs 
with a new health behavior (Prochaska & Velicer, 1997).  
Exclusion Criteria 
 Patients were excluded if they had the following co-morbid diagnoses with 
potential to impact HRQOL: major psychiatric disorders (not including depression), 
dementia, Alzheimer’s, HIV, cancer (requiring chemotherapy or radiation in the last 3 
years), or other chronic conditions that may impact QOL (e.g., sickle cell disease, 
multiple sclerosis, fibromyalgia).  Patients reporting current pregnancy were excluded 
from the study.  The participant screening tool is shown in Appendix B.  
Sample Size Estimation 
Power analyses were completed using G*power version 3.1.2 (F. Faul,  
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Universität Kiel, Germany; Faul, Erdfelder, Lang & Buchner, 2007).  As the three research 
aims have different statistical analyses, three preliminary power analyses were 
conducted using G*power, to obtain minimum sample size for the study.  Medium 
effect sizes were chosen for the power analyses; values for medium effect size were 
provided by G*power.  Alpha was set at 0.05 for all power analyses.  For a fixed-effects, 
one-way ANOVA (3 groups), a total sample size of 159 is required to achieve 80% power 
with an effect size of F=0.25.  For the special effects MANOVA with interactions, a 
sample size of 73 is necessary to achieve an F2 of 0.25 at 95% power with four groups, 
three predictors, and one response variable.  For a fixed-model multiple regression, 
assuming a R2 deviation from zero, a sample size of 138 subjects is required to obtain an 
F2 of 0.15 at 95% power with five predictors.  Details of the power analyses are given in 
Table 6.  Given that 159 is the maximum number of persons needed to meet the aims, 
and that a maximum of missing or incomplete data could be approximately 25 percent, 
the enrollment goal of the study was 199 total subjects.   
 
Table 6.  Power Analysis:  Sample Size Calculations Based on Statistical Test 
Statistical 
Test 
Effect 
size 
Alpha Power Groups Predictors 
Response 
Variables 
N 
required 
ANOVA F=0.25 0.05 0.80 3 n/a n/a 159 
MANOVA F2=0.25 0.05 0.95 4 3 1 73 
Multiple 
regression 
F2=0.15 0.05 0.95 n/a 5 n/a 138 
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Data Collection 
Recruitment 
Participants were recruited through one of seven methods: (1) letter mailed to 
persons with diabetes who have agreed to be informed of diabetes studies through a 
National Institute of Health (NIH)-funded study of women with T2DM informing them of 
the proposed study (Appendix C), (2) flyers posted at outpatient clinics in the Midwest 
suburbs of Chicago (Appendix D), (3) electronic flyers posted to websites of interest to 
people with diabetes (Table 7), (4) Chicago Diabetes EXPO (April 14, 2012, at McCormick 
Place), (5) study notification (containing electronic flyer) sent to all staff members at a 
Chicago-area University Medical Center via Novell Web Access e-mail broadcast, (6) 
community posting of flyers in churches, park districts, coffeehouses, etc. and (7) 
snowball recruitment (study contact information was given by an enrolled subject to a 
friend/family member who then initiated contact with the primary investigator).  The 
query letter and flyer directed participants to contact the primary investigator (Sandra 
McCormick) via phone call.  Within 48 hours, calls were returned to explain the study, 
determine agreement for participation, and screen for eligibility.  Subjects meeting the 
inclusion criteria were asked for their mailing address and the best way to contact them 
(e-mail or phone).  Subsequently, a study packet was sent to their mailing address, 
including a pre-addressed, stamped envelope for return of study materials.    
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Table 7.  Diabetes-Related Websites for Study Recruitment 
Website Name Type Website Address 
American Diabetes 
Association: Chicago  
Social media 
site 
http://www.facebook.com/chicagoada 
American Diabetes 
Association  
Support Forum 
“Adults Living 
with Type 2” 
http://community.diabetes.org/t5/Adults-
Living-with-Type-2/bd-p/Adults-Living-
with-Type-2 
Dailystrength.org  Message Board 
“People with 
Type 2 
Diabetes” 
http://www.dailystrength.org/c/Diabetes-
Type-2/support-group 
Diabetes Blog Network  Diabetes blogs http://www.diabetesblognetwork.com/ 
Diabeticconnect.com Discussion 
boards 
http://www.diabeticconnect.com/ 
Facebook Social media 
site 
http://www.facebook.com/T2Diabetes 
 
Procedure of Data Collection 
The study packet included a cover letter describing the study, the process for 
participation, and instructions to contact the study investigator, Ms. McCormick, with 
any questions (Appendix E).  The letter stated that participation would take about 90 
minutes of their time.  The letter delineated the three steps of participation: (1) 
completion of an 18-page questionnaire booklet, which includes seven study tools, (2) 
performance of a fingerstick A1C test kit with instructions, and (3) return of the 
completed materials by U.S. Mail in the provided pre-paid envelope.  The envelope was 
pre-addressed to the study investigator’s Post Office Box.  Each questionnaire booklet 
and A1C test kit had a pre-assigned ID number.  Upon receipt of the materials, the study 
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investigator sent the A1C blood spots for testing.  Data collection occurred concurrently 
among subjects. 
Measurements 
All additional study variables were assessed using established, psychometrically 
validated instruments as discussed below.  The measurements for the respective 
variables are described below using the framework used to guide this study (Table 8).   
Table 8.  Variables and Measurements of Study 
Revised Wilson and Cleary 
HRQOL Concepts 
Study Variable Measurement Tool 
Individual Characteristics Demographics Questionnaire  
Environmental 
Characteristics 
Access to diabetes care Brief-CIRS item  
Social Support Brief-CIRS 
Biological function 
Insulin dosing frequency Questionnaire 
Co-
morbidities/complications 
Questionnaire 
Glycemic control A1C (Reli On, Heritage Labs) 
Symptoms 
Hypoglycemia DSC-R & self-report items 
Hyperglycemia DSC-R 
Mood Well-Being Questionnaire 12 
Pain DSC-R 
Vision  DSC-R 
Activity tolerance DSC-R 
Functional Performance 
Social Functioning (Mental 
Health Summary) 
SF-12 Health Survey (version 
2): MCS 
Role functioning (Physical 
Health Summary) 
SF-12 Health Survey (version 
2): PCS 
Diabetes Self-Management Self Care Inventory-Revised 
General health perception 
Overall health General health item of SF-12 
(v2) 
Acceptance of diabetes Appraisal of Diabetes Scale 
Quality of life Perceived HRQOL Quality of Life Index 
Note. HRQOL = Health-Related Quality of Life; CIRS = Chronic Illness Resources Survey; A1C = Glycosylated 
Hemoglobin; DSC-R = Diabetes Symptom Checklist-Revised.   
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Instrument costs and access are noted in Table 9.   
Table 9.  Study Instruments: Costs, Access, and Websites 
Instrument 
Name 
Cost 
Need 
Permission 
Website 
Brief Chronic 
Illness Resource 
Survey 
Free No 
https://www.gem-
beta.org/public/MeasureDetail.aspx?mid=116&
cat=2&mode=m 
Diabetes 
Symptom 
Checklist-
Revised 
Free No 
www.vumc.com/afdelingen/diabetes-
psychology/Measures 
Well-Being 
Questionnaire 
12 
$ a Yes a 
http://www.healthpsychologyresearch.com/Ad
min/uploaded/Summary/w-
bq12%20summary%20rev_15jan07.pdf 
SF-12 Health 
Survey, version 
2 
$ b Yes b http://www.sf-36.org/tools/sf12.shtml 
Self-Care 
Inventory-
Revised 
Free Yes c 
http://www.psy.miami.edu/faculty/alagreca/SCI
_manual_2004.pdf 
Appraisal of 
Diabetes Scale 
Free No 
www.musc.edu/dfm/RCMAR/DiabetesTools.ht
ml 
Quality of Life 
Index: Diabetes 
Version 
Free 
Not for 
non-profit 
www.uic.edu/orgs/qli 
a Student licensing agreement received.  No cost for unfunded students. 
b Student license agreement received.  No cost for unfunded students. 
c 
Permission received from copyright holder Dr. LaGreca. 
Individual Characteristics 
Individual characteristics were assessed via demographic questionnaire 
(Appendix F).  The questionnaire also assessed insulin dosing frequency and presence of 
co-morbidities and diabetes complications (Appendix F).  Additional single items were 
scored using Likert-type scoring, ranging from “not at all” to “a great deal”.   
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Biologic Function 
Biologic function was assessed by glycemic control, diabetes complications, and 
insulin dosing frequency.  For glycemic control, hemoglobin A1C was measured using 
the Reli-On Home A1C test (Heritage Labs International, Olathe, KS), an at-home 
fingerstick test kit that uses filter paper and postal submission to their laboratory 
(Heritage Labs, n.d.).  The Reli On Home Diabetes A1C Test is manufactured and tested 
by Heritage Labs International (Olathe, KS).  Designed for home use by retail consumers, 
the test uses fingerstick blood sampling on filter paper to provide A1C assessment.  The 
sample is submitted by mail to the laboratory.  The CLIA-certified results are available 
online within 3 business days or can be mailed directly to the patient and/or researcher 
(CLIA Registration number 17D0943396).  Use of capillary blood filter paper A1C testing 
has been compared to venous laboratory testing (r=0.987) and is considered a valid 
method of measuring A1C, with between-filter coefficient of variation of 1.8 percent 
(Fokkema et al., 2009).   Heritage Labs reports the air-dried filter paper blood specimens 
are stable for at least 30 days at room temperature (Heritage Labs, n.d.).  Precision of 
the Reli On has been demonstrated using within-assay variability at four levels of A1C, 
with a coefficient of variation less than two percent (Table 10).  Linearity was 
established in a full range of A1C values (3.10 to 16.23) with a maximum deviation of 1.3 
percent.  Accuracy of the Reli On was verified using comparison of samples with whole 
blood A1C samples in a diverse range (linear regression R2 = 0.9979; Heritage Labs, n.d.).  
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The Reli On Home Diabetes A1C kit provided a simple, valid, and accurate method of 
measuring A1C in this study.   
Table 10.  Within-assay Variability: Reli On® / Appraise® Hemoglobin A1C Test 
Mean Hemoglobin A1C (%) Standard Deviation Coefficient of Variation (%) 
5.6 0.1 1.8 
7.3 0.0 0.0 
8.7 0.0 0.0 
10.4 0.0 0.0 
Specimens tested 20 times 
From Appraise® Hemoglobin A1C Test, Heritage Labs, Olathe, KS 
Environmental Characteristics 
Access to diabetes care.  Access to care was measured using a single item from 
the Brief-CIRS instrument (discussed below), “Have you had health insurance that 
covered most of the costs of your medical needs including medicine?” (Glasgow, 
Toobert, Barrera & Strycker, 2004).   
Social support.  This was measured using the Chronic Illness Resources Survey.  
The Chronic Illness Resources Survey (CIRS) was developed to provide a measurement of 
socio-ecological support for chronic disease self-management (Glasgow, Strycker, 
Toobert & Eakin, 2000).  The original instrument was 64 items and had subscales of 
personal, family/friends, physician/health care team, neighborhood/community, 
organizations, work, media & policy.  Items were scored on a Likert-type scale (1=not at 
all to 5=a great deal); means were calculated for subscale scores.  High scores denote 
high support for disease self-management.  The original 64-item instrument was 
reduced to 29 items and then to 22 items to create the Brief-CIRS, without sacrificing 
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internal consistency (α = 0.82) or test-retest reliability (r=0.70; Glasgow et al., 2004).  
Some individual subscales from the Brief-CIRS are not as valid as the original CIRS 
(α=0.40-0.55; Glasgow et al., 2004); therefore, the subscales of media & policy, 
organizations, and neighborhood/community were not used individually in this study.  
The Brief-CIRS was administered in original format; however, items from the subscales 
in question were used only to calculate the overall score.  Remaining subscales of the 
Brief-CIRS have acceptable internal consistency (e.g., personal, family/friends and 
physician/health care team).  Convergent validity was tentatively established for the 
Brief-CIRS total score and subscales using correlation with existing measures of social 
support (Interpersonal Support Evaluation Checklist), and healthful eating and activity 
patterns (Social Support for Eating Habits and Exercise Survey; r=0.17 to 0.56; Glasgow 
et al., 2004).  The Brief-CIRS provided a multidimensional assessment of environmental 
support for the study (Appendix F).  For the present study, the Cronbach’s alpha was 
0.810, indicating acceptable reliability (Polit & Beck, 2004). 
Symptoms 
 Hypoglycemia.  Frequency of hypoglycemia was assessed using two self-report 
questions developed by the author: (1) in the last week, how many times have you 
experienced hypoglycemia? and (2) in the past year, how many times have you 
experienced hypoglycemia requiring the help of another person? (Appendix F).   
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Diabetes symptoms.  Designed to measure the symptoms experienced by 
patients with T2DM, the Diabetes Symptom Checklist-Revised (DSC-R) is an instrument 
which quantifies the presence and perceived burden of physical and psychological 
symptoms of diabetes and its complications (Grootenhuis, Snoek, Heine & Bouter, 
1994).  The 34-item questionnaire allows respondents to report the presence (or 
absence) and rate the degree of discomfort the symptom has caused using Likert scaling 
(from 1=”not at all troublesome” to 5=”extremely troublesome”).  The DSC-R explores 
symptoms from eight dimensions: hyperglycemia, hypoglycemia, ophthalmology, 
cardiology, neuro-sensory, neuro-pain, psychology-cognitive, and psychology-fatigue.  
Total scores and subscale scores range from zero to five, with higher scores indicating 
greater diabetes-related symptoms.     
Originally developed in 1994 from literature reviews and consultation with 
physician experts, the DSC was revised in 2009 to clarify scaling and presence of 
symptoms (Arbuckle et al., 2009).  Internal consistency of the DSC-R was measured by 
Cronbach’s alpha ranging from 0.76-0.95 for all dimensions (α=0.69-0.87 subscales, 0.95 
overall; Arbuckle et al., 2009).  Test-retest reliability was established (r=0.79-0.94) and 
confirmatory factor analysis verified validity of subscale dimensions (GFI= .9022; 
Arbuckle et al., 2009).  Concurrent validity was documented by correlations between 
DSC-R scores and SF-36 scores (r=-0.22 to -0.69; Arbuckle et al., 2009).  The DSC-R 
measured the importance and presence of diabetes-related symptoms for the subjects 
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in the study (Appendix F).   For the present study, the Cronbach’s alpha was 0.942, 
indicating a very reliable instrument. 
Mood symptoms.  The Well-Being Questionnaire 12 (W-BQ12) was used to 
measure psychological well-being (Bradley, 2007).  The twelve-item scale is a revision of 
the W-BQ22, which was developed from interviews of clinicians and patients with IDDM 
(Garratt et al., 2000).  The W-BQ12 is a brief assessment of positive and negative 
psychological well-being.  Each of the 12 items is scored from 0 (“not at all”) to 3 (“all 
the time”; Bradley, 2007).  The first three subscales (negative well-being, energy, 
positive well-being) ranging from 0 to 12 points are totaled to obtain the general well-
being, or summary score, of 0 to 36 points (Bradley, 2007).  Higher scores represent 
greater well-being.  The negative well-being subscale is negatively worded and reverse-
scored in the summary total.  The W-BQ12 has been successfully used in subjects with 
IDDM and DM treated with oral medications (Garratt et al., 2000).   
Factor analysis of the W-BQ12 supported the three-factor solution (≥90% of 
variance explained; Pouwer, Snoek, van der Ploeg, Ader & Heine, 2000).  Item-total 
correlations were acceptable (0.38 to 0.75; Pouwer et al., 2000).  Internal consistency, 
as measured by Cronbach’s alpha, ranged from 0.73 (negative well-being) to 0.91 
(general well-being; Pouwer, van der Ploeg, Ader, Heine & Snoek, 1999).  Test-retest 
reliability was 0.66 to 0.83 over two months (Pouwer et al., 1999).  Construct validity 
was demonstrated by correlations between negative well-being and the following 
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instruments: the Hospital Anxiety and Depression Scale (r=0.54-0.60), the State/Trait 
Anxiety Inventory (r=0.63-0.76), and the Center for Epidemiological Studies Depression 
Scale (r=0.67).  Furthermore, general well-being correlated positively with the SF-36 
(r=0.22-0.49) and negatively with the Center for Epidemiological Studies Depression 
Scale (r= -0.80; Pouwer et al., 1999).  In conjunction with the psychological dimensions 
of the DSC-R, the W-BQ12 measured psychological well-being in study subjects 
(Appendix F).  Diagnoses of depression or anxiety were not made.  For the present 
study, the Cronbach’s alpha was 0.883 for general well-being.  For the subscales, the 
Cronbach’s alpha was 0.746 for negative well-being, 0.796 for energy, and 0.829 for 
positive well-being.   
Functional Performance  
Social and role function.  Social and role functioning were assessed using the SF-
12 Health Survey (version 2).  The SF-12 (v2) is an abbreviated version of the SF-36, a 
measure of physical and mental functional health status (Ware, Kosinski, Turner-Bowker 
& Gandek, 2002).    The SF-12 is widely used in health care research and has been used 
with adult patients with a variety of medical diagnoses, including DM.  Each of the 12 
questions is scored on a 5-point Likert-type scale with higher scores equaling better 
functioning.  The SF-12 has eight subscales: physical functioning, role-physical 
functioning, body pain, general health, vitality, social functioning, role-emotional 
functioning, and mental health.  Scoring is provided for each subscale and for both a 
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physical and mental composite score.  The SF-12 has acceptable test-retest reliability 
(0.76 – 0.89; Ware et al., 2002).  The instrument has high internal consistency as 
measured by Cronbach’s alpha of 0.80 to 0.90 for composite scores (Ware et al., 2002).  
Subscale scores are less reliable, with Cronbach’s alpha ranging from 0.66 to 0.90 in the 
general population (Ware et al., 2002).  For this study, only the physical and mental 
composite scores of the SF-12 were used to represent functional status.  The SF-12 is 
shown in Appendix F.  Instrument reliability in this study was demonstrated with a 
Cronbach’s alpha of 0.815 (physical composite score) and 0.792 (mental composite 
score).  
Diabetes self-management.  Another dimension of functional performance, 
diabetes self-management, was assessed using the Self Care Inventory-Revised (SCI-R).  
The Self Care Inventory was originally developed in 1988 to measure patients’ 
perceptions and performance of self-care activities as related to DM (LaGreca et al. in 
Weinger, Butler, Welch & LaGreca, 2005).  It was later revised to reflect changes in DSM 
practice.  The 15-item questionnaire includes assessment of dietary practices, blood 
glucose monitoring, medication administration practices (including insulin), exercise, 
hypoglycemia treatment, and basic diabetes self-care.  Items are rated on a Likert scale 
of “never” to “always”, with the option of “not applicable” for insulin, pills, and ketone 
testing.  Items are averaged and converted to a scale of 0-100 points.  Tested in patients 
with T1 and T2DM, reliability was established with internal consistency of α = 0.87.  
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Concurrent validity was established with an existing measure of diabetes self-care 
(r=0.63); convergent validity was documented via negative correlation with diabetes-
related distress (r=-0.36; Weinger et al., 2005).  Principal components analysis 
confirmed the single-scaling of the measure (Eigenvalue=4.5 explained 38% variance in 
n=199 subjects with T2DM, factor loadings 0.44 to 0.79); responsiveness was 
established by documented improvement in SCI-R scores after receiving DSM education 
(Weinger et al., 2005).  In this study, the SCI-R measured subjects’ performance of DSM 
activities (Appendix F).  For the present study, Cronbach’s alpha was 0.651, indicating 
sub-optimal reliability for the overall scale.  The Cronbach’s alpha was recalculated 
without two items (“check ketones when glucose level is high” and “carry quick acting 
sugar to treat low blood glucose”).  The SCI-R was originally developed for patients with 
T1DM.  Patients with T2DM are less likely to experience hypoglycemia and be instructed 
to check ketones.  In subjects taking oral medication only, the recalculated Cronbach’s 
alpha was 0.714.  The Cronbach’s alpha was 0.713 for subjects on insulin, indicating 
acceptable reliability of the measure in both groups.   
General Health Perceptions 
To assess for subjects’ acceptance of diabetes, the Appraisal of Diabetes Scale 
(ADS) was used.  The ADS is a seven-item questionnaire that can be completed within 
five minutes (Carey et al., 1991).  Originally tested on 200 men with diabetes (n=132 
with IDDM), the ADS was designed as a single factor scale to evaluate personal beliefs 
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about DM and its impact.  The questions assess control, uncertainty, coping, effect of 
diabetes on life goals, predictive view of diabetes and degree of distress caused by 
diabetes (Garratt, Schmidt & Fitzpatrick, 2002).  A higher ADS score indicates a greater 
negative impact of DM or less personal acceptance of the disease.  Internal consistency 
was measured 0.73 by Cronbach’s alpha; reliability was measured by a test-retest 
correlation of 0.85-0.89 (Carey et al., 1991).  Validity was established via correlation 
with existing measures: Diabetic Daily Hassles Scale (r=0.59), Diabetes Health Belief 
Questionnaire (r=0.31-0.42) and the Perceived Stress Scale (r=0.49; Garratt, Schmidt, & 
Fitzpatrick, 2002).  Principal components analysis confirmed single-scaling of the ADS 
(Eigenvalue=2.73 explained 39% variance, factor loadings 0.424 to 0.752; Carey et al., 
1991).  The ADS provided a quantitative measure of subjects’ personal models and 
acceptance of diabetes for this study (Appendix F).  For the present study, Cronbach’s 
alpha was 0.820, indicating acceptable reliability.  
Quality of Life  
Perceived health-related quality of life was assessed by the Quality of Life Index: 
Diabetes Version.  The Ferrans and Powers Quality of Life Index (QLI) was developed 
originally in 1984 as a measure of multidimensional QOL (Ferrans & Powers, 1985).   
Respondents rate their satisfaction with (1=very dissatisfied to 6=very satisfied) and the 
importance of (1=very unimportant to 6=very important) QOL-related items using a 
Likert scale.  Satisfaction ratings are weighted by importance to calculate an overall 
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score and subscores for four domains:  health and functioning, psychological and 
spiritual, social and economic, and family.  Possible total scores range from zero to 30.  
The mean score of 23.00 represents the normal population and 20.56 represents 
persons with diabetes.  From the generic version, additional versions of the QLI have 
been created for a variety of disease populations, including arthritis, cancer, cardiac, 
chronic fatigue, DM, dialysis, epilepsy, renal and liver transplant, multiple sclerosis, 
pulmonary, spinal cord injury, and stroke (Ferrans & Powers, n.d.a).  The diabetes 
version has 34 items and is available in five languages including English.  It is written at 
the fourth-grade reading level and can be self-administered in approximately ten 
minutes.  Construct validity of the QLI was established via strong correlations (r=0.61-
0.93) with the Campbell, Converse, and Rodgers measure of life satisfaction (1976) and 
factor analysis confirming the subscales and explaining 91 percent of the variance 
(Ferrans & Powers, 1992; Ferrans & Powers, n.d.b)  The QLI has demonstrated sensitivity 
to change (DeSouza & Nairy, 2003; Hathaway et al., 1994a; Hathaway et al., 1994b) and 
test-retest reliability (r=0.87 for 2 week interval; Ferrans & Powers, 1985). Both total 
and sub-scales have demonstrated excellent internal consistency, with a Cronbach’s 
alpha ranging from 0.85 to 0.97 (DeSouza & Nairy, 2003; Ozer & Efe, 2006).  Although 
the QLI has not been used in any published studies of DM managed with basal-bolus 
insulin, the QLI-Diabetes version has been used in four studies of patients with T2DM 
(Arun et al., 2008; DeSouza & Nairy, 2003; Hu, Wallace & Tesh, 2010; Quinn, 1996) and 
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one study of patients with either T1 or T2DM (Lewko, et al., 2013; see Table 11).  Also, 
the QLI-generic version was used in a study of patients with T1DM undergoing 
transplantation (Hathaway et al., 1994a; Hathaway et al., 1994b; see Table 11).  
Although the QLI-Diabetes version has not been used with patients using intensive 
insulin management for their DM1, it has well-established reliability and validity and is a 
promising multidimensional tool for QOL assessment in this population.  The QLI: 
Diabetes Version provided a multidimensional measurement of HRQOL in study subjects 
(Appendix F).   For the present study, Cronbach’s alpha was 0.949 for overall quality of 
life and for the subscales was 0.914 for health and functioning, 0.908 for psychological 
and spiritual, 0.773 for social and economic, and 0.714 for family.   
  
                                                             
1   As of 6/1/2014, per searches of OVID, PubMed, and CINAHL, no studies were found using the QLI in DM 
managed with basal or basal-bolus insulin. 
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Table 11.  Studies Using the Quality of Life Index 
Authors Design Setting N 
Mean 
Age  
% 
Female 
DM 
type 
Duration 
(months) 
QLI: Diabetes Version 
Arun et al. 
2008 
RCT: role of 
pharmacist 
Rural India: 
outpatient 
154 58 55 2a 5 
DeSouza & 
Nairy, 
2003 
Longitudinal: 
Nurse-directed 
intervention 
India: 
outpatient 
60 
65% 
are 
41-60 
28 b 2 
Hu, 
Wallace & 
Tesh, 2010 
Cross-
sectional: Diet, 
Exercise, 
Obesity as QOL 
predictors 
Southeastern 
US: 
outpatient 
59 49 68 2c 0 
Lewko et 
al. 2013 
Cross-
sectional: hand 
neuropathy, 
function as 
related to QOL 
and depression 
Poland: 
inpatient 
71 55 52 
1 or 
2d 
0 
Quinn, 
1996 
RCT: impact of 
exercise 
Urban US: 
outpatient 
10 60 50 2e 2 
QLI: Generic Version 
Hathaway 
et al. 
1994a; 
Hathaway 
et al., 
1994b 
Longitudinal: 
Pre-Post 
Transplant 
(Kidney only or 
kidney-
pancreas) 
US:  Large 
medical & 
transplant 
center 
30 40 60 1 6 
Note.  DM = diabetes mellitus; RCT = randomized controlled trial; QOL = quality of life 
a 
Controlled by oral medications only 
b Type of DM not specified; 78% of sample treated with oral medications and diet 
c Majority of subjects took oral medications; 25.6% on insulin 
d 
Majority of subjects (70%) had T2DM.  No medication regimen(s) reported
 
e
 Controlled by diet or oral medications 
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Data Analysis 
Data Entry and Cleaning 
De-identified data was entered directly from questionnaire booklets into an SPSS 
file (SPSS Windows Version 20.0, SPSS, Chicago, IL).  Data cleaning was performed using 
frequency distributions (categorical and interval variables) and descriptive statistics 
(continuous variables) to verify freedom from data entry errors.  Missing data was 
reported using descriptive statistics and is reported in Chapter 4.  Demographic 
information was analyzed using descriptive statistics. 
Analysis per Aims 
Data analysis for each aim included:   
Aim 1:  To describe the HRQOL of persons with T2DM according to type of 
glycemic management.   Analysis:  Patients were divided into groups based on 
medication dosing frequency [Oral meds only, Insulin once or twice daily (basal only), 
Insulin three or more times daily (basal-bolus)].  Descriptive statistics were used to 
report total and subscale QOL and to describe the sample.  
Aim 2:  To determine if HRQOL of persons with T2DM differs depending on type 
of glycemic management.  Analysis:  ANOVA/MANOVA.  Subjects were divided into 
three groups based on the type of glycemic management: oral meds only, insulin once 
or twice daily (basal), insulin three or more times daily (basal-bolus).  The dependent 
variable, quality of life, was represented by QLI scores.   Group differences in QLI scores 
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were examined using Analysis of Variance (ANOVA), with post-hoc testing planned to 
establish pair-wise group differences (Munro, 2005).   
To examine complex interactions that may confound QOL measurement in this 
population, Multifactorial Analysis of Variance (MANOVA) was used.  In the MANOVA, 
the variables tested included: type of glycemic management (oral, basal insulin, or 
basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms, mood 
(psychological well-being), diabetes self-care, acceptance of diabetes, and quality of life.  
These variables were chosen according to the study model, which represents subjects’ 
overall adjustment to life with diabetes.  Sources of variation in the MANOVA included 
main effects as well as interactions between variables.  Analysis of two- and three-way 
interactions can provide a greater understanding of interrelation between complex 
variables that can affect a dependent variable (Munro, 2005). 
Aim 3:  To determine if type of glycemic management is predictive of HRQOL 
after controlling for covariates (age, gender, complications of DM, duration of DM).  
Analysis: Multiple Regression.  Multiple regression is a statistical technique which uses 
several independent variables to predict a dependent variable in an equation format 
(Munro, 2005).  Three multiple regressions were performed.  In the first regression, 
predictor variables such as hemoglobin A1C, diabetes symptoms, diabetes self-care, 
general well-being, and acceptance of diabetes were entered with QLI scores in a 
simultaneous manner to obtain the prediction equation.  In the second regression, the 
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same predictor variables were entered in a forward method to predict QLI scores.  All 
variables’ beta weights were examined for significance (p≤.05) before inclusion into the 
prediction equation (Munro, 2005).  Variables that do not contribute a significant R2 
change to the equation were not included.  Finally, the predictor variables of general 
well-being and diabetes self-care were used in a multiple regression (forward method) 
followed by forced entry of the moderation effect between the two predictors of QOL.  
Details of the analyses are discussed in Chapter Four.   
Human Subjects Protection 
Human subjects procedures included the telephone screening process, 
answering of the questionnaire booklet, and the performance of fingerstick capillary 
blood sampling on filter paper for A1C testing.  The study included both male and 
female adult patients with T2DM.  Patients with major psychiatric disorders (not 
including depression), dementia, Alzheimer’s, HIV, cancer (requiring chemotherapy or 
radiation in the last 5 years), sickle cell disease, fibromyalgia, or active pregnancy were 
excluded from the study, due to the impact of these conditions on QOL and possible 
confounding effects.  Persons who were unable to read, write, and speak English were 
excluded from the study.  As the study was conducted by a graduate student with 
limited funding, it was beyond the scope of this study to provide interpretive services 
for potential subjects.   
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To ensure protection against risks, all data was collected from de-identified 
questionnaire booklets and from fingerstick A1C card, resulted from the company using 
a unique identification number assigned by the study investigator. 
Potential risks included breach of confidentiality and infection at fingerstick site.  
The above potential risks were judged as unlikely to occur as precautions to ensure 
confidentiality were taken.  The list of eligible subjects and recorded data is kept in a 
locked file drawer.  Completed instruments fingerstick card (sent through the mail), and 
results do not have any identifying information.  Only research team members have 
access to this data.  Pregnant women and children were not included in this research 
study.  To prevent infection, explicit directions on how to perform an aseptic fingerstick 
bloodspot sample were provided; however, since most subjects routinely perform self-
monitoring of blood glucose, this fingerstick sample was a familiar experience.  The 
potential risks were minimal and precautions to prevent breach of confidentiality 
continue with the de-identification and aggregation of all data.  For this study, there was 
no breach of confidentiality or infection known to this investigator. 
There were no direct benefits from participation in the study; however, the 
results of the study may help caregivers to better understand the experience of persons 
living with T2DM which may help them to provide better care.  All participants were 
sent a copy of their A1C results by mail.  Subjects who completed the study received a 
$10 gift card as an honorarium for their time.
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CHAPTER FOUR 
RESULTS 
The purpose of the study was to examine quality of life in patients with type 2 
diabetes according to type of glycemic management.  Description of the sample is 
provided via descriptive statistics.   The aims of the study were as follows: (1) to 
describe the HRQOL of persons with T2DM according to type of glycemic management 
[Oral meds only, Basal insulin only (once or twice daily), Basal-bolus insulin (three or 
more times daily)], (2) to determine if HRQOL of persons with T2DM differs depending 
on type of glycemic management, and (3) to determine if type of glycemic management 
is predictive of HRQOL after controlling for covariates. 
Recruitment Information 
One hundred thirty eight people called the study voice mail (See Figure 2 for 
enrollment diagram).  Of these, 120 met criteria and agreed to be enrolled in the study.  
Of the 120 enrolled, 107 subjects completed and returned their study packets.  The final 
sample was 107 adults (73 on oral medications only, 15 on basal insulin, 19 on basal-
bolus insulin).  Sources of recruitment for the sample are shown in Table 12.  The most 
common sources of recruitment were a database of local patients who had agreed to be 
notified of diabetes studies (43%) and internet flier posting (Facebook; 39%).  
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Figure 2.  Enrollment Diagram 
 
Table 12.  Recruitment Sources 
Recruitment Source 
Final Sample Excluded/Non-respondents 
Frequency Percent Frequency Percent 
Database 46 43.0 12 38.7 
Expo 3 2.8 3 9.7 
Facebook 39 36.4 7 22.6 
LUMC Diabetes 4 3.7 2 6.5 
Snowball 9 8.4 4 12.9 
Diabetic Connect 2 1.9 3 9.6 
Staff email LUMC 4 3.7 0 0 
Total 107 100.0 31 100.0 
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Missing Data  
Missing data was limited because all booklets were checked for completion upon 
return.  All subjects with missing data had agreed to be contacted by the primary 
investigator in case of questions regarding survey completion.  Subjects were contacted 
by telephone and provided information regarding missing items (i.e., skipped 
accidentally or on purpose).  Purposeful blank items were accepted.  There was less 
than one percent of unexpected missing data (total 21 items in entire sample).  Some 
data was expected to be missing; for example, the majority of the sample was retired, 
work-related items were not completed by these subjects.  In most cases, expected 
missing data did not affect scoring because authors of the study instruments had 
provided for missing data while designing the scoring metric (CIRS, QLI).   Replacement 
of data was done as reported in Appendix G.  When data could not be deductively 
imputed without excessive risk of distorting relationships between variables, it was not 
replaced.   Data was not replaced in the following items: income (7.5%), history of eye 
problems (<1%), work-related questions (34-67%), children/sex life/spouse (9-20%).  
Details are provided in Appendix G.   
In nine cases, the hemoglobin A1C was unable to be processed by the laboratory 
due to insufficient specimen quantity.  These subjects were all re-contacted to request 
an additional fingerstick specimen; of the three subjects reached, all returned a second 
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specimen for successful testing.  Six subjects were lost to follow-up for obtaining a 
second sample of testing (5.6%).   
Expected missing data included employment- and family-related items.  Both the 
CIRS and QLI had expected missing data related to employment.  The majority of 
subjects (67.3%) reported not currently working outside the home.  The QLI also had 
expected missing data related to family.  Forty-two percent of subjects reported their 
marital status as single, divorced, separated, or widowed.  Also, 9.3% of subjects stated 
no children.  These items were accepted as blank and not replaced.  Total and most 
subscale scores were successfully calculated without the expected missing items.  The 
exception was the CIRS work subscale, which could only be calculated for 35 subjects. 
Characteristics of Overall Sample 
The majority of the sample was female (75.7%), non-Hispanic (96.2%), Caucasian 
(84.1%), married (57.9%), retired (52.3%), and had an average age of 64 years.  
Demographics of the sample are provided in Table 13.  Subjects were divided into 
groups based on type of insulin management (oral medication only, basal insulin, basal-
bolus insulin).  Chi-square tests did not detect differences between groups in gender, 
ethnicity, income, education, and employment.  Using chi-square, significant differences 
were found between groups in race and marital status.  White subjects were most likely 
to be on oral medication only; black subjects were equally likely to be on oral 
medication or basal insulin (χ=27.050, p<.01).  Subjects using basal-bolus insulin were 
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89.5% Caucasian.  Subjects who were never married were most likely to be using basal 
insulin; subjects of every other marital status were most likely to be taking oral 
medications only (χ=30.828, p<.001).  Subjects on basal insulin were slightly younger 
than subjects on oral medications only or basal-bolus insulin; however, per one-way 
ANOVA, this was not statistically significant.   
Table 13.  Description of the Sample  
Variable 
Total 
Sample  
N=107 (%) 
Oral 
Medication 
N= 73 
Insulin 
Basal  
N=15 
Basal-Bolus 
N=19 
Age Mean ± SD  
Range 
63.8 ± 11.8 
27-87 
65.3 ± 11.6 
27-87 
57.4 ± 12.2 
36-82 
63.1 ± 11.2 
42-83 
Gender Female 
Male 
81 (76%) 
26 (24%) 
55 
18 
14 
1 
12 
7 
Ethnicity 
 
Hispanic 
Non-Hispanic 
4 (4%) 
103 (96%) 
3 
70 
0 
15 
1 
18 
Race** 
 
White 
Black 
Asian 
American Indian 
Other 
90 (84%) 
12 (11%) 
3 (3%) 
1 (1%) 
1 (1%) 
65 
5 
3 
0 
0 
8 
6 
0 
1 
0 
17 
1 
0 
0 
1 
Marital 
Status*** 
 
Married 
Divorced 
Never Married 
Widowed 
Separated 
62 (58%) 
16 (15%) 
14 (13%) 
13 (12%) 
2 (2%) 
48 
8 
5 
10 
2 
4 
2 
8 
1 
0 
10 
6 
1 
2 
0 
Income 
(n=99) 
Less than $9,999 
$10,000-14,999 
$15,000-19,999 
$20,000-29,999 
$30,000-39,999 
$40,000-49,999 
$50,000-59,999 
$60,000-69,999 
Over $70,000 
6 (6%) 
4 (4%) 
5 (5%) 
13 (13%) 
11 (11%) 
9 (9%) 
9 (9%) 
5 (5%) 
37 (37%) 
2 
2 
4 
8 
5 
3 
7 
3 
32 
2 
1 
1 
2 
3 
2 
1 
1 
2 
2 
1 
0 
3 
3 
4 
1 
1 
3 
66 
 
 
 
Education Graduate Degree 
Bachelors  
Associate 
Some college 
High School Grad 
9th-12th grade 
Less than 9th 
13 (12%) 
26 (24%) 
11 (10%) 
35 (33%) 
16 (15%) 
4 (4%) 
2 (2%) 
13 
18 
7 
24 
8 
1 
2 
0 
5 
0 
5 
4 
1 
0 
0 
3 
4 
6 
4 
2 
0 
Employment 
 
Working Full-
Time 
Working Part-
Time 
Unemployed 
Homemaker 
Retired 
Disabled 
Other 
26 (24%) 
 
7 (7%) 
 
3 (3%) 
3 (3%) 
56 (52%) 
10 (9%) 
2 (2%) 
17 
 
5 
 
3 
3 
39 
5 
1 
5 
 
2 
 
0 
0 
5 
2 
1 
4 
 
0 
 
0 
0 
12 
3 
0 
**Significant differences between insulin management (p<.01) 
***Significant differences between insulin management groups (p<.001) 
Health history and diabetes-related complications are reported in Table 14.  The 
majority of subjects were overweight (mean BMI 32.9), on oral medications (72.8% on 
metformin), with long-standing T2DM (mean 12.6 years) and at least one diabetes-
related complication (38% with neuropathy) and co-morbid illness (79% hypertension).   
Both simple (0.48/week) and severe (0.60/year) hypoglycemia were rare in the overall 
sample.  Some DM complications [foot ulcers (4%), renal failure (3%), and gastroparesis 
(4%)] were rare in the sample. Type of insulin management strategy was used to 
compare health and diabetes-related items.  Using ANOVA, no significant group 
differences were found in duration of insulin therapy and amount of severe 
hypoglycemia.  The groups did not differ in the frequency of most DM-related 
complications and co-morbidities, with the exception of heart disease and chronic pain.  
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Heart disease was three times greater in subjects taking insulin (26.6% of basal and 
26.3% of basal-bolus groups) than oral medications (8.2%; χ=6.411, p<.05).   Chronic 
pain was most likely in subjects using basal-bolus insulin (36.8%), than basal only insulin 
(6.7%) or oral medications (13.7%; χ=7.057, p<.05).  The insulin management groups 
also differed on type of oral medication used: most subjects on basal-bolus insulin took 
no oral medications (57.9%; χ=40.481, p<.001), most subjects on basal only insulin took 
metformin (66.7%; χ=11.443, p<.01), and subjects on oral medications only had a 
greater frequency of taking two or more oral diabetes medications (45.2%; χ=41.639, 
p<.001).  Subjects using basal-bolus insulin had a longer DM duration [F (2, 100) =6.670, 
p<.01], more frequent simple hypoglycemia [F (2,104) =4.151, p<.05], and total number 
of diabetes-related complications [F (2,104) =6.252, p<.01] than subjects on oral 
medications alone.  Per one-way ANOVA, BMI was highest in the basal insulin group [F 
(2, 102) = 3.876, p<.05].  Erectile dysfunction occurred in the majority of men in the 
sample (57.7%); this parameter could not be compared across insulin management 
groups due to insufficient data.    
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Table 14.  Health History of the Sample  
Variable 
Total 
Sample  
N=107 (%) 
Oral 
Medication 
N= 73 
Insulin 
Basal 
N=15 
Basal-Bolus 
N=19 
BMI* 
 
 
Mean ± SD 
Range 
N=105 
32.9 ± 6.7 
19.1-53.7 
 
32.5 ± 6.8 
20.3-53.7 
N=13 
37.4 ± 4.4 
31.5-44.6 
 
31.2 ± 6.5 
19.1-45.8 
Duration of 
DM** 
 
 
Mean ± SD 
Range 
N=103 
12.6 ± 9.2 
1-39 
 
10.6 ± 7.7 
1-32 
N=12 
16.5 ± 11 
3-39 
N=18 
18.0 ± 10.5 
1-38 
Oral 
Medication*** 
 
None 
Metformin 
Sulfonylurea 
Sitagliptin 
14 (13%) 
78 (73%) 
40 (37%) 
16 (15%) 
0 
60 
31 
15 
3 
10 
6 
1 
11 
8 
3 
0 
Insulin Duration 
(years) 
 
Mean ± SD 
Range 
N=30 
8.3 ± 8.9 
1-31 
 
n/a 
N=14 
5.0 ± 5.8 
1-18 
N=16 
11.1 ± 10.2 
1-31 
Taking byetta? 
 
Yes 
No 
9 (8%) 
98 (92%) 
7 
66 
2 
13 
0 
19 
Simple 
Hypoglycemia1* 
(episodes/wk.) 
Mean ± SD 
Range 
0.5 ± 1.1  
0-6 
0.3 ± 0.9 
0-6 
0.6 ± 1.1 
0-3 
1.1 ± 1.2 
0-4 
Severe 
Hypoglycemia1 
(episodes/year) 
Mean ± SD 
Range 
0.6 ± 1.9 
0-12 
0.4 ± 1.7 
0-12 
0.5 ± 1.6 
0-6 
1.3 ± 2.5 
0-10 
Total # DM 
Complications * 
Mean ± SD 
Range 
1.4 ± 1.7 
0-7 
1.0 ± 1.3 
0-4 
1.5 ± 1.9 
0-6 
2.5 ± 2.2 
0-7 
DM 
Complications 
 
Neuropathy 
Claudication 
PVD 
Heart 
Disease* 
Eye Disease/ 
Laser Surgery 
38 (36%) 
22 (21%) 
16 (15%) 
15 (14%) 
 
15 (14%) 
21 
14 
9 
6 
 
8 
6 
1 
2 
4 
 
3 
11 
7 
5 
5 
 
4 
Erectile Dysfunction  
(men only, N=26) 
15 (57.7%) 9  1  5  
History of 
Depression? 
Yes 
No 
36 (34%) 
71 (66%) 
25 
48 
6 
9 
5 
14 
Co-morbidities Hypertension 79 (74%) 54 11 14 
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 Cataracts 
Arthritis 
DJD 
Sleep Apnea 
Chronic Pain* 
Asthma 
41 (38%) 
39 (36%) 
26 (24%) 
20 (19%) 
18 (17%) 
13 (12%) 
29 
27 
18 
14 
10 
11 
4 
7 
1 
2 
1 
0 
8 
5 
7 
4 
7 
2 
1Hypoglycemia was experienced by a minority of subjects: 79% of subjects reported no 
hypoglycemic episodes in last week; 83% of subjects reported no severe hypoglycemia in the 
past year. 
*Significant differences between insulin management groups (p<.05) 
**Significant differences between insulin management groups (p<.01) 
***Significant differences between insulin management groups (p<.001) 
 Data Analysis per Study Aims 
The aims of the study were as follows: (1) to describe the HRQOL of persons with T2DM 
according to type of glycemic management (Oral meds only, Basal insulin only, Basal-bolus 
insulin), (2) to determine if HRQOL of persons with T2DM differs depending on type of glycemic 
management, and (3) to determine if type of glycemic management is predictive of HRQOL after 
controlling for covariates.  Statistical tests performed and assumptions are discussed per aim. 
Data Analysis: Aim 1 
The first aim of the study was to describe the HRQOL of persons with T2DM according to 
type of glycemic management.   This was done in several steps.   First, using the conceptual 
model for the study, descriptive statistics were generated for measurements on all QOL specific 
domains (environmental, biologic, symptoms, functional performance, general health 
perception and quality of life) and are presented in Table 15.   
 
 
 
Table 15.  Multidimensional Quality of Life Variables per Study Model  
Revised Wilson 
and Cleary 
HRQOL Concepts 
Study Variable Measurement Tool Mean (± SD) Range Norms 
Healthy 
Mean (SD) 
Diabetes 
Mean (SD) 
Environmental 
Characteristics 
Access to 
diabetes care 
CIRS item (#15) 
91% of subjects reported having 
insurance that covered most of 
diabetes costs including medicine  
  
Social Support 
CIRS Overall 2.85 (± 0.55) 1.6 – 4.5  2.7 (0.5) 
CIRS Health Care Team 3.97 (± 0.91) 1.3 – 5.0  3.4 (1.1) 
CIRS Family/Friends 2.30 (± 0.95) 1.0 – 4.7  2.4 (1.0) 
CIRS Personal 3.23 (± 0.94) 1.0 – 5.0  3.3 (0.8) 
CIRS Work (n=35) 2.78 (± 1.13) 1.0 – 5.0  2.5 (0.9) 
CIRS Neighborhood 2.32 (± 0.76) 1.0 – 4.8  2.2 (0.9) 
CIRS Media/Policy 3.46 (± 0.76) 1.7 – 5.0  3.4 (0.8) 
CIRS Organizations 2.03 (± 0.93) 1.0 – 4.7  1.9 (0.9) 
Biological 
function 
Glycemic control A1C  7.990 (±1.579) 5.4 – 13.1 4.0 - 5.6  
 
Symptoms 
 
 
Mood 
WBQ-12: General Well-
Being 
24.12 (± 6.67) 5 – 36  24.4 (7.2) 
Energy 6.60 (± 2.70) 0-12  7.5 (3.0) 
Positive Well Being 7.46 (± 2.97) 0-12  7.6 (2.8) 
Negative Well-Being 1.90 (± 2.23) 1-12  2.7 (2.9) 
DM-related 
(Total) 
DSC-R overall 1.11 (± 0.77) 0 -  3.91  0.82 (0.71) 
Hypoglycemia DSC-R: hypoglycemia 1.21 (± 1.18) 0 – 4.33  0.80 (1.00) 
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Hyperglycemia DSC-R: hyperglycemia 1.44 (± 1.07) 0 – 4.25  1.24 (1.15) 
Pain DSC-R: neurosensory 
subscale 
0.91 (± 1.03) 0 – 4.33  0.60 (0.82) 
Vision  DSC-R: ophthalmologic 0.67 (± 0.93) 0 – 4.6  0.61 (0.87) 
Activity tolerance DSC-R: cardiac 0.89 (± 0.84) 0 – 3.5  0.67 (0.79) 
 
 
Functional 
Performance 
Social functioning SF-12 (v2) Mental 
Composite Score 
50.93 (± 9.91) 23.56 – 
70.71 
50 (10) 47.28 
(10.72) 
Role functioning SF-12 (v2) Physical 
Composite Score 
41.47 (± 11.97) 12.18 – 
60.42 
50 (10) 41.52 
(11.07) 
Diabetes Self-
Management 
Self-Care Inventory-
Revised 
61.61 (± 13.68) 28.85 – 
89.29 
 64.4 (17.9) 
General health 
perception 
Overall health General health item of SF-
12 (v2) 
3.06 (± 0.95) 1 – 5   
Acceptance of 
diabetes 
Appraisal of Diabetes Scale 17.10 (± 4.46) 9 - 28  18.65 (4.04) 
Quality of life 
Perceived HRQOL Quality of Life Index 
Overall 
QLI: Health & Functioning 
QLI: Social & Economic 
QLI: Psych & Spiritual 
QLI: Family 
21.81 (± 4.70) 
 
20.71 (± 5.14) 
22.45 (± 5.11) 
22.81 (± 5.71) 
22.60 (± 5.56) 
8.15 -  
29.45 
5  – 30 
10.29 – 30 
2.57 – 30 
6.25 – 30 
23.00 
 
 
 
 
 
20.56 
Note. HRQOL = Health-Related Quality of Life; CIRS = Chronic Illness Resources Survey; A1C = Glycosylated Hemoglobin; WBQ-12= Well-Being Questionnaire 12; 
DSC-R = Diabetes Symptom Checklist-Revised.   
Sources for Norms:  CIRS: Glasgow, Strycker, Toobert & Eakin, 2000; A1C:  National Diabetes Information Clearinghouse, 2011; WBQ-12: Pouwer et al., 1999; 
DSC-R: Arbuckle et al., 2009; SF-12(v2):  Ware, Kosinski, Turner-Bowker & Gandek, 2002; SCI-R:  Weinger, Butler, Welch & LaGreca, 2005; ADS:  Carey et al., 
1991; QLI:  Ferrans & Powers (n.d.b)
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Second, relationships between key study variables were examined using 
Pearson’s correlations and are presented in Table 16.  Quality of life was found to be 
positively correlated with age (r=.25, p<.05), social support (r=.31, p<.01), general well-
being (r=.65, p<.01), role functioning (SF-12 PCS, r=.43, p<.01), and social functioning 
(SF-12 MCS, r=.50, p<.01).  In contrast, QOL was found to be negatively correlated with 
BMI (r=-.29, p<.01), A1C (r=-.21, p<.05), DM complications (r=-.24, p<.05), DM 
symptoms (r=-.54, p<.01), and ADS scores (r=-.50, p<.01).  This means that QOL 
decreased as obesity, poor glycemic control, and diabetes-related complications and 
symptoms increased.  Quality of life was also decreased in subjects who had poor 
acceptance of their disease as measured by the ADS.  Insulin management and diabetes 
self-care were not significantly correlated with QOL.  As many of the variables are 
significantly correlated, it should be noted that no correlation is greater than .65, which 
is important as correlations greater than .90 indicate collinearity (Field, 2009).   
Third, because gender is a major variable impacting QOL perceptions, the sample 
was examined for gender differences in QOL and related study variables (Table 17).  
Women and men did not significantly differ on several factors:  ethnicity, duration of 
DM, social support, glycemic control (A1C), BMI, diabetes self-care, and acceptance of 
diabetes (ADS).  In addition, there were insufficient numbers per group to analyze 
insulin management by gender.  Details of gender differences are provided in Table 17.  
Men in the sample were older (t= 2.078, p<.05) and more likely to be married (χ=16.918, 
p<.01).  Women in the study reported higher incidences of non-partnered marital status 
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(divorced, never married, or widowed; Table 17).  Although not statistically significant, 
there were more minority women than men in the sample (19.8% vs. 3.8%, χ=5.219, 
n.s.).  Diagnosed depression was more common in women than men (39.5% vs. 15.4%, 
χ=5.130, p<.05).  Diabetes-related complications were more prevalent in men (t=2.634, 
p<.05); however, both genders reported equivalent amounts of diabetes related 
symptoms, with exception of cardiac/activity symptoms, which occurred more 
frequently in women (t= -2.765, p<.01). 
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Table 16.  Correlations between Key Variables 
 CIRS Insulin 
Mgmt. 
BMI  A1C DM 
Complications  
General 
Well-
Being 
DSC 
Total 
SF 
Physical  
SF 
Mental  
Self-
Care  
Appraisal 
of 
Diabetes  
QLI 
overall 
Age  -.119 -.123 -.146 -.169 .019 .208* -.181 -.060 .281** .122 -.293** .246* 
CIRS  -.171 -.132 -.003 -.137 .202* -.110 .195* .063 .302** -.121 .311** 
Insulin 
Management 
  -.009 .368** .323** -.134 .055 -.257** -.002 .336** .212* -.185 
BMI     .157 .078 -.223* .072 -.340** -.131 -.286** .080 -.286** 
A1C     -.007 -.173 .130 -.211* -.096 .046 .292** -.207* 
DM 
Complications 
     -.123 .335** -.421** .113 .095 .331** -.242* 
General Well-
Being 
      
-
.634** 
.442** .738** .122 -.480** .646** 
Diabetes 
Symptoms 
       -.537** -.395** -.124 .611** -.543** 
SF-12 PCS         -.014 .036 -.394** .430** 
SF-12 MCS          .145 -.259** .502** 
Self-Care            -.087 .148 
 ADS             -.504** 
**Correlation is significant at the p<.01 level (2-tailed), *Correlation is significant at the p<.05 level (2-tailed) 
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Table 17.  Study Variables Differing by Gender 
Study Variable Measurement Tool Total Sample 
Mean (± SD) 
Men (n=26) 
Mean (SD) 
Women 
(n=81) 
Mean (SD) 
Age* 
 
63.8 (11.8) 67.9 (9.32) 62.4 (12.24) 
Marital Status** 
 
 92.3% 
married 
46.9% 
married 
18.5% 
divorced 
17.3% single 
14.8% 
widowed 
Diagnosed with Depression*  15.4% 39.5% 
Insulin Management 
--Oral 
--Basal Insulin 
--Basal-Bolus 
  
18 
1 
7 
 
55 
14 
12 
DM Complications* 
 
1.35 (1.67) 2.08 (1.81) 1.11 (1.57) 
Mood: WBQ-12 
General Well-
Being** 
24.12 (6.67) 27.50 (6.54)  23.03 (6.38) 
Energy* 6.60 (2.70) 7.62 (2.74) 6.28 (2.62) 
Positive Well Being** 7.46 (2.97) 8.88 (2.72) 7.00 (2.91) 
Negative Well-Being* 1.90 (2.23) 1.00 (2.10) 2.19 (2.21) 
Diabetes 
Symptoms 
DSC-R overall (n.s.) 1.11 (0.77) 0.94 (0.79) 1.16 (0.76) 
DSC-R: cardiac** 0.89 (0.84) 0.58 (0.56) 0.99 (0.89) 
Social 
functioning 
SF-12 (v2) Mental 
Composite Score* 
50.93 (9.91) 54.91 (9.03) 49.64 (9.89) 
Perceived 
HRQOL 
QLI Overall** 21.81 (4.70) 23.98 (4.13) 21.12 (4.69) 
QLI: Health & 
Functioning* 
20.71 (5.14) 22.77 (4.90) 20.05 (5.06) 
QLI: Social & 
Economic** 
22.45 (5.11) 24.72 (3.11) 21.72 (5.42) 
QLI: Psych & 
Spiritual** 
22.81 (5.71) 25.06 (4.27) 22.09 (5.94) 
QLI: Family* 22.60 (5.56) 24.92 (5.24) 21.86 (5.49) 
* p<.05, **p<.01  
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 The WBQ-12 measured both positive and negative mood in the study.  Men 
reported higher general well-being (t=3.089, p<.01), positive well-being (t=2.917, p<.01), 
and energy (t=2.241, p<.05) than women in the study.  Women reported greater 
negative well-being (t=-2.425, p<.05).  Men also reported higher levels of mental 
performance (mental composite summary) on the SF-12 than women (t=2.389, p<.05).  
The SF-12 did not detect significant physical composite score differences between 
genders.     
Quality of life was also reported as lower by women.  Women reported lower 
overall quality of life (21.12 vs. 23.98, t=2.784, p<.01) than men.  Quality of life per all 
QLI subscales was also reported as significantly lower in women (Table 18).  The effect 
of gender on QOL was tested as a moderating variable with general well-being; 
however, this regression was not significant.  Nevertheless, gender remains an 
important factor in understanding QOL in T2DM. 
Table 18.  Quality of Life by Gender  
 
 Levene's Test for 
Equality of 
Variances 
Equal 
variances 
assumed 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
QLI overall .434 .511 Yes 2.784 105 .006 
Health & Functioning  .030 .864 Yes 2.397 105 .018 
 Social & Economic 13.558 .000 No 3.491 75.087 .001 
 Psychological &  
 Spiritual    
3.192 .077 Yes 2.359 105 .020 
Family .151 .698 Yes 2.499 104 .014 
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Finally, type of management among the groups based on medication dosing 
frequency [Oral meds only, Basal Insulin (once or twice daily), Basal-Bolus Insulin (three 
or more times daily)] was examined.   Descriptive statistics for QOL and the subscales of 
QOL are presented below (Table 19).   
Table 19.  Quality of Life by Type of Glycemic Management 
Quality of Life 
Index 
Total Sample 
Oral 
Medication 
Insulin 
Basal Basal-Bolus 
N=107 N=73 N=15 N=19 
Overall 21.81 (± 4.70) 22.40 (±4.42) 20.91 (±4.34) 20.27 (±5.74) 
Health & 
Functioning 
20.71 (± 5.14) 21.31 (±4.93 ) 19.89 (±4.56) 19.07 (±6.09) 
Social & Economic 22.45 (± 5.11) 23.38 (±4.82) 20.61 (±5.16) 20.35 (±5.43) 
Psych & Spiritual 22.81 (± 5.71) 23.43 (±5.10) 22.44 (±5.72) 20.73 (±7.49) 
Family 22.60 (± 5.56) 22.71 (±5.49) 21.77 (±6.04) 22.87 (±5.71) 
Data Analysis: Aim 2 
To determine if HRQOL of persons with T2DM differs depending on type of 
glycemic management, subjects were divided into three groups based on the type of 
glycemic management: oral meds only, insulin once or twice daily (basal), insulin three 
or more times daily (basal-bolus).  The dependent variable, quality of life, was 
represented by QLI scores.   Group differences in QLI scores were examined using 
Analysis of Variance (ANOVA), with post-hoc testing to establish pair-wise group 
differences (Munro, 2005).   
Group means of the total and subscale QOL were compared using one-way 
ANOVA.  ANOVA assumptions include homogeneity of variance, independent 
observations, and normality; these are discussed in Appendix H.  There was no violation 
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of homogeneity of variance in QLI among the three groups per Levene’s test. Remaining 
assumptions of ANOVA were met.  The analysis revealed that participants’ overall 
quality of life was not significantly different across the three groups [Table 20; F (2, 104) 
= 1.89, p>.05].   
A post-hoc power analysis was conducted to verify the power achieved by the 
one-way ANOVA of QOL by insulin management in this sample (n=107).  Per post-hoc 
analysis, the power obtained was 38 percent.  To achieve 80% power in the one-way 
ANOVA, a sample size of 285 participants was required.  Due to lack of significant 
findings, which may be due to low study power, the second study aim was not 
supported.  That is, no significant group differences in QOL were detected based on 
insulin management.   
Table 20.  Examining Quality of Life by Insulin Management (ANOVA) 
 
 Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
QLI overall 
Between Groups 82.354 2 41.177 1.892 .156 
Within Groups 2263.090 104 21.760   
Total 2345.445 106    
 
To examine complex interactions that may confound QOL measurement in this 
population, Multifactorial Analysis of Variance (MANOVA) was used (Table 21).  In the 
MANOVA, the variables tested included: type of glycemic management (oral, basal 
insulin, or basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms, 
mood (psychological well-being), diabetes self-care, acceptance of diabetes, and quality 
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of life.  These variables were chosen according to the study model, which represents 
subjects’ overall adjustment to life with diabetes.  Sources of variation in the MANOVA 
included main effects as well as interactions between variables.   
Table 21.  Study Model and MANOVA Variables 
Revised Wilson and Cleary 
HRQOL Concepts 
Study Variable Measurement Tool 
Biological function 
Insulin dosing frequency 
Oral Medication 
Basal Insulin 
Basal-bolus Insulin 
Glycemic Control A1C 
Symptoms 
Mood 
WBQ-12: General Well-Being 
(overall) 
Diabetes-related 
Symptoms 
DSC-R overall 
Functional Performance 
Diabetes Self-
Management 
Self-Care Inventory-Revised 
General health perception Acceptance of diabetes Appraisal of Diabetes Scale 
Quality of life Perceived HRQOL Quality of Life Index Overall 
 Assumptions of MANOVA include independence, random sampling, multivariate 
normality, and homogeneity of covariance matrices (Appendix H).  Wilks’ Lambda (p = 
.001, p<.01) indicated that the set of six dependent variables significantly differed for 
the independent variable (insulin management).  To determine what variables the 
groups differed on, the between-group effects were examined (Table 22). Glycemic 
control [A1C; F (2, 95) = 7.044; p=.001] and diabetes self-care [F (2, 95) = 4.620, p<.05) 
significantly differed for the insulin management groups.  Post-hoc testing revealed that 
A1C was significantly higher in subjects on basal insulin (p<.05) and basal-bolus insulin 
(p<.05) than subjects on oral medication (Table 23).  Also, subjects using basal-bolus 
80 
 
 
68
 
insulin management performed considerably more diabetes self-care than patients on 
oral medications (p<0.05).  Per MANOVA, the remaining dependent variables (general 
well-being, diabetes symptoms, and acceptance of diabetes) and QOL were not found to 
differ significantly between insulin management groups.   
Table 22.  Tests of Between-Subjects Effects (MANOVA) 
Source Dependent Variable 
Type III Sum 
of Squares 
df 
Mean 
Square 
F Sig. 
Corrected 
Model 
Hemoglobin A1C 28.674a 2 14.337 7.044 .001 
QLI 77.891b 2 38.946 1.840 .165 
DSC Total .257c 2 .129 .237 .789 
Self-Care Score 1559.868d 2 779.934 4.620 .012 
General Well-Being 46.107e 2 23.054 .533 .588 
ADS total score 69.921f 2 34.961 1.818 .168 
Intercept 
Hemoglobin A1C 4189.057 1 4189.057 2058.065 .000 
QLI 27068.731 1 27068.731 1278.967 .000 
DSC Total 75.319 1 75.319 139.011 .000 
Self-Care Score 243848.681 1 243848.681 1444.525 .000 
General Well-Being 34395.081 1 34395.081 795.935 .000 
ADS total score 17875.180 1 17875.180 929.324 .000 
Insulin 
Hemoglobin A1C 28.674 2 14.337 7.044 .001 
QLI 77.891 2 38.946 1.840 .165 
DSC Total .257 2 .129 .237 .789 
Self-Care Score 1559.868 2 779.934 4.620 .012 
General Well-Being 46.107 2 23.054 .533 .588 
ADS total score 69.921 2 34.961 1.818 .168 
Error 
Hemoglobin A1C 189.295 93 2.035   
QLI 1968.301 93 21.165   
DSC Total 50.390 93 .542   
Self-Care Score 15699.226 93 168.809   
General Well-Being 4018.851 93 43.213   
ADS total score 1788.818 93 19.235   
Total 
Hemoglobin A1C 6225.140 96    
QLI 47644.991 96    
DSC Total 164.592 96    
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Self-Care Score 374737.464 96    
General Well-Being 61200.000 96    
ADS total score 29433.000 96    
Corrected 
Total 
Hemoglobin A1C 217.970 95    
QLI 2046.193 95    
DSC Total 50.647 95    
Self-Care Score 17259.093 95    
General Well-Being 4064.958 95    
ADS total score 1858.740 95    
a. R Squared = .132 (Adjusted R Squared = .113) 
b. R Squared = .038 (Adjusted R Squared = .017) 
c. R Squared = .005 (Adjusted R Squared = -.016) 
d. R Squared = .090 (Adjusted R Squared = .071) 
e. R Squared = .011 (Adjusted R Squared = -.010) 
f. R Squared = .038 (Adjusted R Squared = .017) 
Table 23.  Post Hoc Tests (MANOVA) 
 
Dependent 
Variable 
(I) Taking insulin 
(J) Taking 
insulin 
Mean 
Diff. 
(I-J) 
Std. 
Error 
Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Hgb A1C 
No 
Yes, Basal -1.312* .420 .010 -2.356 -.267 
Yes, Basal-Bolus -1.042* .398 .036 -2.031 -.053 
Yes, Basal 
No 1.312* .420 .010 .267 2.356 
Yes, Basal-Bolus .270 .522 .875 -1.029 1.569 
Yes, Basal-Bolus 
No 1.042* .398 .036 .053 2.031 
Yes, Basal -.270 .522 .875 -1.569 1.029 
QLI overall 
No 
Yes, Basal 1.215 1.354 .670 -2.153 4.582 
Yes, Basal-Bolus 2.349 1.282 .192 -.840 5.538 
Yes, Basal 
No -1.215 1.354 .670 -4.582 2.153 
Yes, Basal-Bolus 1.134 1.684 .797 -3.054 5.322 
Yes, Basal-Bolus 
No -2.349 1.282 .192 -5.538 .840 
Yes, Basal -1.134 1.684 .797 -5.322 3.054 
DSC Total 
No 
Yes, Basal -.021 .217 .995 -.560 .518 
Yes, Basal-Bolus -.141 .205 .789 -.652 .369 
Yes, Basal 
No .021 .217 .995 -.518 .560 
Yes, Basal-Bolus -.120 .269 .906 -.790 .550 
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Yes, Basal-Bolus 
No .141 .205 .789 -.369 .652 
Yes, Basal .120 .269 .906 -.550 .790 
Self-Care 
Score 
No 
Yes, Basal -3.834 3.823 .606 -13.345 5.6766 
Yes, Basal-Bolus -10.88* 3.621 .013 -19.888 -1.875 
Yes, Basal 
No 3.834 3.823 .606 -5.677 13.345 
Yes, Basal-Bolus -7.048 4.755 .338 -18.876 4.781 
Yes, Basal-Bolus 
No 10.882* 3.621 .013 1.875 19.888 
Yes, Basal 7.048 4.755 .338 -4.781 18.876 
General 
Well-Being 
No 
Yes, Basal 1.78 1.934 .657 -3.03 6.59 
Yes, Basal-Bolus 1.16 1.832 .818 -3.40 5.72 
Yes, Basal 
No -1.78 1.934 .657 -6.59 3.03 
Yes, Basal-Bolus -.62 2.406 .968 -6.60 5.37 
Yes, Basal-Bolus 
No -1.16 1.832 .818 -5.72 3.40 
Yes, Basal .62 2.406 .968 -5.37 6.60 
ADS total 
score 
No 
Yes, Basal .52 1.290 .921 -2.69 3.73 
Yes, Basal-Bolus -2.15 1.222 .219 -5.19 .89 
Yes, Basal 
No -.52 1.290 .921 -3.73 2.69 
Yes, Basal-Bolus -2.67 1.605 .256 -6.66 1.32 
Yes, Basal-Bolus 
No 2.15 1.222 .219 -.89 5.19 
Yes, Basal 2.67 1.605 .256 -1.32 6.66 
 Scheffe test of multiple comparisons based on observed means. 
 The error term is Mean Square (Error) = 19.235. 
*The mean difference is significant at the .05 level. 
Data Analysis: Aim 3 
The third aim of the study was to determine if type of glycemic management is 
predictive of HRQOL after controlling for covariates.   This aim was met through multiple 
regression analysis.  Assumptions of multiple regression include variable types, non-zero 
variance, multicollinearity, non-externally correlated predictors, homoscedasticity, independent 
error terms, normally distributed errors, independence, and linearity.  The assumptions of 
multiple regression were met (Appendix H). 
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 First, multiple regression was used to examine the effect of five predictors on QOL.  The 
simultaneous method, or forced entry, was used to enter glycemic control (A1C), general well-
being, diabetes symptoms, diabetes self-management (SCI-R), and appraisal of diabetes as 
predictors of QOL.  The results indicated that the five predictors accounted for 49% of the 
variance [R2 = .49, F (5, 90) = 17.04, p< .001] (Table 24).  Of these predictors, examination of 
beta weights showed that only general well-being (β = .51, p<.001) and appraisal of diabetes (β 
= -.23, p<.05) significantly contributed to prediction of QOL (Table 25).   
Table 24.  Regression Analysis  
Model Summaryb 
Model R R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics Durbin-
Watson R 
Square 
Change 
F 
Change 
df1 df2 Sig. F 
Change 
1 .697a .486 .458 3.41745 .486 17.041 5 90 .000 2.160 
a. Predictors: (Constant), ADS, Self-Care Score, A1C, General Well-Being, Diabetes Symptoms 
b. Dependent Variable: QLI overall 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 995.087 5 199.017 17.041 .000b 
Residual 1051.106 90 11.679   
Total 2046.193 95    
a. Dependent Variable: QLI overall 
b. Predictors: (Constant), ADS, Self-Care Score, A1C, General Well-Being, Diabetes Symptoms 
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Table 25.  Regression Coefficients 
Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence 
Interval for B 
Correlations Collinearity 
Statistics 
B Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
Zero-
order 
Partial Part Tolerance VIF 
(Constant) 17.020 3.474  4.899 .000 10.118 23.921      
Hemoglobin A1C -.115 .241 -.037 -.476 .636 -.594 .365 -.198 -.050 -.036 .920 1.087 
DSC Total -.247 .682 -.039 -.362 .718 -1.601 1.108 -.502 -.038 -.027 .496 2.016 
Self-Care Score .020 .027 .059 .771 .443 -.032 .073 .182 .081 .058 .963 1.039 
General Well-
Being 
.362 .068 .510 5.282 .000 .226 .498 .653 .486 .399 .613 1.632 
Appraisal of DM -.243 .102 -.232 -2.386 .019 -.446 -.041 -.499 -.244 -.180 .605 1.632 
a. Dependent Variable: QLI overall 
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An additional multiple regression analysis was performed to examine a 
moderated model of diabetes self-care, general well-being, and QOL (Figure 3).   
General well-being had a main effect on QOL, but diabetes self-care did not have a 
significant main effect on QOL.  However, an interaction term between general well-
being and diabetes self-care showed a significant predictive effect on QOL (β = -.155, 
p<.05).  The model of general well-being moderated by diabetes self-care to predict QOL 
was significant [R2 = .45, F (3, 102) = 27.73, p<.001].  Model summary is provided in 
Table 26.   
Figure 3.  Moderation  Model  
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Table 26.  Moderated Model Summary  
Model R 
R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
R Square 
Change 
F 
Change 
df1 df2 
Sig. F 
Change 
1 .646a .418 .412 3.61046 .418 74.569 1 104 .000 
2 .653b .426 .415 3.60215 .008 1.480 1 103 .227 
3 .670c .449 .433 3.54545 .023 4.321 1 102 .040 
1. Predictors: (Constant), General Well-Being 
2. Predictors: (Constant), General Well-Being, Diabetes Self-Care 
3. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI) 
 
To further understand the moderation effects of diabetes self-care on QOL, the 
model was analyzed with high and low levels of self-care.  Multiple regressions using 
high and low self-care were performed with the moderated model (Table 27).  Using the 
coefficients from these regressions, equations representing QOL moderated by self-care 
were developed using one standard deviation of general well-being.  General well-being 
significantly increased participants’ quality of life when self-care scores were lower.  
Diabetes self-care moderates the relationship between general well-being and QOL.  
General well-being was more likely to increase participants’ quality of life when they 
reported lower self-care scores, compared to the participants whose self-care scores 
were higher.  The moderation effect of self-care is shown graphically in Figure 4. 
  
87 
 
 
68
 
Table 27.  Moderated Model of Quality of Life by High and Low Self-Care 
 
Coefficients 
   Dependent variable: QLI overall 
  
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
95.0% 
Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 22.474 .499  45.068 .000 21.485 23.463 
 General Well-Being .329 .078 .466 4.238 .000 .175 .483 
High Self-Care .040 .026 .114 1.524 .131 -.012 .092 
Interaction: High SC x 
GWB 
-.008 .004 -.227 -2.079 .040 -.015 .000 
(Constant) 21.400 .490  43.663 .000 20.428 22.372 
General Well-Being .543 .069 .769 7.835 .000 .405 .680 
Low Self-Care .040 .026 .114 1.524 .131 -.012 .092 
Interaction: Low SC x 
GWB 
-.008 .004 -.206 -2.079 .040 -.015 .000 
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Figure 4. Quality of Life Moderated by Self-Care  
 
Given the gender differences noted in mood and QOL, an exploratory analysis 
was conducted to further analyze the moderated model of general well-being, self-care 
and QOL.  The statistical analyses were repeated separately by gender (Tables 28 & 29).  
The results differed significantly by gender.  In men, the moderated model was not 
supported.  Only general well-being had a significant main effect on QOL.  Self-care and 
the interaction had no significant effects.  In women, the moderated model approached 
statistical significance [R2 = .39, F (3, 76) = 15.88, p=0.066].  General well-being had a 
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well-being was a near-significant predictor of QOL in women (p=0.066).  As the study 
had low power, these findings indicate that self-care has a potential to moderate 
general well-being on QOL in women.  The moderated model, split by gender, is shown 
in Figure 5.   
Table 28.  Moderated Model Summary (by Gender) 
Males 
Model R 
R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
R Square 
Change 
F 
Change 
df1 df2 
Sig. F 
Change 
1 .749b .562 .543 2.79206 .562 30.746 1 24 .000 
2 .752c .565 .527 2.84170 .003 .169 1 23 .685 
3 .752d .566 .506 2.90285 .001 .041 1 22 .841 
a. Gender = Male 
b. Predictors: (Constant), General Well-Being 
c. Predictors: (Constant), General Well-Being, Diabetes Self-Care 
d. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI) 
Females 
Model R 
R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
R Square 
Change 
F 
Change 
df1 df2 
Sig. F 
Change 
1 .582b .339 .330 3.84644 .339 39.950 1 78 .000 
2 .598c .357 .340 3.81730 .018 2.196 1 77 .142 
3 .621d .385 .361 3.75704 .028 3.490 1 76 .066 
a. Gender = Female 
b. Predictors: (Constant), General Well-Being 
c. Predictors: (Constant), General Well-Being, Diabetes Self-Care 
d. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI) 
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Table 29.  Moderated Model of Quality of Life by High and Low Self-Care (by Gender) 
Coefficients:  Males 
 
Coefficients:  Females 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
95.0% 
Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 23.805 .868  27.417 .000 22.005 25.606 
 General Well-Being .451 .148 .714 3.051 .006 .145 .758 
High Self-Care -.014 .048 -.043 -.281 .782 -.114 .087 
Interaction: High SC x 
GWB 
-.002 .009 -.049 -.203 .841 -.020 .017 
(Constant) 24.165 .846  28.574 .000 22.411 25.918 
General Well-Being .499 .146 .789 3.417 .002 .196 .802 
Low Self-Care -.014 .048 -.043 -.281 .782 -.114 .087 
Interaction: Low SC x 
GWB 
-.002 .009 -.049 -.203 .841 -.020 .017 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
95.0% 
Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 21.993 .607  36.223 .000 20.784 23.202 
 General Well-Being .278 .100 .377 2.790 .007 .079 .476 
High Self-Care .054 .031 .155 1.700 .093 -.009 .116 
Interaction: High SC x 
GWB 
-.009 .005 -.250 -1.868 .066 -.018 .001 
(Constant) 20.534 .599  34.296 .000 19.342 21.727 
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Figure 5.  Quality of Life and General Well-Being Moderated by Self-Care (by Gender) 
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CHAPTER FIVE  
DISCUSSION 
This dissertation study was conducted to examine quality of life in patients with 
type 2 diabetes according to type of glycemic management.  The aims of the 
dissertation study were: (1) to describe the HRQOL of persons with T2DM according to 
type of glycemic management [Oral meds only, Basal insulin only (once or twice daily), 
Basal-bolus insulin (three or more times daily)], (2) to determine if HRQOL of persons 
with T2DM differs depending on type of glycemic management, and (3) to determine if 
type of glycemic management is predictive of HRQOL after controlling for covariates.  
Based on a review of the literature, it was hypothesized that persons with T2DM on 
basal-bolus insulin would report higher quality of life when covariates were controlled.  
Intensive diabetes management is recommended to minimize diabetes-related 
complications and maximize longevity.  However, the QOL effects of intensive diabetes 
management have not been extensively explored, especially in T2DM.   
The vast majority of prior research has examined quality of life in persons with 
T1DM (Table 1; Appendix A).  Subjects with T2DM have been included in a minority of 
trials, although this has been recently changing (Table 1; Appendix A).  Also, existing 
studies have not conceptualized quality of life as a multidimensional construct. 
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  This dissertation study attempted to understand quality of life in T2DM by using 
the Revised Wilson and Cleary Model of Quality of Life (Ferrans, Zerwic, Wilbur & 
Larson, 2005).  This model quantifies QOL by recognizing both individual and 
environmental influences.  Five dimensions (biological function, symptoms, functional 
status, general health perceptions, and overall quality of life) are identified in the model 
as constructs depicting QOL.   
Characteristics of Overall Sample 
The majority of the sample was female (75.7%), non-Hispanic (96.2%), Caucasian 
(84.1%), married (57.9%), retired (52.3%), and an average age of 64 years.  Although 
T2DM occurs in all ages and racial groups, it is more prevalent in older adults (≥65 years 
of age), men, and racial/ethnic minorities (CDC, 2014).   Diabetes more frequently 
occurs in Native Americans/Alaskan Natives (15.9%), Non-Hispanic blacks (13.2%), and 
Hispanics (12.8%) than in non-Hispanic whites (7.6%; CDC, 2014).  The dissertation 
study’s homogenous sample represents only one subset of the population of persons 
with diabetes.  Despite the small sample size and composition, differences were noted 
between groups based on type of insulin management.   The insulin management 
groups did not differ in key areas (gender, ethnicity, income, education, and 
employment).  However, differences were found between groups in race and marital 
status.  Subjects using basal-bolus insulin, or intensive insulin management, were more 
likely to be Caucasian.  Black subjects were most likely to be on basal insulin only.  
Subjects taking basal insulin only were most likely to be single (never married).   
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In health history and diabetes-related complications, the majority of subjects 
were similar to the overall population of persons with T2DM (CDC, 2014; Davies, 
Brophy, Williams & Taylor, 2006; The Action to Control Cardiovascular Risk in Diabetes 
Study Group, 2008; Shah et al., 2011).  The dissertation study subjects were overweight 
(mean BMI 32.9), on oral medications (72.8% on metformin), with long-standing T2DM 
(mean 12.6 years) and had at least one diabetes-related complication (38% with 
neuropathy) and co-morbid illness (79% hypertension).   As expected, hypoglycemia was 
rare in the overall sample.  Comparing subjects based on insulin management strategy 
revealed no differences in the frequency of most DM-related complications and co-
morbidities, with the exception of heart disease and chronic pain.  Subjects taking 
insulin had more heart disease than those taking oral medications only; however, this 
may be due to the significantly longer duration of DM among subjects taking insulin.  
Subjects using basal-bolus insulin were most likely to report chronic pain, despite 
equivalent (or lower) rates of obesity, neuropathy, and joint disease.  The etiology of 
this finding is unclear, but the impact of chronic pain on QOL cannot be discounted.  
Basal-bolus subjects also had more frequent simple hypoglycemia and total number of 
diabetes-related complications than subjects on oral medications alone.  The majority of 
male subjects reported erectile dysfunction, which can decrease QOL (McCabe & Althof, 
2013).  Due to insufficient data, this parameter could not be compared across insulin 
management groups.   
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Discussion of Aim 1: Describing QOL  
The first aim was to describe the HRQOL of persons with T2DM according to type 
of glycemic management.   This was done in three ways:  reporting QOL domains from 
the dissertation study’s conceptual model, examining correlations between key study 
constructs, and comparing QOL based on gender differences.   The conceptual model for 
the dissertation study was used to describe participants’ QOL by specific domains 
(environmental, biologic, symptoms, functional performance, general health perception 
and quality of life). 
Environmental 
Subjects reported high levels of access to diabetes care and social support.  The 
vast majority of subjects (91%) reported coverage of most of their diabetes costs, 
including medicine.  This is significantly higher than the percentage of adults with health 
insurance in the last US census (81% having private and/or government health 
insurance; DeNavas-Walt, Proctor & Smith, 2010).  The dissertation study subjects 
reported high levels of social support.  Overall social support was reported at higher 
levels (M=2.85) than in other studies using the CIRS (M=2.7; Glasgow, Strycker, Toobert 
& Eakin, 2000; Glasgow, Toobert, Barrera & Strycker, 2004).  Prior studies using the CIRS 
are limited by size and lack of racial/ethnic diversity (>90% Caucasian).  In a study of 
adults with chronic illness including DM (n=123), support provided by the health care 
team was reported as lower (M=3.4) than the dissertation study’s findings (M=3.97; 
Glasgow et al., 2000).  Another study of older adult females with T2DM (n=293) 
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reported lower social support than the dissertation study participants, specifically in 
health care team (M=3.64), personal (M=3.06), neighborhood (M=2.14), and 
organizational (M=1.71; Glasgow et al., 2004) dimensions.  In a systematic review of the 
literature, Strom and Egede found that the vast majority of studies provided strong 
evidence for the relationship between social support and improved DM outcomes 
(2012).  Greater social support was linked to improved clinical outcomes (glycemic 
control, less DM-symptoms) in 34 of 37 research studies and to improved self-care 
and/or DSM in 12 of 13 studies (Strom & Egede, 2012).  Social support is an important 
dimension of QOL.  In access to care and social support, the dissertation study subjects 
had average or above average environmental function.   
Biological Function 
Participants had a mean A1C of 7.9, with a wide range (5.4-13).  Similar to 
national averages, the majority of the dissertation study subjects had inadequate 
glycemic control.  In 2010, per National Health and Nutrition Examination Survey data, 
only 52.5% of U.S. adults with diabetes achieved the treatment goal of A1C less than 7% 
(Casagrande et al., 2013).  In this study, 27% of subjects met the treatment goal of A1C 
less than 7%.  Suboptimal control (A1C between 7-8%) was achieved by an additional 
33% of the dissertation study sample.  This study’s suboptimal glycemic control may be 
due to the revised glycemic control recommendations developed from the ACCORD 
trial, which revealed a significantly increased rate of death in intensively-treated 
patients with DM and cardiovascular disease (The Action to Control Cardiovascular Risk 
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in Diabetes Study Group, 2008).   An additional study of adults with T2DM found an 
increased risk of cardiovascular events (stroke, myocardial infarction, or death due to 
cardiovascular causes) in patients with an A1C of less than 6 or greater than 8 (Colayco, 
Niu, McCombs & Cheetham, 2011).  Currently, the ADA recommends the 
individualization of A1C goals based on several factors, including age, comorbid 
conditions, and known cardiovascular disease (American Diabetes Association, 2014).  
As 14% of the dissertation study sample reported having cardiovascular disease, the 
rates of suboptimal glycemic control are not surprising.   
Diabetes Symptoms 
The sample reported a substantial number of diabetes symptoms.  Ninety-six 
percent of subjects reported the presence of at least one symptom (ranging from 
“present but not troublesome” to “extremely troublesome”).  Hyperglycemic symptoms 
were experienced by 80% of the sample, followed by cardiac symptoms (74% of 
subjects) and neuro-sensory symptoms (66% of subjects).  Compared to several other 
studies of persons with T2DM, the dissertation study participants reported greater 
diabetes symptom burden (Table 30).  However, one small study by Opsteen and 
colleagues (n=34 adults with T2DM, 38% female; Opsteen, Qi, Zinman & Retnakaran, 
2012) reported greater overall symptom burden (M=2.3) than the dissertation study 
(M=1.11 ±0.77, 95% CI= 0.96 to 1.26).   This is remarkable as the Opsteen study sample 
was slightly younger (59 vs. 63 years), with shorter duration of DM (5.9 vs. 12.6 years), 
less DM complications (e.g. 28% vs. 36% self-reported neuropathy), and better glycemic 
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control (A1C 7% vs. 7.9%).  Due to the very small sample size in the Opsteen study, the 
findings should be considered preliminary and possibly spurious.   
Diabetes symptom distress varied per subscale.  In the neuro-sensory, cardiac, 
and hypoglycemic subscales, subjects reported higher more burdensome symptoms 
than other studies using the DSC-R (Table 30).  Several studies using the DSC or DSC-R 
used a variety of scoring methods.  The variable calculations made between-study 
comparisons challenging; therefore, Table 30 includes only the studies with same 
scoring as the dissertation study.  In the ophthalmologic and hyperglycemic subscales, 
subjects’ scores were consistent with other studies (Table 30).  The literature 
demonstrates that diabetes symptoms are burdensome for patients with T2DM and can 
affect QOL.  Physical symptoms, such as pain, sensory, and cardiovascular, are more 
common in patients over age 60; however, psychological symptoms such as negative 
mood or depression are greater in those younger than age 60 (p<0.001, Sudore et al., 
2012).  Patients with T2DM and depression experience approximately three times more 
symptom burden than patients with DM and no depression (p<0.01, Adriaanse et al., 
2008).  In the dissertation study, patients with a history of depression reported greater 
symptom burden (DSC total score 1.48 vs. 0.92, t=-3.732, p<0.001).  Clearly, diabetes 
symptoms have an impact on QOL.  
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Table 30.  Diabetes Symptoms in Other Studies Using the Diabetes Symptom Checklist-Revised (DSC-R) 
 
Study N Sample Characteristics 
Diabetes Symptom Checklist-Revised 
Subscales: Mean (SD) TOTAL 
score 
M (SD) 
Neuro-
Sensory 
CV Ophthalmologic Hypo Hyperglycemia 
McCormick
, 2014 
107 
 0.91 
(1.03) 
0.89 
(0.84) 
0.67 (0.93) 
1.21 
(1.18) 
1.44 (1.07) 1.11(0.77) 
Arbuckle, 
2009 
2023 
Mean age 51 years, 42% 
female; 88% Caucasian; 
newly diagnosed w/ T2DM 
(US, Canada, Europe) 
0.60 
(0.82) 
0.67 
(0.79) 
0.61 (0.87) 
0.80 
(1.00) 
1.24 (1.15) 
0.82 
(0.71) 
Kleefstra 
2010+ 
18 
Mean age 59 yrs., 28% 
female; DM duration 8 
yrs.; 11% with ≥1 DM 
complication (Netherlands) 
     
0.7 (0.4, 
1.0) 
Opsteen 
2012++ 
34 
Mean age 59 yrs., 38% 
female; DM duration 6 
years; 28% with ≥1 DM 
complications (Canada) 
0 (0-2.0) 0 (0-2.0) 0 (0-2.0) 0 (0-2.0) 2.0 (1-2.3) 2.3 
Vadstrup 
2011 
143 
Mean age 58 years, 40% 
female, DM duration 6.4 
years; 33% with ≥1 DM 
complications (Denmark) 
0.5 (0.7) 0.7 (0.7) 0.5 (0.8) 1.0 (1.0) 1.5 (1.1) 0.9 (0.6) 
+Values presented are Median (25th percentile, 75th percentile) due to right-skewed distribution 
++ Values are Median with interquartile range; no range provided for total score; Additional subscales:  Fatigue 2.0 (0-2.3), Cognitive 2.0 (1.5-2.3) 
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Mood Symptoms 
In the overall sample, mood was not dissimilar from other studies of persons 
with diabetes.  Three studies have used the WBQ-12 to analyze mood in subjects with 
T2DM (Table 31).  None of the studies are from the US.  Subjects in two studies had 
shorter disease duration (mean DM duration less than 6 years).   The dissertation 
study’s WBQ-12 results are most similar to those of Pouwer et al. (1999), whose 
subjects had a longer DM duration and at least one complication of DM.  The presence 
of DM-related complications and/or longer disease duration is associated with lower 
psychological well-being and mood (Nicolucci et al., 2009; Savli & Sevinc, 2005).  In the 
dissertation sample, mean reports of mood-related symptoms were as expected.  
Gender differences existed and are discussed below.   
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Table 31.  Psychological Well-being in Other Studies Using the Well Being Questionnaire-
12  
 
Author N 
Sample Characteristics 
(all T2DM outpatients) 
WBQ Scores:  Mean (SD) 
General 
well-being 
Energy 
Positive 
Well-
Being 
Negative 
Well-
Being 
McCormick, 2014 24.1(6.7) 6.6 (2.7) 7.5(3.0) 1.9 (2.2) 
Pouwer 
et al., 
1999 
349 Mean age 51 years, 
49% female; DM 
duration 16 years; 
Dutch with at least 1 
complication of DM 
24.4(7.2) 7.5 (3.0) 7.6(2.8) 2.7(2.9) 
Reid et 
al., 2010 
218 Mean age 54 years, 
35% female, DM 
duration 5.4 years; 
Canadians treated 
with diet and/or oral 
medications (no 
insulin) 
26.1(5.4) -- -- -- 
Van den 
Donk et 
al., 2013 
2217 Mean age 65 years, 
43% female; DM 
duration 5.7 years; 
from 318 European 
clinics (4 centers) 
25.0(6.3)  
to  
28.5(5.9) 
7.0(2.7) 
to 
8.5(2.6) 
8.0(2.9)  
to 
 9.4(2.5) 
1.1(1.8) 
to 
2.1(2.5) 
 
Functional Performance 
Subjects’ functional performance was equal or greater than average.  Subjects in 
the dissertation study reported physical and mental functioning at similar levels to other 
persons with DM.  SF-12 normative data was developed from the National Survey of 
Functional Health Status (1998; n=14906), representing the non-institutionalized US 
adult population (Ware, Kosinski, Turner-Bowker & Gandek, 2002).  In the dissertation 
study, physical functioning (SF-12 physical composite scores, M=41.47± 11.97) was very 
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similar to the diabetes normative data (M=41.52±11.07).  Social functioning (SF-12 
mental composite score) from the dissertation study (M= 50.93 ± 9.91) were slightly 
above normative data for persons with DM (M=47.28±10.72). 
Diabetes self-management was similar to published instrument data.  The mean 
SCI-R score in the dissertation study was 61.61(± 13.68).  A study of 159 US adults with 
T2DM (88% Caucasian, 57% female, age 47±15 years, diabetes duration 13±12 years) 
revealed the mean score on the SCI-R to be 64.4 (SD=17.9; Weinger, Butler, Welch & 
LaGreca, 2005).  Similar results were found in a study of 353 UK adults with T2DM (39% 
female, age 66±9 years, diabetes duration 17±7 years; mean SCI-R score 69.0±12.8; 
Khagram, Martin, Davies & Speight, 2013).  As with other studies, subjects in the 
dissertation study reported a wide range of diabetes self-management performance 
(Range: 28.85-89.29).  
Health Perceptions 
The Appraisal of Diabetes Scale assesses patients’ acceptance of DM and its 
related burdens.  A higher score indicates a greater disease burden.  In the dissertation 
study, subjects reported their DM as moderately challenging (M= 17.10 ± 4.46).  In a 
study of adults with similar demographics to the dissertation study (n=94 Midwestern 
US outpatients with T2DM; mean age 61 years; 62% female), Poradzisz (2001) reported 
similar scores on the ADS (M=17.84 ±5.05).  The original study using the ADS reported 
greater disease burden (M=18.65 ±4.04); however, all participants were male veterans 
from the VA outpatient clinic (Carey et al., 1991).  The ADS assesses control, uncertainty, 
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effects of disease on life goals, and DM related distress.  In the dissertation study, 
subjects reported these dimensions at expected levels.   
Quality of Life 
Participants in the dissertation study rated their QOL highly.  This is consistent 
with other studies of persons with diabetes.  The dissertation sample reported very high 
quality of life in three subscales:  Social & Economic, Psychological & Spiritual, and 
Family.  QOL was reported slightly lower in the Health and Functioning subscale, which 
may be expected due to the presence of DM complications in the dissertation sample.  
Other studies using the same instrument have reported overall means ranging from 20.5 
to 23.40 (Table 32).  This variability may be due to the diverse settings of the studies.  
The highest mean QLI scores (23.40±3.55) were reported in a study of Hispanic adults 
with T2DM, primarily immigrants from Mexico (74%) with an average of nine years living 
in the US (Hu, Wallace & Tesh, 2010).  Duration of DM was 4.5 years (SD ± 0.25).  These 
QOL findings are consistent with the findings of Naranjo and colleagues, who reported 
decreased QOL in in Black adults with DM but not in their Latino peers, despite greater 
perception of disease burden among Latinos (Naranjo, Hessler, Deol & Chesla, 2012).  
Acculturation was found to have a significant moderating effect on QOL.  Shorter 
duration of DM has been linked to higher QOL (Narajo et al., 2012).  These factors 
should be considered in comparing these QLI scores to the dissertation study findings.  
The dissertation study’s sample mean is within the range of the other studies’ findings.  
The QOL reported by participants was good and in accordance with existing data. 
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Table 32.  Quality of Life in Other Studies Using the Quality of Life Index: Diabetes 
Version  
 
Author 
Sample 
Size 
Sample Characteristics 
QLI overall  
mean (SD) 
McCormick, 2014 107  21.81 (4.70) 
Hu, Wallace & 
Tesh, 2010 
59 Mean age 49 years; 68% female; 
Hispanic outpatients in Southeast US 
23.40 (3.55) 
Lewko et al. 2013 71 Mean age 55 years; 52% female; 
Inpatients in Poland 
Gp. 1: 20.5 (3.8) 
Gp. 2: 21.9 (4.5) 
Poradzisz, 2001 
 
94 Mean age 61 years; 62% female; 
T2DM outpatients in Midwest US 
21.10 (4.38) 
 
By examining QOL in a multidimensional manner, the construct is depicted more 
fully.  The dissertation study subjects reported adequate HRQOL.  Certain dimensions of 
QOL were rated highly.  Study subjects reported better than average access to care, 
social support, mood, social functioning, and diabetes self-management.  Other 
dimensions were equivalent to normative data, such as glycemic control, disease 
appraisal, and role functioning.  In contrast, diabetes symptoms were rated poorly by 
subjects and were greater than several comparable studies.   
The first study aim also examined using Pearson’s correlations to describe the 
relationships between key study variables.  Higher QOL was found with greater age, 
social support, general well-being, role functioning, and social functioning.  The positive 
correlation between older age and quality of life is consistent with the higher mental 
QOL reported by older adults in several studies.  In a study of 353 adults with T2DM, 
older adults (age > 65 years) reported better QOL and positive well-being despite lower 
energy and more DM complications than their younger peers (age ≤65 years; Speight, 
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Khagram & Davies, 2012).   Similar findings were documented by a study of 191 adults 
with insulin-dependent DM (68% T2DM; Trief, Wade, Pine & Weinstock, 2003).  When 
compared to middle-aged and young adults, older adults in the dissertation study 
reported significantly better DM coping and less DM-related distress, despite having 
worse physical functioning and role limitations.  These findings are not specific to 
diabetes.  According to the US Behavioral Risk Factor Surveillance System, older adults 
report better mental QOL, despite worse physical QOL and more self-ratings of “fair or 
poor” health (Zack, 2013). This may be a generational or experiential effect.   
The dissertation study subjects reported worse QOL with higher levels of obesity, 
poor glycemic control, and diabetes-related complications and symptoms.  Also, QOL 
was decreased in subjects who had poor acceptance of their disease as measured by the 
ADS.   Individuals with a negative perception of their diabetes have reported lower QOL 
(Scollan-Koliopoulos et al., 2013).  Insulin management and diabetes self-care were not 
significantly correlated with QOL.  However, both correlations had low statistical power 
(0.49 and 0.34, respectively) per post-hoc power analysis (G*Power 3.1.6).  Power 
should be 0.8 or greater to minimize the likelihood of a type II error (Field, 2009).   
Finally, the first study aim described the gender differences in QOL and related 
study variables.  There were no significant gender differences in ethnicity, duration of 
DM, social support, glycemic control (A1C), BMI, diabetes self-care, or acceptance of 
diabetes (ADS).  Insulin management could not be analyzed according to gender due to 
insufficient numbers.  Male and female subjects had some demographic differences.  
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Males were older and most were married.  Women were most likely to be non-
partnered (divorced, never married, or widowed).  This is significant because being 
married may provide a uniquely effective source of social support to some persons with 
diabetes.  Positive spousal support has been linked to decreased diabetes distress, 
increased DSM behaviors, greater dietary adherence, and more physical activity 
(Dempster, McCarthy & Davies, 2011; Franks et al., 2012; Khan, Stephens, Franks, Rook 
& Salem, 2013; Stephens et al., 2013; Stephens, Rook, Franks, Khan & Lida, 2010).  It 
should be noted however, wives have been shown to provide greater psychological 
support for their husbands with T2DM (Lida, Parris Stephens, Rook, Franks & Salem, 
2010).   
Health-related differences included both physical and psychological.  Men 
reported a greater number of diabetes-related complications.  Despite men having more 
complications, both genders reported equivalent amounts of diabetes-related 
symptoms.  This means that women experienced more diabetes-related symptoms even 
with fewer diabetes complications.  Numerous studies have documented greater 
diabetes symptoms in women.  One large study (n=14206) found a 50% greater risk of 
painful neuropathic symptoms in women vs. men with T2DM (OR = 1.5, p<0.0001), 
despite less clinical neuropathy (19 vs. 23%, p<0.0001; Abbott, Malik, van Ross, Kulkarni 
& Boulton, 2011). Women with T2DM are also more likely than men to report symptoms 
of gastroparesis (OR = 1.838, p<0.05; Dickman, Wainstein, Glezerman, Niv & Boaz, 
2014).  Significant fatigue has been reported in women with T2DM (Fritschi et al., 2012).  
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Women also reported higher levels of cardiac symptoms, despite equal cardiac disease 
prevalence as male participants.   This is consistent with the findings of Tamis-Holland 
and colleagues, who found that women with T2DM had more anginal symptoms than 
men but had less obstructive cardiac disease (Tamis-Holland et al., 2011; Tamis-Holland 
et al., 2013).  Physical symptoms related to T2DM are different in women than in men. 
Women in the dissertation study reported a greater prevalence of diagnosed 
depression than men (OR = 3.61, p<.05).   Per meta-analysis, depression is twice as likely 
in people with DM as in their peers without DM (OR = 2.0, 95% CI 1.8-2.2; Anderson, 
Freedland, Clouse & Lustman, 2001).  Depressive symptoms are even more common, 
reported by 44% of persons with DM in a large, multi-national study (Nicolucci et al., 
2013).  Depression is especially prevalent in women with diabetes.  There is a two-fold 
increased likelihood of depressive symptoms in women with T2DM (Egede, 2007).  In 
the dissertation study, male participants reported higher general well-being, energy, 
and positive well-being.  When compared to data from other studies (Pouwer et al., 
1999; Reid et al., 2010; Van den Donk et al., 2013; see table 31 above), both general and 
positive well-being were higher in dissertation study males.   Female participants 
reported more negative well-being than men in the dissertation study; however, 
comparison with other studies (Pouwer et al., 1999; Van den Donk et al., 2013) reveals 
that this sample (men and women) had less or equivalent negative well-being.  Details 
are provided in Figure 6.  In addition to higher well-being, male subjects also reported 
higher levels of mental performance per the SF-12.    
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Figure 6.  Well-Being by Gender  
 
In addition to well-being, quality of life was also reported as lower by women in 
the dissertation study.  In overall QOL and all subscales, women reported significantly 
lower quality of life than men.    Gender differences in QOL have been reported in 
several studies.  Compared to men, women with T2DM have lower QOL (Papadopoulos, 
Kontodimopoulos, Frydas, Ikonomakis  & Niakas, 2007; Glasgow, Ruggiero, Eakin, 
Dryfoos & Chobanian, 1997) and more self-rated “unhealthy days” (OR = 0.66, p<0.01; 
Clifford, Collins, Buckley, Fitzgerald & Perry, 2013).  QOL is especially lower in obese 
women with T2DM (Svenningsson, Marklund, Attvall, & Gedda, 2011).  Women with 
depression and T2DM are particularly vulnerable to QOL effects.  Gender is clearly an 
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important factor in understanding QOL in T2DM.  Further research on this topic is 
essential. 
Discussion of Aim 2: QOL Differences  
Aim 2 hypothesized that QOL would differ according to type of insulin 
management.  This study aim was not supported by the data--there were no significant 
differences in QOL based on type of insulin management.  The one-way ANOVA 
achieved only 38 percent power, per post-hoc power analysis.  Unfortunately, a sample 
size of 285 would be required to achieve acceptable power of 80 percent.  Therefore, 
the second study aim was not statistically supported.     
MANOVA testing was utilized to clarify the multiple interactions that may have 
affected QOL measurement in the study.  The study model was used to select variables 
for MANOVA examination, and included type of glycemic management (oral, basal 
insulin, or basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms, 
mood (psychological well-being), diabetes self-care, acceptance of diabetes, and quality 
of life.  Despite accounting for related dependent variables, QOL was still not shown to 
differ based on insulin management type.   
Although QOL did not differ, MANOVA showed significant differences in diabetes 
self-care performed by subjects using basal-bolus insulin and those using oral 
medications alone. Subjects using basal-bolus insulin management scored higher on the 
SCI-R than subjects on oral medications only.  It should be noted that the SCI-R accounts 
for different diabetes regimens.  Persons completing the SCI-R may choose “not 
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applicable” for certain items, such as checking ketones, taking insulin and/or pills, or 
treating low blood glucose (Weinger, Welch, Butler & LaGreca, 2005).  SCI-R scores 
represent patients’ adherence to their prescribed DSM regimen.  Therefore, subjects on 
basal-bolus insulin were actually performing a greater proportion of prescribed diabetes 
self-care.  Even though these subjects had more required diabetes self-care activities, 
they still performed a greater proportion of the prescribed self-care.   
MANOVA also revealed differences in glycemic control.  Subjects taking insulin 
(basal only and basal-bolus) had worse glycemic control than those taking oral 
medication alone. Historically, insulin has been prescribed later in the disease course of 
T2DM, due to both physician and patient reluctance (Ratanawongsa et al., 2012; Nam, 
Chesla, Stotts, Kroon & Janson, 2010).  Newer diabetes guidelines seek earlier treatment 
with insulin as needed to meet glycemic control goals (ADA, 2014; Shubrook, 2014).  As 
a cross-sectional study, it is impossible to know the temporal correlation of insulin 
management and poor glycemic control in this sample.   
After accounting for the effects of glycemic control and diabetes self-care with 
MANOVA, QOL did not vary based on insulin management.  Greater power would be 
required to make conclusions regarding the original study aim.   
Discussion of Aim 3: Predicting QOL  
Multiple regression analysis was used to determine if type of glycemic 
management was predictive of HRQOL after controlling for covariates.   First, 
simultaneous multiple regression tested the effects of five predictors on QOL.  In this 
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regression, glycemic control, diabetes symptoms, and diabetes self-management were 
not significant predictors per beta weight analysis.  Significant QOL predictors were 
general well-being and appraisal of diabetes.  Examination of beta weights showed that 
general well-being positively predicted QOL (β = .47, p<.001).  Appraisal of diabetes 
(ADS) negatively predicted QOL (β = -.22, p<.05).  As a proxy measure for mood, it is 
clear that general well-being would predict QOL in a positive manner.  Correlations 
between the WBQ and the mental health component of the SF-36 have been robust 
(r=0.80, p<0.001; McMillan, Bradley, Gibney, Russell-Jones & Sonksen, 2006 and r=0.75, 
p<0.001; Pouwer et al., 1999).  The negative predictive relationship between the ADS 
and QOL was expected:  poor disease acceptance has been linked to lower QOL (r=-0.55, 
p<0.01; Poradzisz, 2001).   
A moderated model of diabetes self-care, general well-being, and QOL was 
tested by multiple regression analysis (Figure 3).   The model showed significant effects 
on QOL by general well-being (main effect) and the interaction between general well-
being and diabetes self-care.  The relationship between general well-being and QOL is 
moderated by diabetes self-care.  This effect is most clearly evident with low general 
well-being, where high self-care is related to a significantly higher QOL.   The 
moderation effect of self-care is shown graphically in Figure 4.   
These findings are consistent with descriptions of moderated models.  A 
moderating variable is defined as a third variable that affects the relationship between 
two other variables (Baron & Kenny, 1986).  A moderator is an independent variable 
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which affects the dependent variable (outcome) through interaction with the predictor 
variable.  The predictor variable may or may not have a significant main effect on the 
outcome variable (Holmbeck, 1997).  Traditionally, moderators are not antecedent or 
causal (Baron & Kenny, 1986).  The cross-sectional nature of the dissertation study 
precludes temporal conclusions.  The moderated model of this study should be 
considered preliminary.  Further testing is required to understand the directionality of 
the relationship between general well-being, self-care, and QOL.  However, these 
concepts are indisputably linked.  
Summary of Major Findings 
The major study findings are summarized as follows.  First, examination of major 
study variables showed that the sample experienced satisfactory QOL and related 
domains.  Compared to other studies of persons with diabetes, subjects reported above 
average access to care, social support, social functioning, diabetes self-management, 
overall QOL, and subscale QOL (Social & Economic, Psychological & Spiritual, and 
Family).  Glycemic control, well-being (general and positive), role functioning, disease 
acceptance, and health and functioning subscale QOL were consistent with existing 
studies.  However, study participants reported more diabetes symptoms, and less 
energy than their peers.   Second, correlations revealed that QOL was positively 
influenced by age, social support, general well-being, role functioning, and social 
functioning.  QOL was negatively influenced by obesity, poor glycemic control, disease 
acceptance, and diabetes-related complications and symptoms.  Third, when analyzed 
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by gender, women reported lower well-being and greater negative well-being, as well as 
lower QOL.  Female participants were also more likely to have diagnosed depression and 
report more diabetes symptoms, despite less prevalence of diabetes-related 
complications 
  Fourth, the study was designed to evaluate the relationship between insulin 
management strategy and QOL.  Both ANOVA and MANOVA failed to provide statistical 
evidence to support this relationship.  The study was insufficiently powered to declare 
negative findings and will require further testing before conclusions can be made.  
However, statistical modeling revealed that disease acceptance and general well-being 
are significant predictors of QOL.  Per multiple regression analysis, greater disease 
acceptance and general well-being are positive predictors of QOL.   
Finally, a moderated model of diabetes self-care, general well-being, and QOL 
was examined by multiple regression analysis.  The regression model revealed that self-
care is a moderator in the relationship between general well-being and QOL.  Analysis 
by gender revealed the moderating effect of self-care is most significant in women in 
the presence of negative mood.  Clearly, this area is grounds for future research.   
Study Limitations 
This study has limitations to both internal and external validity.  Internal validity 
is limited by several factors.  First, the non-experimental design affects the internal 
validity of the findings.  As a cross-sectional, observational study, no conclusions of 
causality can be made.  Second, the study is limited by selection bias.  The participants 
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were a non-random convenience sample.  A substantial minority of the sample (43%) 
was recruited from a database of persons interested in diabetes and depression studies.  
This may have resulted in a disproportionate share of women with depressive 
symptoms in the sample.  Third, instrumentation may have affected internal validity.  
The questionnaires rely upon accurate self-assessment and honest reporting.   It is 
impossible to know if subjects over- or under-estimated parameters such as diabetes 
self-management activities or negative mood symptoms.  Fourth, although many 
confounding variables were minimized through exclusion criteria, not all could be 
eliminated.  For example, duration of DM and presence of co-morbidities (heart disease, 
chronic pain) were greater in the basal-bolus insulin group.  Disease duration and co-
morbid illness have potential QOL effects.  Due to uneven distribution of these factors 
among insulin management groups, it is impossible to rule out confounding effects on 
QOL.  Additionally, the study had low power due to a small sample size and lower than 
expected effect size.  Finally, although minimized, any missing data may affect internal 
validity.   
External validity of the study was also affected by several factors.  Most of the 
threats to external validity are related to sampling; the sample was fairly homogenous.  
Racial minorities were not sufficiently represented in the sample, nor younger adults.  
Non-English speakers were excluded from the study.  Recruitment was done through a 
database of prior study volunteers, outpatient clinics in the Midwest US, and via the 
internet.  This means that the sample represented only people with media, clinic, and/or 
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internet access.  All participants were volunteers; this fact limits generalizability to those 
who voluntarily participate in research.  This study’s limitations should be noted when 
interpreting the findings.    
Nursing Implications 
 Nurses encounter persons with DM in nearly every healthcare setting.  As 
worldwide rates of T2DM are only expected to increase, it is essential for nurses to 
understand QOL in DM.  The study revealed gender differences in QOL.  Women in the 
study reported lower QOL and negative well-being, as well as more cardiac symptoms 
than men.  This is an important finding for nursing clinical practice.  Nurses should be 
aware of the higher risk of depressive symptoms in women with diabetes and the 
resulting impact on QOL.  Study subjects reporting lower general well-being and less 
diabetes self-management activities experienced lower QOL.  Although the study 
findings do not demonstrate causality, nursing assessment of persons with DM should 
include mood and performance of DSM behaviors.  Nurses are very capable at 
recognizing depressive symptoms and diabetes-related distress (Pouwer, Beekman, 
Lubach & Snoek, 2006).  Because women are at greater risk for depressive symptoms 
(Egede, 2007), they are at particular risk for lower QOL and self-care.  Nurses should be 
aware of the relationship between mood, DSM practices and glycemic control.   Nursing 
interventions may include reinforcement of diabetic teaching, mood assessment, and 
facilitating treatment of depression.  Nurse-led psychoeducational group therapy for 
depressed women with T2DM has been successful (Penckofer et al., 2012).  A minimal 
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psychological intervention by nurses has been shown to modestly improve glycemic 
control, diabetes symptoms, and diabetes-related distress (Lamers, Jonkers, Bosma, 
Knottnerus & van Eijk, 2011).  Patients who report decreased DSM practices and lower 
mood are at risk for loss of glycemic control.  Nurses have the potential to minimize this 
risk. 
Future Research 
 This study provides inspiration for future research.  A larger study should be 
conducted to confirm the potentially negative findings.  Ideally, the larger study would 
utilize a greater sample size and control for confounding factors such as DM duration 
and co-morbidities with case-controls per insulin management strategy.  Other future 
studies could change the design or population.  A longitudinal study of patients before 
and after initiation of basal-bolus insulin therapy would provide a more rigorous 
evaluation, as patients would serve as their own control subjects.  Subjects could be 
tested at 6 and 12 months after basal-bolus insulin initiation.  Additional studies could 
also focus on different age groups.  A study of insulin management strategies and QOL 
should be conducted in young adults with T2DM.  The correlation between older age 
and higher QOL could be further explored with qualitative research such as interviews 
or focus groups of older adults with T2DM.  This would provide greater insight into the 
details of the age-QOL relationship.  Future studies should include non-English speakers 
as well as teenagers with T2DM.   
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 The moderating effect of DSM on well-being and QOL is grounds for future 
research.  Future studies to explore causality and temporal precedence of these 
variables are crucial.  One study could examine well-being and QOL in subjects before 
and after intense DSM education programs, with a longitudinal follow-up.    Most 
importantly, studies should be conducted to explore the gender differences in the effect 
of self-care on negative well-being and QOL.  Studies sufficiently powered to detect the 
effects of self-care in women are seminal.   Qualitative studies, such as focus groups, 
could facilitate greater understanding of self-care in women with diabetes and negative 
mood.  As the rates of type 2 diabetes continue to rise, future research is the key to 
understanding the multiple dimensions of quality of life for all persons with diabetes. 
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Database Search Strategy 
# Search terms Operator Prior Search Results (PubMed) 
S3 
(diabetes mellitus, type 2) or (MeSH Major Topic “diabetes mellitus, 
type 2”) 
AND Insulin  66256 
S4 
(quality of life) or (QOL) or (“quality of life”, MeSH Major Topic, MeSH 
Term) 
AND S3 1458 
S9 
(“insulin infusion systems”, MeSH Major Topic, MeSH Term) or (CSI) or 
(Continuous subcutaneous insulin) or (MDI) or (multiple daily) 
AND S4 150 
Limits: 2009-2014, English language, human 71 
After review of titles & abstracts 29 
After review of full-text articles 12 
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Study 
Sample 
 (all T2DM unless specified) 
Design Outcomes Findings 
Banerjee, Maji & 
Baruah, 2013 
 
A1chieve sub-study 
 
 
 
India 
N=343 
Age: 53 yrs. 
41% female 
DM duration: 9 yrs. 
Longitudinal (24 wks.)  
Observational 
 
Analog basal-bolus 
initiation  
 
75% of sample insulin-
naïve at baseline 
Glycemic Control 
Hypoglycemia 
QOL (EQ-5D) 
Huge A1C improvements 
(9.3 to 7.7%, p<.001):  
Less hypoglycemia in pts on 
insulin prior to study 
(p<.001) 
↑QOL in both insulin-naïve 
and experienced groups 
(p<.001)  
Dieuzeide et al., 2014 
 
A1chieve sub-study 
 
 
 
 
28 countries 
N=1024ŧ 
Age 56±13 yrs. 
52% female 
DM duration: 10±8 yrs. 
 
ŧ Note: only 52% (533) 
remained in study (others 
lost to follow-up) 
Longitudinal (24 wks.) 
Observational 
 
MDI to premix analogs 
(N=770 Reg-NPH,  
N=136 Reg-Lantus, 
N=104 analog basal-
bolus) 
Glycemic Control 
Hypoglycemia 
QOL (EQ-5D) 
Huge A1C improvements 
(2%, p<.001) 
 
Less hypoglycemia, esp. in 
NPH group (p<.001).   
 
QOL greater after starting 
premix(p<.001)  
Hajos et al., 2012 
 
 
 
 
Netherlands 
N=447 w/T2DM 
Age: 59±11 yrs. 
49% female 
DM duration: 11 yrs. 
Longitudinal (6 mo.) 
 
Started basal-bolus 
insulin (baseline: basal 
only or premix) 
Glycemic control 
Fear of hypoglycemia 
Diabetes symptoms 
(DSC-r) 
QOL (WHO-5 well-
being) 
DM Symptoms improved 
(p<0.001) 
QOL/emotional well-being 
improved (p<0.001)  
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Study 
Sample 
 (all T2DM unless specified) 
Design Outcomes Findings 
Hermanns et al., 
2012 
 
 
Germany 
N=167 
Age: 64±8 yrs. 
45% female 
DM duration: 14±7 yrs. 
RCT (6 months) 
 
Intensive basal-bolus 
education vs. standard 
Glycemic Control 
QOL (SF-12)  
DM distress (PAID) 
Diabetes Knowledge  
Self-care activities 
Exp. Gp. had less DM 
distress (p<.001), improved 
PCS of SF-12 (p<.05), 
improved diabetes 
knowledge  
Levin et al., 2011 
 
 
 
 
U.S. 
N=197 
Age: 56 yrs. 
54% female 
DM duration: 13 yrs. 
RCT (9 months) 
 
Basal-bolus vs. premix 
Glycemic control 
QOL (DQOL, EQ-5D) 
Hypoglycemia 
Cost-effectiveness 
Work Productivity & 
Activity  
Exp. gp.: less work days 
missed (p<.05), more cost-
effective 
 
No signif. changes in QOL  
Opsteen et al., 2012 
 
 
 
Canada 
N=34  
Age: 59 yrs. 
 38% female 
DM duration: 6±7 yrs. 
Longitudinal (8 weeks) 
 
Short-term intensive 
(basal-bolus) insulin 
therapy 
Glycemic control 
QOL (SF-36, DQOL) 
Diabetes Symptoms 
(DSC-r) 
SF-36 improved: PCS 
(p<.01), MCS (p<.05) 
DQOL “DM worries” 
subscale improved (p<.01) 
Less DM symptoms (p<.05) 
Peyrot & Rubin, 
2011 
 
 
U.S. 
N=618 
Age: 56±10 yrs. 
53% female 
DM duration: 13±7 yrs. 
RCT (45 weeks) 
 
Basal-bolus (inhaled 
bolus insulin)  vs. 
premix 
Glycemic control 
QOL (SF-36) 
Treatment 
Satisfaction (IITQ) 
No signif. changes in QOL 
 
Less DM worries in B-B 
group 
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Study 
Sample 
 (all T2DM unless specified) 
Design Outcomes Findings 
Peyrot et al., 2011 
 
U.S. N=54 
Age: 57±10 yrs. 
50% female 
DM duration: 13±6 yrs. 
Longitudinal (16 weeks) 
 
CSI initiation 
Glycemic ctrl (A1C, 
CGMS) 
QOL (EQ-5D) 
DM Symptoms (DSC-r) 
Treatment Satisf. 
(IDSRQ) 
 
No change in QOL overall 
 
Less DM symptoms (p<.05) 
Rubin et al., 2010 
 
 
 
U.S. 
Longitudinal (16 weeks) 
All started CSI (differed by 
baseline RX: 
N=17 orals, N=17 basal, 
N=20 basal-bolus 
Oral gp.: No QOL or Sx 
changes 
Basal and B-B groups: QOL 
improved (p<.05), less DM 
symptoms (p<.05) 
Shah et al., 2011 
 
A1chieve study 
 
28 countries 
(33% South Asia; 
22% Middle East) 
N=66,726 
Age: 54±12 yrs. 
44% female 
DM duration: 8±6 yrs. 
 
67% of sample insulin-
naïve at baseline 
Longitudinal (24 weeks) 
Observational 
 
Routine analog initiation or 
intensification (to premix, 
basal, or basal-bolus) 
Glycemic Control 
Hypoglycemia 
QOL (EQ-5D) 
Huge A1C improvements 
(9.5 to 7.4%, p<.001):  
 
QOL improved in all 
subgroups (p<.001) & 
countries (p<.001) in similar 
amounts 
Testa et al., 2012 
 
 
 
 
U.S. 
N=388 (80% T2DM) 
Age: 54±11 yrs. 
 53% female 
DM duration: 16±9 yrs. 
RCT: Crossover (24 weeks) 
 
Analog basal-bolus vs. 
premix 
Glycemic control & 
variability (A1C, 
CGMS) 
Treatment satisfaction 
QOL (Author’s own 
instrument) 
With basal-bolus:   
Better QOL (p<.001) 
↓ symptom distress  
(p<.0001) 
Better glycemic control and 
variability (p<.0001) 
Vinagre et al., 
2013 
 
Spain 
N=37  
Age 65±8 yrs. 
38% female 
DM duration 18±8 yrs. 
Longitudinal (6 months) 
 
Basal only or premix (89%) 
started basal-bolus insulin 
Glycemic control 
Severe hypoglycemia 
QOL (DQOL) 
No change in QOL (all 
subscales) 
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Date of initial call:    Name:    Phone:  
Screening Questions: Inclusion Yes No* 
1. Are you at least 18 years old?   
2. Do you have diabetes?   
3. Do you have “adult-onset” / “type 2” diabetes?   
4. Do you take medication for your diabetes at least one time a day?   
5. Have you been taking diabetes medicine for at least six months?    
6. Have you had the same diabetes medication schedule for at least 3 months? 
(for example, insulin doses per day) 
  
7. Are you able to read, write, and speak English?   
*A “No” answer disqualifies a subject from study enrollment 
Screening Questions: Exclusion  Yes** No 
1. Are you pregnant right now?   
2. Do you have sickle cell disease?   
3. Have you been treated for cancer (chemo or radiation) in the last 3 years?   
4. Do you have HIV (Human-Immunodeficiency Virus) or AIDS?   
5. Do you have Alzheimer’s or dementia?   
6. Do you have bipolar disorder or manic depressive disorder?   
7. Do you have schizophrenia or schizoaffective disorder?   
8. Do you any other major psychiatric disorder? (depression is acceptable)   
9. Do you have fibromyalgia?   
**A “Yes” answer disqualifies a subject from study enrollment. 
To assure appropriate distribution of subjects among diabetes management groups: 
Screening Questions: Verification Yes No 
1. Do you take insulin?   
2. How many times per day do you take insulin: 
a. Once a day?   
b. Two times a day?   
c. Three or more times a day?   
3. Do you have an insulin pump?   
4. Do you take short-acting insulin (i.e., Regular, Humalog, Novolog, Apidra)?   
5. Do you take long-acting insulin (i.e. NPH, Lantus, Levemir, Lente)?   
 
Can we mail you the study packet? No / Yes If yes, address:  
 Can I call you (with message if you are not home) or 
email you to see if you got the booklet?  No / Yes 
Gender: M / F How recruited: 
Accepted into study: No / Yes If yes, Subject #:  
Contact attempts: 
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June 14, 2012 
Dear Sir or Madam, 
I am a graduate student in nursing at Loyola University Chicago.  I am conducting a 
research project on quality of life in persons living with type 2 diabetes.   Dr. Susan 
Penckofer is my supervisor during this study and has given me permission to inform you 
about this project.  The study will consist of a questionnaire booklet and finger-stick 
blood test for hemoglobin A1C which you will complete at home and return to me in a 
pre-paid envelope.  It will take about one hour to complete.  You will be informed of 
your hemoglobin A1C test results.  Upon completion of the survey, you will also receive 
a $10 gift card. 
The results of this project will be used to help me complete my graduate studies.  
Through your participation, I hope to understand more about the quality of life in 
people with type 2 diabetes.  The results will hopefully be useful for doctors and nurses 
who care for people with diabetes.  I also hope to share my results by publishing them in 
a scientific journal. 
There are no risks to you in participating in this survey, beyond what you already 
experience in everyday life with diabetes.  Your responses will be kept confidential.  
Your name will not appear in any study results.   
If you are interested in learning more about the study or participating in the study, 
please call me at (630)-219-1331.  I appreciate your time and help!  Thank you. 
Sincerely, 
Sandra McCormick, RN, BSN 
Graduate Student in Nursing 
Loyola University Chicago 
Marcella Niehoff School of Nursing 
2160 South First Avenue 
Maywood, Illinois 60532 
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IRB LU# 204151 
Volunteers Needed for Research Study: 
Quality of Life in Type 2 Diabetes 
      
 The purpose of the study is to understand the quality of life for people 
with type 2 diabetes 
 The study is open to all English-speaking adults age 18 and older who 
take medications (pills and/or insulin) for type 2 diabetes 
 The study is not a treatment.  Participants will fill out a questionnaire 
booklet and complete a finger-stick blood test and return the study 
packet by mail.  You will receive a $10 gift card and your hemoglobin 
A1C result. 
Principal Investigator: Sandra McCormick, RN, BSN 
Graduate Nursing Student 
     Loyola University Chicago 
Faculty Advisor: Susan Penckofer, RN, PhD 
If interested, please contact: 
Sandra McCormick at (630)-219-1331 
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Dear Sir or Madam, 
Thank you for taking the time to participate in my research study.  The information you provide 
for the study is very valuable.  It is important to complete the survey and blood test as soon as 
possible.  Once the survey packet and blood test are complete, you will mail both by U.S. Mail in 
the pre-paid envelope within 10 days.  Please feel free to contact me by phone (information 
below).  Instructions for completing the study materials are provided below. 
1. Blood test (Hemoglobin A1C): 
o Detailed instructions on how to complete the blood test are on the next page 
o Sign and date the “Test Authorization Form”. 
o Blood test should take less than 5 minutes to collect 
o Allow the blood test to dry for at least 30 minutes before placing in envelope. 
 
2. Survey (Questionnaire booklet): 
o Fill out the questionnaire booklet.  It will take about 1 hour to complete.  
o If you have questions, please contact me at the number below.   
o If you do not want to answer a question, you can leave the question blank.   
 
3. Place your completed booklet and blood test card in the large stamped envelope.  Send by 
U.S. Mail. 
You may contact me at (630)-219-1331 or my faculty advisor (Susan Penckofer, 708-216-9303) 
with any questions or concerns. If you have any questions concerning your rights as a research 
participant, you may contact Dr. Kenneth Micetich, Chairman, Institutional Review Board for the 
Protection of Human Subjects-Medical Center (708-216-4608).    
Thank you again for your time and effort in participating in my study! 
Sincerely, 
Sandra McCormick, RN, BSN 
Graduate Nursing Student 
Loyola University Chicago  
Marcella Niehoff School of Nursing 
2160 South First Avenue 
Maywood, Illinois 60532 
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HEMOGLOBIN A1c COLLECTION INSTRUCTIONS 
PLEASE READ THOROUGHLY 
Remember to complete all your personal information on the Hemoglobin A1C Test Authorization Form.  Please read 
and provide your signature and date under the Patient Consent in order to approve your sample for testing.  Heritage 
labs will not complete any testing without your signature and date.   
Toll-free ReliOn customer support:  1-888-764-2384 
1. Review the Contents of Your Kit 5. Use the Lancet Provided 
Your test kit contains: 
 Collection instruction sheet 
 Hemoglobin A1C Test Authorization & Collection Form 
 Lancet 
 Alcohol Pad 
 Gauze Pad 
 Adhesive Bandage 
 Postage Paid Return Envelope 
Using the lancet provided, 
remove the cap, place palm 
up and position lancet on 
finger.  Press down on lancet 
to puncture site.  Wipe off 
the first blood drop with the 
alcohol pad.   
 
2. Fill Out the Hemoglobin A1C Test 
Authorization Form 
6. Blood Should Begin to Flow 
The Hemoglobin A1C Test 
Authorization Form has 
already been completed by 
the researcher.  Please 
initial and date the testing 
form, or testing cannot be 
done. 
 
Blood should begin to 
flow freely.  Place a 
LARGE free-flowing drop 
of blood on each circle of 
the Collection Form as 
shown.  Do NOT place 
one drop of blood on top 
of the other.  If blood 
flow stops, wipe with 
alcohol pad again to 
assist blood flow. 
 
  
3. Prepare Hands 7. Let the Blood Spot Air-Dry 
Rinse hands in warm tap 
water.  Clean the selected 
puncture site with the 
alcohol pad and dry it with 
the gauze pad. 
 
Let the blood spot air-dry for at least 30 minutes.  Make 
sure spot is dry before folding the Test Form. 
 
4. Stimulate Blood Flow 8. Mailing Instructions 
Stimulate blood flow to the 
selected finger by letting your 
hand hang down at your side for 
15-20 seconds.  Shake your hand 
back and forth several times.  
 Place the Hemoglobin A1C Test Authorization form 
into the postage-paid return envelope. 
 Mail the sample within three days of collecting the 
blood sample. 
The Hemoglobin A1C 
Test  Authorization 
Form has already b en 
completed by the 
researcher.   
Please sign and date the 
test form, or testing 
cannot be done. 
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Response Card (attached to front of questionnaire booklet) 
 
Please circle the answer to the questions and return 
this card with your packet. 
1. You can call me if you have questions 
about my booklet. 
Yes No 
2. I would like to receive my 
Hemoglobin A1C results. 
Yes No 
3. I would like to receive my “thank 
you” $10 gift card. 
Yes No 
My initials: ___________ ID #  ___________ 
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 6. Please check your highest level of 
education: 
1. What is your birth date?  1. □ Less than 9
th grade 
______/_____/_____ 
2. □ 9
th to 12th grade, no diploma 
3. □ High school graduate (includes 
GED)  
Month / Date / Year 4. □ Some college, no degree 
 5. □ Associate degree 
2. What is your gender? 6. 
□ Bachelor’s degree 
7. □ Graduate degree 
1. □ Male  
2. □ Female 7. Please indicate your total household 
income: 
 1. □ Less than $9,999 
 2. □ $10,000 to $14,999  
3. What is your ethnicity? 3. □ $15,000 to $19,999 
 4. □ $20,000 to $29,999 
1. □ Hispanic 5. □ $30,000 to $39,999 
2. □ Non-Hispanic 6. □ $40,000 to $49,999 
 7. □ $50,000 to $59,999 
4. What is your race? 8. 
□ $60,000 to $69,999 
9. □ $70,000 and over 
1. □ American Indian or Alaskan Native  
2. □ Asian or Pacific Islander 8. What is your employment status? 
3. □ Black or African-American 
1. □ Working full time, 35 hours or 
more per week 
4. □ White 
2. □ Working part-time, less than 35 
hours per week  
5. □ Other 
3. □ Unemployed or laid off and looking 
for work 
5. What is your marital status? 4. □ Unemployed and not looking for 
work 
1. □ Never Married 5. □ Homemaker 
2. □ Married 6. □ In School 
3. □ Separated 7. □ Retired 
4. □ Divorced 8. □ Disabled, not able to work 
5. □ Widowed 9. □ Other, please specify: 
____________  
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Health Questionnaire 
1. What is your height?  ______ feet  _____ inches 
2. What is your weight? ______ pounds 
3. What year were you told that you have diabetes? __________ 
4. Do you take pills for your diabetes? 
1. □ No  2. □ Yes, name of medicine(s): ___________________________ 
5. Do you take insulin for your diabetes? 
1. □ No 
  
2. □ Yes   5a. How many times a day do you usually take your 
insulin? (check ONE box) 
  1. □ Once a day 
 2. □ Twice a day 
 3. □ Three times a day 
 4. □ Four (or more) times a day 
 5. □ I use an infusion pump 
  
 5b. How long have you taken insulin? ________ years 
  5c. Do you take short-acting insulin (Humulin Regular, 
Humalog, Novolog, Apidra)? 
1. □ No 
2. □ Yes 
  5d. Do you take long-acting insulin (NPH, Lantus, Levemir, 
Lente)? 
1. □ No 
2. □ Yes 
 
6. Do you take Byetta (exenatide) injection for your diabetes? 
1. □ No 
2. □ Yes 
7. In the last week, how many times have you experienced hypoglycemia? ______________  
8. In the past year, how many times have you experienced hypoglycemia requiring the help of 
another person?  _______________ 
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9. Have you ever been told you have depression? 
1. □ No 
2. □ Yes 
10. Have you ever been treated for depression? 
1. □ No 
2. □ Yes 
11. Are you taking medication for depression? 
1. □ No  
2. □ Yes, name of medicine(s): 
________________________________________________ 
12. Which of the following medical problems do you have?  
Check off those that apply to you—even if treated 
 a. Asthma   m. Depression 
 b. Chronic Obstructive Pulmonary 
Disease or Emphysema 
  n. Anxiety 
 c. Angina   o. Panic Disorder 
 d. Congestive Heart Failure   p. Vision problems (cataracts, glaucoma, 
macular degeneration) 
 e. High Blood Pressure 
(Hypertension) 
  q. Hearing impairment (very hard of 
hearing, even with hearing aids) 
 f. Heart Disease   r. Arthritis (rheumatoid or 
osteoarthritis) 
 g. Heart Attack (Myocardial 
Infarction) 
  s. Degenerative disc disease (back 
problems, spinal stenosis, severe back 
pain) 
 h. Neurological Disease (Multiple 
sclerosis, Parkinson’s) 
  t. Sleep apnea 
 i. Stroke, Mini-Stroke, or Transient 
Ischemic Attack (TIA) 
  u. HIV or AIDS 
 j. Peripheral Vascular Disease   v. Fibromyalgia 
 k. Cancer   w. Chronic Pain 
 l. Sickle Cell Disease   x. Other: 
 
13. Have you ever had any of the following procedures related to your heart? (circle one 
number on each line) 
 No Yes 
a. Coronary Artery Bypass Surgery (Open Heart Surgery) 1 2 
b. Coronary angioplasty (“Balloon” Heart Procedure) 1 2 
c. Cardiac stent placed 1 2 
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14. Do you have any of the following? (circle one number on each line) 
 No Yes 
a. Peripheral vascular disease (poor circulation to the legs) 1 2 
b. Intermittent claudication (cramping in the legs after exercise) 1 2 
c. Peripheral neuropathy (nerve problems causing numbness, 
tingling, or burning in the feet or hands)  
1 2 
d. Foot ulcers (wounds that do not heal) 1 2 
 
15. Have you ever had an amputation of a part of your leg or foot for a poorly healing 
sore or poor circulation?  (NOT due to an injury or accident: car crash, power tool 
injury, war injury, etc.)—Circle one number on each line. 
  No One (right side) One (left side) Both 
a. Toes 1 2 3 4 
b. Part of a foot or feet 1 2 3 4 
c. Leg below knee 1 2 3 4 
d. Leg above knee 1 2 3 4 
 
16. Have you ever have any of the following eye problems?  (circle one number on each 
line) 
  No Yes/ 
One eye 
Yes/Both 
Eyes 
a. Cataracts 1 2 3 
b. Glaucoma 1 2 3 
c. Detached Retina 1 2 3 
d. Blurred vision (not corrected by eyeglasses) 1 2 3 
e. Retinopathy (diabetic eye disease) 1 2 3 
f. Laser eye surgery 1 2 3 
 
17. Do you have the following medical problems? (circle one number on each line) 
 No Yes 
a. Kidney failure? 1 2 
b. Renal insufficiency or nephropathy? 1 2 
c. Have you ever been on kidney dialysis? 1 2 
d. Have you ever been told you have diabetic gastroparesis? 1 2 
e. Do you vomit (throw up) after eating large meals? 1 2 
f. Men Only: Do you have difficulty getting or maintaining an 
erection? 
1 2 
  
138 
 
 
 
Brief-Chronic Illness Resources Survey (CIRS) 
The following questions ask about a variety of different resources that people may use 
to manage their illness.  For each item, select the number that best indicates your 
experience over the past 6 months.   
Over the past 6 months, to what extent: Not 
at all 
A 
little 
A 
moderate 
amount 
Quite 
a  
bit 
A 
great 
deal 
1. Has your doctor involved you as an equal 
partner in making decisions about illness 
management strategies and goals?              1 2 3 4 5 
2. Has your doctor or other health care 
advisor listened carefully to what you had 
to say about your illness?                                           1 2 3 4 5 
3. Has your doctor or other health care 
provider thoroughly explained the results 
of test you had done (e.g., cholesterol, 
blood pressure, or other laboratory tests?                                    1 2 3 4 5 
4. Have family or friends exercised with you? 
 1 2 3 4 5 
5. Have you shared healthy low-fat recipes 
with friends or family members?                         1 2 3 4 5 
6. Family or friends bought food or prepared 
food for you that were especially healthy 
or recommended?                                              1 2 3 4 5 
7. Have you focused on the things you did 
well to manage your illness instead of 
those you did not?                                                                        1 2 3 4 5 
8. Have you thought about or reviewed how 
you were doing in accomplishing your 
disease management goals?                                            1 2 3 4 5 
9. Have you arranged your schedule so that 
you could more easily do the things you 
needed to do for your illness?                                              1 2 3 4 5 
10. Have you walked or exercised outdoors in 
your neighborhood?                                       1 2 3 4 5 
11. Have you walked or done other exercise 
activities with neighbors?                             1 2 3 4 5 
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Over the past 6 months, to what extent: Not 
at all 
A 
little 
A 
moderate 
amount 
Quite 
a  
bit 
A 
great 
deal 
12. Have you eaten at a restaurant that 
offered a variety of tasty, low-fat good 
choices?       1 2 3 4 5 
13. Have you gone to parks for picnics, 
walks, or other outings?                                                     1 2 3 4 5 
14. Have you read articles in newspapers or 
magazines about people who were 
successfully managing a chronic illness?       1 2 3 4 5 
15. Have you had health insurance that 
covered most of the costs of your 
medical needs including medicine?                                        1 2 3 4 5 
16. Have you seen billboards or other 
advertisements that encouraged not 
smoking, low-fat eating, or regular 
exercise?             1 2 3 4 5 
17. Have you attended free or low-cost 
meetings (for example, Weight 
Watchers, church groups, hospital 
programs) that supported you in 
managing your illness?                                  1 2 3 4 5 
18. Have you volunteered your time for 
local organizations or causes?                                   1 2 3 4 5 
19. Have you attended wellness programs 
or fitness facilities?                                                1 2 3 4 5 
20. Have you had a flexible work schedule 
that you could adjust to meet your 
needs? (Leave blank if you don’t work.)                                  1 2 3 4 5 
21. Has your workplace had rules or policies 
that made it easier for you to manage 
your illness (such as no smoking rules or 
time off work to exercise)?  (Leave blank 
if you don’t work.) 
 1 2 3 4 5 
22. Have you had control over your job in 
terms of making decisions and setting 
priorities?  (Leave blank if you don’t 
work.)                      1 2 3 4 5 
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Self Care Inventory-Revised Version (SCI-R) 
This survey measures what you actually do, not what you are advised to do.  How have you 
followed your diabetes treatment plan in the last 1-2 months? 
 Never Rarely Sometimes Usually Always  
 ↓ ↓ ↓ ↓ ↓  
1. Check blood glucose with 
monitor 1 2 3 4 5 
 
2. Record blood glucose results 1 2 3 4 5  
3. If type 1: check ketones 
when glucose level is high 1 2 3 4 5 
Have type 
2 diabetes 
4. Take the correct dose of 
diabetes pills or insulin 1 2 3 4 5 
Not taking 
diabetes 
pills or 
insulin 
5. Take diabetes pills or insulin 
at the right time 1 2 3 4 5 
Not taking 
diabetes 
pills or 
insulin 
6. Eat the correct food 
portions 
1 2 3 4 5  
7. Eat meals/snacks on time 1 2 3 4 5  
8. Keep food records 1 2 3 4 5  
9. Read food labels 1 2 3 4 5  
10. Treat low blood glucose 
with just the recommended 
amount of carbohydrate 
1 2 3 4 5 
Never had 
low blood 
glucose 
11. Carry quick acting sugar to 
treat low blood glucose 1 2 3 4 5  
12. Come in for clinic 
appointments 1 2 3 4 5  
13. Wear a Medic Alert ID 1 2 3 4 5  
14. Exercise 1 2 3 4 5  
15. If on insulin: Adjust insulin 
dosage based on glucose 
values, food, and exercise 
1 2 3 4 5 
Not on 
insulin 
©Copyright 2005: Annette M. LaGreca, University of Miami   
141 
 
 
 
Diabetes Symptom Checklist 
Instructions 
Please circle whether you have experienced the symptom or not in the last 4 weeks, 
today included.  If you circled “yes” then indicate to what extent the symptom listed has 
caused you discomfort by circling the number that most closely reflects your experience. 
If a symptom did not occur, please circle “No” in the column “DID SYMPTOM OCCUR” 
EXAMPLE 
 DID 
SYMPTOM 
OCCUR? 
THE SYMPTOM DID OCCUR AND WAS 
…………………TROUBLESOME TO ME 
  Not at all A little Moderately Very Extremely 
Sore 
throat? 
No       
 Yes →→→→ 1 2 3 4 5 
This answer means: In the last 4 weeks I did have a sore throat and it was a little 
troublesome to me. 
 
How much trouble have these symptoms given you  
over the last 4 weeks? 
 
 DID 
SYMPTOM 
OCCUR? 
THE SYMPTOM DID OCCUR AND WAS 
…………………TROUBLESOME TO ME 
  Not at 
all 
A 
little 
Moderately Very Extremely 
1. Lack of energy? No 
Yes→→→→ 1 2 3 4 5 
2. Aching calves when 
walking? 
No 
Yes→→→→ 1 2 3 4 5 
3. Numbness (loss of 
sensation) in the feet? 
No 
Yes→→→→ 1 2 3 4 5 
4. An overall sense of 
fatigue? 
No 
Yes→→→→ 1 2 3 4 5 
5. Shortness of breath at 
night? 
No 
Yes→→→→ 1 2 3 4 5 
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 DID 
SYMPTOM 
OCCUR? 
THE SYMPTOM DID OCCUR AND WAS 
…………………TROUBLESOME TO ME 
  Not at 
all 
A 
little 
Moderately Very Extremely 
6. Sleepiness or 
drowsiness? 
No 
Yes→→→→ 1 2 3 4 5 
7. Difficulty concentrating? No 
Yes→→→→ 1 2 3 4 5 
8. Moodiness? No 
Yes→→→→ 1 2 3 4 5 
9. Numbness (loss of 
sensation) in the hands? 
No 
Yes→→→→ 1 2 3 4 5 
10. Persistently blurry vision 
(even with glasses on)? 
No 
Yes→→→→ 1 2 3 4 5 
11. Tingling sensations in 
arms or legs at night? 
No 
Yes→→→→ 1 2 3 4 5 
12. Being very thirsty? No 
Yes→→→→ 1 2 3 4 5 
13. Palpitations or pounding 
in the heart region? 
No 
Yes→→→→ 1 2 3 4 5 
14.  Deteriorating vision? No 
Yes→→→→ 1 2 3 4 5 
15. Burning pain in the 
calves at night? 
No 
Yes→→→→ 1 2 3 4 5 
16. Dry mouth? No 
Yes→→→→ 1 2 3 4 5 
17. Increasing fatigue during 
the course of the day? 
No 
Yes→→→→ 1 2 3 4 5 
18. Flashes or black spots in 
the field of vision? 
No 
Yes→→→→ 1 2 3 4 5 
19. Irritability just before a 
meal? 
No 
Yes→→→→ 1 2 3 4 5 
20. Fatigue in the morning 
when getting up? 
No 
Yes→→→→ 1 2 3 4 5 
21. Shooting pains in the 
legs? 
No 
Yes→→→→ 1 2 3 4 5 
22. Alternating clear and 
blurred vision? 
No 
Yes→→→→ 1 2 3 4 5 
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 DID 
SYMPTOM 
OCCUR? 
THE SYMPTOM DID OCCUR AND WAS 
…………………TROUBLESOME TO ME 
  Not at 
all 
A 
little 
Moderately Very Extremely 
23. Frequent need to 
urinate? 
No 
Yes→→→→ 1 2 3 4 5 
24. Pains in the chest or 
heart region? 
No 
Yes→→→→ 1 2 3 4 5 
25. Burning pain in the legs 
during the day? 
No 
Yes→→→→ 1 2 3 4 5 
26. Tingling or prickling 
sensations in hands or 
fingers? 
No 
Yes→→→→ 1 2 3 4 5 
27. Easily irritated or 
annoyed? 
No 
Yes→→→→ 1 2 3 4 5 
28. Sudden deterioration of 
vision? 
No 
Yes→→→→ 1 2 3 4 5 
29. Odd feeling in (lower) 
legs or feet when 
touched? 
No 
Yes→→→→ 1 2 3 4 5 
30. Shortness of breath 
during physical exertion 
(walking, chores)?  
No 
Yes→→→→ 
 
1 
 
2 
 
3 
 
4 
 
5 
31.  Fuzzy feeling in your 
head (difficulty thinking 
clearly)? 
No 
Yes→→→→ 1 2 3 4 5 
32. Drinking a lot (all sorts 
of beverages)? 
No 
Yes→→→→ 1 2 3 4 5 
33. Difficulty paying 
attention? 
No 
Yes→→→→ 1 2 3 4 5 
34. Tingling or prickling 
sensations in lower legs 
or feet? 
No 
Yes→→→→ 1 2 3 4 5 
Any other symptoms: 
35.  
 
Yes→→→→ 1 2 3 4 5 
36.   
Yes→→→→ 1 2 3 4 5 
37.   
Yes→→→→ 1 2 3 4 5 
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SF-12 v2 TM Health Survey 
This survey asks for your views about your health.  This information will help keep track 
of how you feel and how well you are able to do your usual activities. 
Answer every question by selecting the answer as indicated.  If you are unsure about 
how to answer a question, please give the best answer you can. 
 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
O O O O O 
2. The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities?  If so, how much? 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
a. Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
 
O O O 
b. Climbing several flights of stairs 
 
O O O 
3. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health? 
 All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A 
little 
of the 
time 
None 
of the 
time 
a. Accomplished less than you would like 
 
O O O O O 
b. Were limited in the kind of work or other 
activities 
 
O O O O O 
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4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A 
little 
of the 
time 
None 
of the 
time 
a. Accomplished less than you would like 
 
O O O O O 
b. Did work or activities less carefully than 
usual 
 
O O O O O 
5. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
O O O O O 
6. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling. 
 
How much of the time during the past 4 weeks . . .  
 All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A 
little 
of the 
time 
None 
of the 
time 
a. Have you felt calm and peaceful? 
 
O O O O O 
b. Did you have a lot of energy? 
 
O O O O O 
c. Have you felt downhearted and depressed? O O O O 
 
O 
7. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)? 
All 
of the time 
Most  
of the time 
Some  
of the time 
A little  
of the time 
None  
of the time 
O O O O O 
Thank you for completing these questions! 
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Well-Being Questionnaire (W-BQ12) 
 
 
 
 
all 
the time 
  
not 
at all 
1. I have crying spells or feel like it ………………………… 3 2 1 0 
2. I feel downhearted and blue ………………………..…. 3 2 1 0 
3. I feel afraid for no reason at all …………………..…….. 3 2 1 0 
4. I get upset easily or feel panicky …………..……………. 3 2 1 0 
5. I feel energetic, active, or vigorous …………...……… 3 2 1 0 
6. I feel dull or sluggish ……………………………………….. 3 2 1 0 
7. I feel tired, worn out, or exhausted ……………….…… 3 2 1 0 
8. I have been waking up feeling fresh and  
rested ………………………………………………………………. 
3 2 1 0 
9. I have been happy, satisfied, or pleased  
with my personal life …………………………………………. 3 2 1 0 
10. I have lived the kind of life I wanted to ……………. 3 2 1 0 
11. I have felt eager to tackle my daily tasks or  
make new decisions ………………………………………. 3 2 1 0 
12. I have felt I could easily handle or cope with any 
serious problem or major change in my life………. 3 2 1 0 
Please make sure that you have considered each of the 12 statements and 
have circled one number in response to each statement. 
Please circle one number on each scale, from 3 (all the time) to 0 (not 
at all), to indicate how often you feel each statement has applied to 
you in the past few weeks. 
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Appraisal of Diabetes Scale 
People differ in their thoughts and feelings about having diabetes.  We would like to know how 
you feel about having diabetes.  Therefore, please circle the answer to each question which is 
closest to the way you feel. Please give your honest feelings—we are interested in how you 
feel, not what your doctor or family may think. 
1. How upsetting is having diabetes for you? 
 1 2 3 4 5 
 Not at 
all 
Slightly 
upsetting 
Moderately 
upsetting 
Very 
upsetting 
Extremely 
upsetting 
2. How much control over your diabetes do you have? 
 1 2 3 4 5 
 None at 
all 
Slight 
amount 
Moderate 
amount 
Large 
amount 
Total 
amount 
3. 
How much uncertainty do you currently experience in your life as a result of being 
diabetic? 
 1 2 3 4 5 
 None at 
all 
Slight 
amount 
Moderate  
amount 
Large 
amount 
Extremely 
large amount 
4. 
How likely is your diabetes to worsen over the next several years? (Try to give an estimate 
based on your personal feeling rather than based on a rational judgment.) 
 1 2 3 4 5 
 Not likely 
at all 
Slightly 
likely 
Moderately  
likely 
Very 
likely 
Extremely  
likely 
5. 
Do you believe that achieving good diabetic control is due to your efforts as compared to 
factors which are beyond your control? 
 1 2 3 4 5 
 Totally 
because 
of me 
Mostly 
because 
of me 
Partly because 
of me and partly 
because of other 
factors 
Mostly 
because 
of other 
factors 
Totally 
because 
of other 
factors 
6. How effective are you in coping with your diabetes? 
 1 2 3 4 5 
 Not 
at all 
Slightly 
effective 
Moderately  
effective 
Very effective Extremely 
effective 
7. To what degree does your diabetes get in the way of your developing life goals? 
 1 2 3 4 5 
 Not at 
all 
Slight 
amount 
Moderate  
amount 
Large 
amount 
Extremely 
large amount 
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Ferrans and Powers 
QUALITY OF LIFE INDEX© 
DIABETES VERSION – III 
 
PART 1. For each of the following, please choose the answer that best describes how satisfied 
you are with that area of your life. Please mark your answer by circling the number. There are no 
right or wrong answers. 
HOW SATISFIED ARE YOU WITH: V
er
y
 D
is
sa
ti
sf
ie
d
 
M
o
d
er
at
el
y
 D
is
sa
ti
sf
ie
d
 
S
li
g
h
tl
y
 D
is
sa
ti
sf
ie
d
 
S
li
g
h
tl
y
 S
at
is
fi
ed
 
M
o
d
er
at
el
y
 S
at
is
fi
ed
 
V
er
y
 S
at
is
fi
ed
 
1. Your health? 1 2 3 4 5 6 
2. Your health care? 1 2 3 4 5 6 
3. The amount of energy you have for everyday activities? 1 2 3 4 5 6 
4. Your ability to take care of yourself without help? 1 2 3 4 5 6 
5. Your ability to control your blood sugar?  1 2 3 4 5 6 
6. The changes you have had to make in your life because 
of diabetes (such as diet, exercise, taking insulin or 
diabetes pill, checking blood sugar)? 
1 2 3 4 5 6 
7. The amount of control you have over your life? 1 2 3 4 5 6 
8. Your chances of living as long as you would like? 1 2 3 4 5 6 
9. Your family’s health? 1 2 3 4 5 6 
10. Your children? 1 2 3 4 5 6 
11. Your family’s happiness? 1 2 3 4 5 6 
12. Your sex life? 1 2 3 4 5 6 
13. Your spouse, lover, or partner? 1 2 3 4 5 6 
14. Your friends? 1 2 3 4 5 6 
15. The emotional support you get from your family? 1 2 3 4 5 6 
(Please Go To Next Page) 
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HOW SATISFIED ARE YOU WITH: V
er
y
 D
is
sa
ti
sf
ie
d
 
M
o
d
er
at
el
y
 D
is
sa
ti
sf
ie
d
 
S
li
g
h
tl
y
 D
is
sa
ti
sf
ie
d
 
S
li
g
h
tl
y
 S
at
is
fi
ed
 
M
o
d
er
at
el
y
 S
at
is
fi
ed
 
V
er
y
 S
at
is
fi
ed
 
       
16. The emotional support that you get from people other 
than your family? 
1 2 3 4 5 6 
17. Your ability to take care of family responsibilities? 1 2 3 4 5 6 
18. How useful you are to others? 1 2 3 4 5 6 
19. The amount of worries in your life? 1 2 3 4 5 6 
20. Your neighborhood? 1 2 3 4 5 6 
21. Your home, apartment, or place where you live? 1 2 3 4 5 6 
22. Your job (if employed)? 1 2 3 4 5 6 
23. Not having a job (if unemployed, retired, or disabled)? 1 2 3 4 5 6 
24. Your education? 1 2 3 4 5 6 
25. How well you take care of your financial needs? 1 2 3 4 5 6 
26. The things that you do for fun? 1 2 3 4 5 6 
27. Your chances for a happy future? 1 2 3 4 5 6 
28.  Your peace of mind? 1 2 3 4 5 6 
29. Your faith in God? 1 2 3 4 5 6 
30. Your achievement of personal goals? 1 2 3 4 5 6 
31. Your happiness in general? 1 2 3 4 5 6 
32. Your life in general? 1 2 3 4 5 6 
33. Your personal appearance? 1 2 3 4 5 6 
34. Yourself in general? 1 2 3 4 5 6 
(Please Go To Next Page) 
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PART 2. For each of the following, please choose the answer that best describes how important 
that area of your life is to you. Please mark your answer by circling the number. There are no 
right or wrong answers. 
HOW IMPORTANT TO YOU IS: V
er
y
 U
n
im
p
o
rt
an
t 
M
o
d
er
at
el
y
 U
n
im
p
o
rt
an
t 
S
li
g
h
tl
y
 U
n
im
p
o
rt
an
t 
S
li
g
h
tl
y
 I
m
p
o
rt
an
t 
M
o
d
er
at
el
y
 I
m
p
o
rt
an
t 
V
er
y
 I
m
p
o
rt
an
t 
       
1. Your health? 1 2 3 4 5 6 
2. Your health care? 1 2 3 4 5 6 
3. Having enough energy for everyday activities? 1 2 3 4 5 6 
4. Taking care of yourself without help? 1 2 3 4 5 6 
5. Controlling your blood sugar?  1 2 3 4 5 6 
6. The changes you have had to make in your life 
because of diabetes (such as diet, exercise, taking 
insulin or diabetes pill, checking blood sugar)? 
1 2 3 4 5 6 
7. Having control over your life? 1 2 3 4 5 6 
8. Living as long as you would like? 1 2 3 4 5 6 
9. Your family’s health? 1 2 3 4 5 6 
10. Your children? 1 2 3 4 5 6 
11. Your family’s happiness? 1 2 3 4 5 6 
12. Your sex life? 1 2 3 4 5 6 
13. Your spouse, lover, or partner? 1 2 3 4 5 6 
14. Your friends? 1 2 3 4 5 6 
15. The emotional support you get from your family? 1 2 3 4 5 6 
16. The emotional support you get from people other 
than your family? 
1 2 3 4 5 6 
 
(Please Go To Next Page) 
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HOW IMPORTANT TO YOU IS: V
er
y
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n
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t 
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t 
V
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y
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m
p
o
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an
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17. Taking care of family responsibilities? 1 2 3 4 5 6 
18. Being useful to others? 1 2 3 4 5 6 
19. Having no worries? 1 2 3 4 5 6 
20. Your neighborhood? 1 2 3 4 5 6 
21. Your home, apartment, or place where you live? 1 2 3 4 5 6 
22. Your job (if employed)? 1 2 3 4 5 6 
23. Having a job (if unemployed, retired, or disabled)? 1 2 3 4 5 6 
24. Your education? 1 2 3 4 5 6 
25. Being able to take care of your financial needs? 1 2 3 4 5 6 
26. Doing things for fun? 1 2 3 4 5 6 
27. Having a happy future? 1 2 3 4 5 6 
28.  Peace of mind? 1 2 3 4 5 6 
29. Your faith in God? 1 2 3 4 5 6 
30. Achieving your personal goals? 1 2 3 4 5 6 
31. Your happiness in general? 1 2 3 4 5 6 
32. Being satisfied with life? 1 2 3 4 5 6 
33. Your personal appearance? 1 2 3 4 5 6 
34. Are you to yourself? 1 2 3 4 5 6 
©
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APPENDIX G 
MISSING DATA
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Missing Data Replaced by Imputation 
Measurement Tool Item  
Missing 
Group 
Mean  
Individual 
Mean 
Replaced 
Value 
Count 
(n) 
% 
Health Questionnaire  
Duration of 
Diabetes 
4 3.7 12.6  -- 12.5 
Access to diabetes care item  CIRS #15 1 0.9 4.11 3.5 4 
CIRS 
#5 1 0.9 2.39 1.5 2 
#11 1 0.9 1.51 2.3 2 
#14 1 0.9 3.01 2.0 2 
#17 1 0.9 1.90 2.0 2 
Well-Being Questionnaire 12 #4 1 0.9 0.53 0.66 1 
DSC-R 
#16 1 0.9 1.47 2.0 2 
#29 1 0.9 0.54 2.0 1 
SF-12 Health Survey (v2) #2a 1 0.9 2.28  1.6 2 
Appraisal of Diabetes Scale #2 1 0.9 3.64 2.7 3 
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Missing Data Not Replaced 
Measurement Tool Item Description 
Missing 
Reason not replaced 
Count (n) % 
Demographics 
Questionnaire  
Income  8 7.5 2 
Height 1 0.9 2 
Weight 1 0.9 2 
CIRS  
#20 (work-related) 68 63.6 
Expected missing3 #21 (work-related) 72 67.3 
#22 (work related) 72 67.3 
Health History 
Questionnaire 
Detached Retina 1 0.9 
Subject (#109) did not 
know history 
Retinopathy 1 0.9 
Laser Eye Surgery 1 0.9 
Glycemic control A1C 6 5.6 2 
Well-Being 
Questionnaire 12 
#5 (energy/vigor) 1 0.9 Subj.  (#135) left blank 
2/4 items on subscale #6 (sluggish) 1 0.9 
Appraisal of Diabetes 
Scale 
#3 (uncertainty) 1 0.9 
Subject (#178) left blank 
3/7 of instrument  
#5  (locus of control) 1 0.9 
#7  (life goals impact) 1 0.9 
Quality of Life Index 
SAT9 (family health) 1 0.9 
Subject (#194) left blank 
all family subscale items  
IMP9 (family health) 1 0.9 
SAT11 (family happiness) 1 0.9 
IMP11(family happiness) 1 0.9 
SAT15 (family support) 1 0.9 
IMP15 (family support) 1 0.9 
SAT10 (children) 10 9.3 
Expected missing4 
IMP10 (children) 10 9.3 
SAT12 (sex life) 15 14 
IMP12 (sex life) 18 16.8 
SAT13 (spouse/partner) 21 19.6 
IMP13 (spouse/partner) 20 18.7 
SAT22 (work-related) 72 67.3 
Expected missing3 
IMP22 (work-related) 69 64.5 
SAT23 (work-related) 45 42.1 
IMP23 (work-related) 37 34.6 
 
                                                             
2
Data cannot be deductively imputed without excessive risk of distorting relationships between variables. 
3Missing data related to employment was expected as 67.3 % subjects not currently working outside the 
home. 
4 Missing data related to partner/children was expected as 42% of subjects are unpartnered (single, 
divorced, separated or widowed) and 9.3% of subjects stated no children. 
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APPENDIX H 
DATA ANALYSES ASSUMPTIONS
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Assumptions for ANOVA 
Assumption Description Assumption Met 
Homogeneity of Variance 
(Homoscedasticity) 
Similar variance in each 
experimental condition/group 
Levene’s Test non-
significant 
Independent Observations -Uncorrelated error terms 
-Uncorrelated independent 
variables 
Durbin-Watson = 1 to 3 
Dependent variable is an 
interval or continuous scale 
Variable is interval or greater 
scale 
Yes 
Normality (of residuals) Distributions within groups are 
normally distributed 
Yes 
 
Tests of Normal Distribution 
Test Description Quality of Life 
(QLI) 
Assumption 
met? 
Skewness Symmetry (should be zero) -0.623 No 
Kurtosis Distortion from bell-curve (should be 
zero) 
-0.002 Yes 
Kolmogorov-
Simirnov 
Goodness-of-fit test; should be >.05 0.200 Yes 
Shapiro-Wilk Comparison to normal distribution, 
should be >.05 
0.007 No 
 
Assumptions for MANOVA 
Assumption Description Assumption Met 
Independence Uncorrelated independent 
variables 
Wilks’ Lambda significant 
Random Sampling Dependent variable is randomly 
sampled from population at 
interval scale (at least) 
Yes 
Multivariate Normality Dependent variables are 
normally distributed within 
groups 
Yes 
Homogeneity of Covariance 
Matrices 
Variance-covariance matrices of 
groups are equal 
Levene’s test then Box’s 
Test (both nonsignificant) 
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Assumptions for Multiple Regression 
Assumption Description Assumption Met 
Variable Type -Interval or greater scale 
-Unbounded = no constraints 
per instrument’s scale 
Yes 
Variance is non-zero Predictors’ variance ≠ zero Yes, per descriptive statistics 
Multicollinearity Predictors are not highly 
correlated 
VIF should be <10 
Tolerance > 0.1 
Predictors not correlated with 
external variables 
External variables are those 
not included in the analysis 
but are related to the 
outcome 
Review of literature per 
Chapter 2. 
Homoscedasticity Predictor residuals should 
have similar variance 
Non-significant Levene’s test 
Independent error terms Subjects’ residuals are not 
correlated 
Durbin-Watson = 1 to 3 
Normally distributed errors Residuals are random, 
normally distributed, mean = 
zero. 
Yes 
Independence All dependent variable  
measurements come from 
separate subjects 
Chapter 3, methods show 
simultaneous cross-sectional 
data collection 
Linearity Model relationship is linear Yes 
Note: Assumptions and descriptions are from Field, 2009.   
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